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SUMMARY
The hereditary porphyrias are a group of disorders in 
which the genetic defect results in an abnormality in the 
biosynthetic pathway leading to the respiratory pigment haem. 
The characteristic result of this is excessive synthesis and 
excretion of the tetrapyrrolic porphyrins and, in the acute 
porphyrias, their precursors 6-aminolaevulinic acid.(ALA) 
and porphobilinogen.
The acute attacks of acute porphyria show certain 
similarities to psychiatric disorders and the finding of a 
pyrrolic metabolite in the urine of patients with acute 
intermittent porphyria (AIP) and certain psychiatric 
disorders was the common factor that implicated this 
metabolite in the aetiology of certain manifestations of 
these disorders. Identification of the metabolite proved 
difficult but it was eventually unambiguously identified 
as 5-ethyl-5-hydroxy-4.5-dimethvl-A^-pyrrolin-2-one (OHHPL). 
The work contained in this thesis describes clinical and 
biochemical investigations into the occurrence and properties 
of this compound.
Initially a qualitative method was used to detect OHHPL 
and it was shown to be present in the urine of patients with 
acute porphyria in attack and remission but to be undetectable 
in patients who were latent for the disease.
XIV
Using a gas-liquid chromatography method developed for 
the quantitative assay of OHHPL, it was shown that in carriers 
of the AIP gene defeot there was no significant difference in 
OHHPL excretion in latency, attack and remission, but that 
levels in these patients were significantly greater than in 
control subjects. No correlation could be shown between 
OHHPL excretion and clinical condition either in the group 
of patients or in multiple estimations in single patients. 
However, a significant association was found between the 
excretion of OHHPL and that of ALA and PBG and it was also 
shown that in the porphyric patients ALA and PBG excretion 
were related in a linear fashion.
Quantitation of OHHPL in groups of psychiatric patients 
showed that there was' a""significant elevation of OHHPL 
excretion in psychotic patients who were undergoing drug 
therapy and also in groups of patients with schizophrenia 
and organic brain disease. In the patients with schizophrenia 
there was a negative correlation between the clinical 
condition of the patients as assessed on the Hamilton-Lorr 
rating scale and urinary OHHPL.
In an attempt to examine further the relationship between 
OHHPL and PBG and ALA in the patients with porphyria a group 
of patients, industrial lead workers, with sub-clinical lead 
poisoning were studied. These patients had raised blood lead 
and increased urinary excretion of A M  resulting from an
XV
inhibition by lead of the enzyme 6-aminolaevulinic acid 
dehydratase (AIA.D). OHHPL and PBG concentrations in the 
urine of these workers were within the normal range. It 
was found that there was a negative association between 
OHHPL and ALA levels which suggested that the ALA-OHHPL 
association in the porphyric patients was purely a result 
of the ALA-PBG relationship.
In patients with liver disease raised levels of OHHPL 
were found in the urine of a proportion of patients with 
cirrhosis while all patients with hepatitis alone had 
normal OHHPL excretion.
To study the biochemical properties of OHHPL and other 
pyrroles a group of alkyl pyrroles and some of their oxidised 
derrivatives (including OHHPL) were administered to rats. 
Porphyrin and porphyrin precursor excretion and hepatic 
porphyrin levels were monitored and, in the case of OHHPL 
and its p3* isomer (OHKPL), the activities of the enzymes of 
haem biosynthesis and that of haem oxygenase (HAEM.O), the 
haem degrading enzyme, were measured. Microsomal haem and 
cytochrome levels were also measured in the latter two cases.
It was found that treatment with each of the pyrroles 
caused increased porphyrin synthesis and excretion. Results 
from OHHPL and OHKPL treated animals suggested that this was 
due to an increase in 6-aminolaevulinic acid synthase (ALA.S), 
the rate controlling enzyme of haem biosynthesis, and that
XVI
this in turn was due to a reduction in microsomal levels of 
haem. Microsomal cytochrome P-450 levels were also depressed 
by this treatment.
Neither OHHPL nor OHKPL had an effect on the enzymes of 
haem biosynthesis in vitro. However, it was found that at 
high concentrations OHHPL caused an inhibition of HAEM.O.
The proportion of the porphyrin intermediates produced 
in response to monopyrrole treatment in vivo was studied by 
high performance liquid chromatography (HPLC). It was shown 
there were inconsistent changes in the proportion of 
individual porphyrins but that OHHPL increased porphyrin 
excretion without msirkedly altering the proportion of each 
porphyrin present. Increasing the dosage of a single non- 
toxic monopyrrole was associated with changes in the excretion 
of porphyrins, the proportion of 7- and 8-carboxylic porphyrins 
increasing with dose.
The finding in four patients with AIP of an attack 
associated increase in thyroid hormone levels, was followed by 
an attempt to show an effect of OHHPL or experimental porphyria 
on thyroid hormone excretion in the rat and an effect of thyroid 
hormone on the induction of ALA.S by OHHPL. Both of these 
experiments gave negative results.
Finally, the behavioural pharmacology of OHHPL was studied 
in two systems used to demonstrate behavioural changes in 
response to ALA. OHHPL was found to have no effect on the
xvii
spontaneous activity of rats or on the social and non-social 
behaviour of mice.
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C H A P T E R  1
GENERAL INTRODUCTION
CHAPTER 1
GENERAL INTRODUCTION
1.1. HISTORY AND BACKGROUND OP THE PORPHYRIAS
The porphyrias are a rare group of genetic disorders first 
reported in the 19th century, although the first classification
of the diseases in terms of disordered porphyrin metabolism was
\
not made until 1922 by Gunther, The diseases are characterised 
by excessive excretion of porphyrins'and their precursors due to 
a genetically defined metabolic defect. The porphyrins, a class 
of heterocyclic compounds, play essential roles in the formation 
of the respiratory pigments in animals, plants and microorganisms, 
the most important of which is haem (Figure l).
The work of the Nobel Laureate Hans Fischer laid the found­
ations of the chemistry and biochemistry of porphyrins and it 
was he who introduced the tem ’porphyria*. Subsequent work by 
Waldenstrom formed the basis of the modem classification of the
porphyrias and has led to the general acceptance of the term.
«
The porphyrias can be subdivided according to the site of the 
production of the bulk of the excreted porphyrins and precursors 
(Schmid et al, 1954)? hepatic porphyria where the excess 
porphyrin is produced by the liver and erythropoietic porphyria 
where the bone marrow is the site of the overproduction.
Although the incidence of porphyria is low (about 1.5 cases 
per 100,000 for acute intermittent porphyria), interest has been 
great because of the ways in which the diseases manifest themselves 
and the similarity to other non-hereditary disorders such as lead
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FIGURE 1 THE STRUCTURE OP Ekm
poisoning and anaemia, or more so in the cases of toxic porphyria 
where the condition is indistinguishable from a form of hereditary 
porphyria.
It is now generally believed that each of the porphyrias is 
primarily the result of an abnormality in the biosynthetic pathway 
of haem and that the symptomatology associated with each of the 
porphyrias may be ascribed to the overproduction of intermediary 
metabolites seen in that porphyria.
Our knowledge of the particular effects of individual 
metabolites has progressively increased and, with the improve­
ments brought with modem research technologies, will continue to 
do so.
1.2. mm  BIOSYNTHESIS
The mechanisms involved in the biosynthesis of haem have 
been the subject of many investigations since the elucidation 
of the biosynthetic pathway (Figure 2) following the work of 
Shemin (1955). As a part of the work in this thesis is 
concerned with abnormalities in the pathway, whether naturally 
■ occurring or experimentally produced, a resume of the present 
knowledge will be presented here. The enzymes are the active 
principals of the pathway and it will therefore be described 
in terms of their actions.
As can be seen from Figure 2, the enzymes of this pathway 
are located both in the cell sap and in the mitochondria 
necessitating translocation of pathway intermediates between 
these compartments. Ag. yet, little is known of the processes 
involved in such transport; whether they are active or passive. 
These mechanisms represent a possible controlling area which 
will not be reviewed.
As haem catabolism plays an active role in the maintenance 
of haem levels, the initial enzyme of haem degradation will also 
be mentioned in the final sub-section.
1.2.1. 5-AMINOLAEVTJLINIC ACID SYNTHASE
(ALA.S; Succinyl CoA : Glycine C Suecinyltransferase 
(decarboxylating); E.G. 2.3.1.37)
ALA.S, the initial enzyme, catalyses the condensation of glycine 
and succinyl CoA forming 0-aminclaevulinic acid (ALA) (Figure 3)
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FIGURE ? THE PORPHYRIN PRECURSORS
I 0-Aminolaevulinic acid (ALA.) 
II Porphobilinogen (PBG)
via the transient intermediate a-amino-(3~ketoadipic acid 
(Granick and Urata, 1963)» This enzyme, active in the mito­
chondrion, is rate controlling (Lascelles, I964» Levere and 
Granick, 1965) and requires as cofactors pyridoxal phosphate 
(Schulman and Richert, 1956) and ferrous iron (Bro\vn, 1958).
The control of ALA.S activity is mediated mainly by feed­
back regulation by the end product haem, which appears to act 
at a translational level (Sassa and Granick, 1970» Padmanaban 
et al, 1973» London et al, 1976). However, there is evidence 
to suggest that certain steroids can act in a permissive role 
at a transcriptional level (Matsuoka et al, 1968). The turnover 
of ALA.S is also a regulatory factor, the enzyme having a half- 
life of 60 minutes, (Marver et al, I966).
Haem has also been shown to exert a direct inhibitory
effect on ALA.S (Burnham and Lascelles, I963» Whiting and 
Elliot, 1972), although nonphysiological concentrations are 
required for this effect using a partially purified form of 
ALA.S (Schachter et al, 1976).
ALA.S is synthesised on cytoplasmic ribosomes and undergoes
translocation to the mitochcndria (Hayashi et al, 1970) with a
concomitant decrease in molecular weight. This process can also 
be inhibited both in vivo (Kurashima et al, 1970; Hayashi et 
al, 1972) and in vitro (Ohashi and Kikuchi, 1977) by exogenous 
haem although the physiological significance of these results is 
uncertain.
The activity of ALA.S can be altered by treatment with a 
great number of drugs and xenobiotics of which allylisopropyl- 
acetaraide (AIA) and 3,5-dicarbethoxy-l,4-dihydrocollidine (DDC) 
are two classic examples. The majority of these effects however 
are thought to be mediated by changes in intracellular haem 
levels. Possible mechanisms important in this respect are 
utilisation for haeraoprotein synthesis, degradation by haem 
oxygenase or direct chemical degradation.
The mechanisms involved in the regulation of ALA.S activity, 
described above, apply mainly to hepatic tissue. There is 
evidence that the factors involved in such regulation differ from 
tissue to tissue. For example, it has been shown that ALA.S in 
adrenal tissue is refractory to treatment with AIA and DDC which 
markedly increase the activity of the hepatic enzyme and that the 
activity of the liver enzyme does not respond to treatment with 
adrenocorticotrophin (ACTH) which increases the activity of the 
adrenal enzyme (Condie et al, 1976).
Finally it should be noted that ALA.S can be demonstrated in
vitro in bacteria, yeasts, avian and mammalian tissues, but not 
in plants. It would appear that in plants the immediate precursors
of ALA are not glycine and succinyl CoA, hence the inability to
show ALA.S activity, but that cc-ketoglutarate and glutamate 
directly provide the carbon skeleton of ALA (Jurgenson et al,
1976),
1.2.2. 6-AMINOLAEYULINIC ACID DEHYDRATASE
(ALA.D; porphobilinogen synthase; 5-a-minolaevulinate 
hydrolase (adding 5-aminolaevulinate and cyclizing);
E.G. 4.2.1.24)
This, the second enzyme of the pathway, catalyses the 
condensation of two molecules of ALA to form the monopyrrole 
porphyrin precursor porphobilinogen (PBG) (Figure 5) (Shemin, 1976) 
The enzyme is cytoplasmic and activity of the enzyme from 
various sources requires metallic cations (Wu et al, 1974).
ALA.D purified from bovine liver is an octomer with a molecular 
weight of about 30,000 daltons (Wu et al, 1974).
Human erythrocyte ALA.D is very sensitive to inhibition by 
inorganic lead. The inactive enzyme species, however, can be 
reactivated by incubating with reagents providing sulphydryl 
(-SH) groups (Hapke and.Prigge, 1973) suggesting that lead binds 
to the enzyme at -SH groups.
1.2.3. ÜROPORPHYRIHOGEH-1-SYNTHASE/imOPORPHYRINOGEN-III- 
COSYHTHASE
(URO.S; porphobilinogen deaminase; porphobilinogen 
ammonia-lyase (polymerising); E.C. 4.3.1.8/URO.CoS; 
no E.C. number)
The third enzymic step of the pathway is essentially at a 
branch point. Acting alone, URO.S catalyses the formation of 
the functionally inactive symmetrical uroporphyrinogen I 
(Figure 4) from four molecules of PBG. Uroporphyrinogen 1 is not
10
lO
CO
00
&
.Sr4II
n I I I I
LU
Oo
z
cc
>•
X
0.
Xo
O O- (D 0) 0) 
Q O P n C P k S S S S
0 0) -P
0)
VO(Ii(IiPL,pL,PL,PL,S:
O O 0) 0) 0) 0) -P m < i 5 < j S S 2 : s W
0)
'4-^,PL,PL,P4p4>S
O O 0) 0) 0) 0)fo<<siS2:sspH
CMpL,PL,pHpL,>>Pk
u 0 0) 0) 0) 0) 0)
64 rH <; "< S  S s  s  s
0
I M  M  M  M M  M  M  M
Ü2
c I X
W m 0 c M
EC •H
£h 0 Pi c
•H C
c {4 •H
•H A
Pi
g è&0A &•§,
0 p4 0 0 0 Pi
H •H U A Pi A 0
-P 0 0 0 0 A
•H A Pi 'p -P 0
C3 CO 0 A U p m
M 0 k 0 fl5 Pi 0)
pC4 PL, P 0 P A
incorporated into haem and is excreted in its oxidised form as
uroporphyrin I or as coproporphyrin I.
The formation of the functional isomer, the asymmetrical 
uroporphyrinogen III, (Figure 4) requires the concerted action 
of both URO.S and URO.CoS. The mechanism by which this is
effected is still unclear, although it is thought that in the
presence of URO.CoS the primary reaction is as proposed by 
Russell (1974); namely the condensation of two molecules of 
PBG in a ’head to head’ configuration forming an enzyme bound 
dipyrrylmethane (Frydman et al, 1976; Battersby and McDonald, 
1976). Uroporphyrinogen III is then completed by the sequential 
condensation of two further molecules of PBG.
1.2.4. UROPORPHYRINOGEN DECARBOXYLASE
(URO.D; uroporphyrinogen carboxy-lyase; E.C. 4.1.1.37)
URO.D catalyses the ordered sequential decarboxylation of 
uroporphyrinogens I and III although the specificity of the 
reaction is much in favour of the III isomer (Jackson et al, 
1976). As a by-product of the reaction porphyrinogens with 7»
6 and 5 carboxyl groups are produced as well as the product 
coproporphyrinogen (Figure 4). This effect is exaggerated in 
some pathological conditions (Doss et al, 1971) and under in 
vitro conditions (Kushner et al, 1976). There is evidence to 
suggest (Tomio et al, 1970) that all the decarboxylations tsLke 
place on the same enzyme protein, although it can be shown that
hepta-, hexa- and penta-carbcxylic porphyrinogens act as substrate 
for the enzyme (Elder and Tovey, 1977) showing that any proposed 
mechanism need not require the binding of the porphyrinogen 
throughout the four decarboxylations.
1.2.5. COPROPORPHYRINOGEN OXIDASE
(COPRO.O; coproporphyrinogen : oxygen oxidoreductase 
(decarboxylating) ; E.C. 1.3.5.3)
COPRO.O unlike the preceding three enzymes is mitochondrial.
It catalyses the conversion of coproporphyrinogen III in a two 
step process to protoporphyrinogen IX (Figure 4) (Akhtar et al,
1976). As with the decarboxylations from uroporphyrinogen to 
coproporphyrinogen, the enzyme appears to act in a specific 
manner (Jackson et al, 1976) decarboxylating the propionic acid 
on the A ring before that on the B ring. The intermediate 
tricarboxylic porphyrinogen, harderoporphyrinogen (Figure 4) 
does not accumulate to any extent but is found in quantity in 
the harderian gland of certain rodents.
1.2.6. PROTOPORPHYRINOGEN OXIDASE
(p r o t o.0; protoporphyrin IX dehydrogenase; No E.C. number)
The final step in porphyrin synthesis involves the removal of 
six hydrogen atoms from protoporphyrinogen IX forming protoporphyrin 
IX (Figure 4). Under aerobic extraction procedures protoporphyrin 
readily autooxidises and it was originally thought that this occurred
in vivo. The isotope labelling studies of Jackson et al (1974)
provided definite evidence in favour of an enzymic mechanism
for the conversion.
The enzyme responsible (PROTO.O) has been shown to be bound
to mitochondrial membranes (Poulson and Polglase, 1975) and would
appear to contain active sulphydryl groups. Cyanide, 2,4-
dinitrophenol and azide inhibitors of mitochondrial respiration
2+ 24-do not affect the activity of the enzyme while Cu , Co haem 
and haemin all cause inhibition.
1.2.7. FSRROCHELATASE
(FERRO.C; haem synthetase; protohaem ferro-lyase;
E.C. 4.99.1.1)
The final step in haem synthesis is the chelation of ferrous 
ions (Fe^^) with protoporphyrin,a reaction catalysed by the 
enzyme ferrochelatase. The enzyme, particulate in nature, is 
attached to the inner mitochondrial membrane (McKay et al, I969). 
It is not specific for protoporphyrin but can also insert Fe^^ 
into both mesoporphyrin (Llambias, 1976) and deuteroporphyrin 
(Figure 4) (Bonkowsky et al, 1975). The mechanism has not been 
fully elucidated, although the overall reaction is complex 
involving the penetration of substrate into the mitochondrial 
matrix and the transport and reduction of Fe^ "^  to give the 
CO sub strate Fe^ "*".
1.2.8. HAEM OXYGENASE
(HAEM.O; E.C. 1.14.99-3)
Haem catabolism in mammalian systems is catalysed by the 
microsomal enzyme haem oxygenase which cleaves the tetrapyrrole 
ring at the a-methene bridge, with concomitant oxidation, to 
form biliverdin IXa. Intracellular free haem levels control 
the activity of haem oxygenase by substrate mediated induction 
(Pimstone et al, 1971).
The enzyme which was originally thought to be of the mixed 
function oxidase type (Tenhunen et al, 1972) is induced by 
certain trace metals (Maines and Kappas, 1974» 1976a and b; 
Kappas and Maines, 1976). More recent studies have shown that 
haem oxygenase activity can be dissociated from cytochrome P-450 
(Maines and Kappas, 1974)* Maines and Kappas (1977) have 
proposed a mechanism by which haem substrate is bound to the 
enzyme forming a transient haemoprotein which catalyses the 
oxidation of its own prosthetic group. Evidence in favour of 
this mechanism has still to be described.
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1.3. THE PORPHYRIAS
As has been mentioned, the porphyrias are a group of six 
hereditary disorders (cutaneous hepatic porphyria may also be 
acquired) characterised by excessive production and excretion 
of the intermediates in the haem biosynthetic pathway. They 
can be classified according to whether the bulk of the excessive 
porphyrins and precursors is produced in the liver or the bone 
marrow (Table l) or according to the nature of the symptoms 
observed as acute or non-acute.
The acute porphyrias, acute intermittent porphyria (AIP), 
hereditary coproporphyria (HG) and variegate porphyria (VP) all 
exhibit sporadic acute attacks which can be induced by 
endogenous or exogenous influences. Accompanying the acute 
attack, the common biochemical finding is the excretion in the 
urine of the porphyrin precursors ALA and PBG in increased 
amounts. As well, each of the acute porphyrias shows an 
individual pattern of porphyrin excretion. Both HO and VP can 
present in sub-acute phases with the solar sensitivity 
characteristic of the non-acute porphyrias.
The non-acute porphyrias, cutaneous hepatic porphyria (CHP), 
congenital porphyria (CP) and erythropoietic protoporphyria (EPP) 
all show solar sensitivity which has been shown to be due to the 
presence of porphyrins in the skin. As with the acute porphyrias, 
each of the non-acute porphyrias exhibits a characteristic 
pattern of porphyrin excretion which is never associated with 
increased porphyrin precursor excretion.
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TABLE 1 CLASSIFICATION OF THE PORPHYRIAS
ACUTE INTERMITTENT PORPHYRIA
HEREDITARY COPROPORPHYRIA
VARIEGATE PORPHYRIA
CUTANEOUS HEPATIC PORPHYRIA
ERYTHROPOIETIC PROTOPORPHYRIA
CONGENITAL PORPHYRIA
ACUTE
PORPHYRIA
HEPATIC
PORPHYRIA
NON-ACUTE
PORPHYRIA
ERYTHROPOIETIC
PORPHYRIA
It has long been suspected that each of the porphyrias was 
the result of a single enzymopathy and the recent accumulation 
of evidence, reviewed recently by Gajdos (1976) and Brodie et 
al (1977&) has supported this point of view. It would appear, 
however, that the disease process is influenced by many 
extraneous factors, as can be seen from the following review of 
each of the porphyrias.
1.3.1. ACUTE INTERMITTENT PORPHYRIA (AIP)
Acute intermittent porphyria, clinically the most severe of 
the porphyrias is,in most areas, the most prevalent (Goldberg and 
Rimington, 1962). The disease has been shown to be transmitted 
as an autosomal dominant disorder and it is surprising to find 
that in its acute form it affects more women than men. One of 
the main features of the disease is the intermittency of acute 
attacks and it can be distinguished from other forms of porphyria 
by the dominance of gastrointestinal and neuropsychiatrie 
features in the total absence of solar photosensitivity. AIP 
has been the subject of several reviews in the literature 
(Waldenstrom, 1937; Goldberg and Rimington, 1962; Tschudy et 
al, 1975; Boucherat, 1977).
Clinical Manifestations
The clinical features associated with AIP are summarised in 
Figure 3. Most of these can be explained by lesions in various 
areas of the nervous system (Goldberg, 1959), although the
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distribution of the lesions and hence the symptomatology can 
vary from patient to patient. The disease can exist in 
latency though the fundamental abnormality is still present. 
Precipitation of acute attacks can be caused by endogenous 
and exogenous factors and the possible mechanisms of this will 
be discussed below.
Abdominal pain, probably an automomic neuropathy (Tschudy 
et al, 1975) is the presenting symptom in about 85^ of acute 
attacks and almost always precedes a peripheral neuropathy.
Other autonomic manifestations which may be prominent in the 
acute attack include tachycardia, postural hypotension, labile 
hypertension, retinal artery spasm and urinary incontinence or 
retention.
The pattern and rate of progression of the attacks may vary 
greatly. The peripheral neuropathy which may accompany or follow 
abdominal pain may be sensory or motor. Motor neuropathies can 
be symmetrical or localised and may progress over a period of 
weeks or months or can appear explosively resulting in complete 
quadraplegia. Sensory signs and symptoms include paraesthesia, 
numbness and objective evidence of sensory impairment such as 
loss of pinprick sensation.
The pathological nature of the neuropathic lesions is 
uncertain although patchy demyelination has been found at all 
levels of the neuraxis including the autonomic nervous system 
(Ten Eyck et al, I96I). Recently it has been proposed that these 
findings are part of a dying-back neuropathy, the toxic effect
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being exerted at the cell body.
A small percentage of patients may exhibit epilepsy and 
abnormal electroencephalograms have been recorded both in 
patients with and without epilepsy. More common, however, is 
the presence of psychiatric aberrations (Wetterberg, I967) in 
the form of simple neuroses, endogenous depression, schizophrenia 
and various psychoses. Although these symptoms are occasionally 
severe enough to have warranted mental certification, they do 
not appear to last beyond the period of the somatic illness.
The disease is rarely fatal, the most common cause of death 
being respiratory failure, or associated complications.
Biochemical Abnormalities
The most important biochemical finding in AIP is the 
excessive urinary excretion of the porphyrin precursors ALA and 
PBG (Haeger, 1958)• This has been shown in latent subjects as 
well as subjects in attack and in remission. Alternatively 
though,, patients in remission or latent subjects can have 
normal or near normal excretion. Patients in attack have also 
been shown to excrete abnormally high amounts of uroporphyrin.
The abnormality originally thought to be fundamentally 
responsible for the increased ALA and PBG excretion was an 
increase in the activity of the rate controlling enzyme of haem 
biosynthesis - ALA.S (Tschudy et al, 1965). Later work, 
however, has shown this to be secondary to a decrease in hepatic 
URO.S - probably the primary enzymatic defect in AIP (Nakao et
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al, 1966; Dowdle et al, 1967; Strand et al, 1970).
Brodie et al (1977b) have demonstrated decreased URO.D in 
the peripheral blood of patients with AIP providing a possible 
reason for abnormal uroporphyrin excretion which was originally 
thought to be due to non-enzymic polymerisation of PBG.
The observed increase in hepatic ALA.S activity is likely 
to be due to decreased haem formation as a result of the 
partial blockage at the level of URO.S. This in turn would 
lead to derepression of ALA.S. Evidence for depressed haem 
levels has been shown by decreased drug metabolism in patients 
with AIP who showed excessive excretion of ALA and PBG (Song 
et al, 1974; Anderson et al, 1976). Latent patients who showed 
normal porphyrin precursor excretion had normal drug metabolism. 
It appears that in the asymptomatic conditions of latency and 
remission the diminished level of URO.S is partially or 
completely compensated by an increase in ALA.S which results in 
adequate, if not normal, haem formation.
The level of ALA and PBG excretion cannot be correlated with 
ALA.S or URO.S activities and the normal excretion of these 
products in some latents with raised ALA.S and lowered URO.S 
remains to be explained.
Other biochemical abnormalities have been described although 
patients with AIP, essentially a hepatic disorder, usually show 
normal liver function tests. Possibly the most relevant finding 
has been the demonstration of increased excretion of certain
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steroid metabolites (Goldberg et al, 1969; Moore et al, 1973; 
Paxton et al, 1974) and a deficit in steroid 53H reductase 
activity in AIP (Kappas et al, 1972a,b; Bradlow et al, 1976). 
About 40% of patients with AIP have hypercholesteraemia 
(Taddeini et al, I964) and an even greater percentage have 
hyperbetalipoproteinaeraia (Lees, 1970). These findings would 
seem to suggest a common control mechanism for porphyrin and 
lipid metabolism.
Precipitation of the Acute Attack
Acute intermittent porphyria can be present in the latent 
form for an indefinite period and the genetic defect remains 
innocuous until acted upon by superimposing factors. These 
factors, not all exogenous, can be divided into four main 
categories
1. Drugs and xenobiotics
2. Steroids
3. Dietary factors
4 . Infections
One of the first cases of porphyria ever recorded was a fatal 
attack precipitated by sulphonal one year after its introduction 
in 1888. Since then many drugs have been implicated in the 
precipitation of an acute attack. One of the most important 
groups of drugs in this respect is the barbiturates (Tschudy et 
al, 1975).
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Experimental studies in animals and cell culture systems 
have shown that a number of drugs known to precipitate the 
acute porphyric attack can induce ALA.S or an experimental 
form of porphyria in these systems (Granick, 1966; Moore et 
al, 1970; Tschudy and Bonkowsky, 1972; Rifkind et al, 1973)* 
Many of these drugs have also been shown to alter microsomal 
cytochrome P-450 levels (Rifkind et al, 1973) and it is thought 
that the drugs increase ALA.S activity by altering a regulatory 
haem pool causing derepression of ALA.S and that this is the 
mechanism by which they precipitate the acute attack. Direct 
evidence for this is still lacking. The experimental systems, 
however, have proved useful in the screening of drugs for use 
in porphyria, although it has not been proved conclusively that 
drugs which stimulate ALA.S in experimental systems will 
precipitate an acute attack.
Steroid hormones and related steroids comprise the second 
group of precipitating factors. Clinical findings provided 
circumstantial evidence in favour of this; the disease is 
rarely manifest before puberty (Marver and Schmid, 1972) and 
there is an overall predominance of woman sufferers (Goldberg, 
1959), some of whom experience regular pre-menstrual attacks 
(Perlroth et al, 1965) or attacks associated with pregnancy.
Exogenous steroids in the form of the contraceptive pill 
have been shov,Ti to be responsible for the precipitation of an 
acute attack, although in some patients oral contraceptives
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have been shown to be beneficial in the prevention of attacks 
related to menstruation.
Work in experimental systems has shown that certain 
steroids can increase the activity of ALA.S (Granick, 1966) 
especially those, steroids with the configuration (Granick 
and Kappas, 1967a.,b; Kappas and Granick, 1968). This, 
considering the abnormal excretion of steroid metabolites and 
steroid metabolism in the porphyrias (see previous section) 
suggested a role for 53H steroids in the pathogenesis of the 
disease (Kappas et al, 1972a,b). Recent evidence demonstrating 
the equipotency of and 5PH steroids in inducing ALA.S 
(Edwards and Elliot, 1975; Stephens et al, 1977) would cast 
doubts on a specific role of 5pH steroids. However, it 
remains- clear that certain steroids have a porphyrin inducing 
effect related to precipitation of the acute porphyric attack.
The role of dietary factors is less clear cut than that 
of drugs or steroids. Acute attacks have been associated with 
water diets or carbohydrate restriction. Conversely high 
carbohydrate intake has been shown to have beneficial effects 
(Welland et al, 1964; Bonkowsky et al, 1976; Brodie et al, 
1977b). This effect reflects those in experimental animals 
where high carbohydrate diet can prevent induction of ALA.S by 
chemicals (Tschudy et al, 1964; Bonkowsky et al, 1975).
The mechanism of this co-called 'glucose effect' is 
unknown, although there is speculation that it may be due to
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inhibition of RNA formation and thus similar to bacterial 
catabolite repression, or to a blocking of glucocorticoid 
effects (Goldberg, 1974) resulting in altered formation of 
RNA specific for ALA.S and lowering levels of this enzyme.
The final category in this section, infections, is the 
least well understood. Precipitation of the attack may be by 
both bacterial or viral infection (Goldberg and Rimington,
1962-; Tschudy, 1974), although the mechanism is unknown.
The effect may be mediated by"changes in hormone- levels due 
to stress.
Possible Biochemical Origin of the Neuropathy of AIP
As has been said the majority of the clinical features 
of the acute porphyric attack can be explained on the basis 
of an autonomic or peripheral neuropathy. It is surprising 
that, although the fundamental defect in AIP and the 
exacerbation of the acute attack are now well understood, 
the biochemical mechanism of the production of the neuropathy 
remains a mystery. There are a number of theories on the 
possible mechanisms giving rise to the acute attack, but 
there are two of special note because of their simplicity. 
Firstly, that the partial block in haem synthesis is present 
in neural tissue and gives rise to a deficiency of haem which 
results in degeneration and death of the nerve cells or, 
secondly, that the partial block results in elevated circulating
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levels of the porphyrin precursors and that either ALA or PBG 
(or a derivative of them) exerts a direct toxic effect on the 
nerves.
Early studies on the pharmacological properties of the 
porphyrin precursors suggested that they had little or no 
activity (Goldberg et al, 1954; Jarrett et al, 1956).
Clinical evidence in agreement with these results was provided 
by the existence of latent subjects and patients with porphyria 
in remission who excreted large amounts of the porphyrin 
precursors without any adverse effects. In individual 
patients, however, excretion is generally-raised during an 
attack falling again with remission.
More recent studies have shown that both ALA and PBG have 
significant behavioural and pharmacological properties. 
McGillion et al (1973) have shown that ALA causes significant 
changes in the spontaneous activity of mice. It has also been 
shown that ALA can inhibit brain and red cell Na^ K*** dependent 
ATPase (Becker et al, 1971) and that both ALA and PBG can 
affect neuromuscular transmission and motor end-plate 
potentials (Feldman et al, 1971; Loots et al, 1975). Doubt, 
however, has been cast on the significance of these results by 
the recent studies of Percy and Shanley (1977) who have shown 
that ALA and PBG levels in the cerebrospinal fluid (CSF) are 
much lower than those in plasma and well below the levels shown 
to exert effects on neural tissue in vitro.
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There is no direct evidence in favour of the alternative 
hypothesis, that the neuropathy of the acute attack is due to 
a deficiency of haem in neural tissue. It is apparent, however, 
that raised ALA.S activity observed in liver and leucocytes 
(Brodie et al, 1977b) is due to reduced haem levels in these 
tissues and that exacerbation of the acute attack by most 
exogenous agents is due to further depletion of a regulatory 
haem pool. The hypothesis requires that this be true also for 
nerve tissue. Exacerbation of the acute attack by steroids, 
thought to act at a transcriptional level, would possibly 
provide evidence to the contrary. Unless haem levels are also 
lowered by steroids an increase in ALA.S due to steroids would 
be expected to be beneficial. A beneficial effect of steroids 
has, however, been demonstrated in a small number of cases 
(Perlroth et al, I965).
It remains virtually impossible to differentiate between 
the two possible mechanisms based on present knowledge. A 
decrease in haem will almost invariably be associated with 
increased ALA.S activity and increased porphyrin precursor 
excretion. The two therapeutic regimens at present used in the 
treatment of acute phases, high carbohydrate intake and haematin 
infusion both appear to produce beneficial effects associated 
with decreases in porphyrin precursor excretion (Bonkowsky et al, 
1976; Brodie et al, 1977b? Watson et al, 1977). As yet nothing 
is known about the effects of these treatments on tissue haem 
levels.
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One alternative not yet mentioned is that there is another 
substance, possibly a metabolite of ALA. or PBG, which is produced 
during the acute attack possibly resulting in the neuropathy.
As the quantitation of such a substance forms a major part of 
this thesis discussion of this will take place in a later 
section.
1.5.2. HEREDITARY COPROPORPHYRIA (HC)
Hereditary coproporphyria, the second acute hepatic porphyria, 
is characterised as its name suggests by excessive excretion of ' 
coproporphyrin. Like AIP it is transmitted as an autosomal 
dominant. It has been the subject of a recent review (Brodie et 
al, 1977c).
Clinically, the disease usually presents during an acute 
attack which remarkably^resembles that of AIP (Figure 6), 
except that there is also a high incidence of solar photo­
sensitivity which presents as a bullous eruption and skin 
fragility on exposed parts.
The laboratory findings in HC in latency or remission show 
elevated excretion of coproporphyrin in faeces and usually urine, 
with excretion of porphyrin precursors and other porphyrins mainly 
within the normal ranges. During the acute attack, however, 
urinary excretion of coproporphyrin is massively elevated as is 
that of uroporphyrin in a majority of cases. The excretion of 
the porphyrin precursors also becomes grossly elevated in these
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subjects (Brodie et al, 1977c). Enzymatic studies have shown 
that the main abnormality is a decreased activity of COPRO.O 
(measured in leucocytes, lymphocytes and skin fibroblasts)
(Elder et al, 1976; Brodie et al, 1977c; Grandchamp and 
Nordmann, 1977). Secondary to this there is an increase in 
the activity of hepatic ALA.S (Kaufman and Marver, 1970»
McIntyre et al, 1971; Brodie et al, 1977c).
As has been found with AIP, there are a number of reports 
of acute episodes being precipitated by the administration of 
drugs (including barbiturates), or steroids, or by calorific 
restriction. This would suggest that the precipitation occurs 
by the same mechanism as in AIP which in turn suggests that the 
development of the acute manifestations common to both disorders 
occur in the same manner. The excretion of ALA and PBG in the 
acute attack in the absence of a deficiency in PBG.D remains to 
be explained. It has been proposed that in the attack situation, 
where there is induction of ALA.S, the flow through the pathway 
becomes so’great (reflected by massive excretion of coproporphyrin) 
that the activity of ÜRO.S becomes limiting, resulting in 
excretion of ALA and PBG (Brodie et al, 1977&).
The occurrence of photosensitivity, probably due to the 
presence of porphyrin in the skin, will be discussed under 
erythropoietic protoporphyria where it is the main presenting 
feature.
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1.3.5. VARIEGATE PORPHYRIA (VP)
Variegate porphyria, like the other hepatic porphyrias, is 
transmitted as an autosomal dominant. In South Africa, where 
the disease is most common, the genetic trait can be traced for 
almost 500 years. The disease can present with an acute attack, 
which is similar to those of AIP or HC, or with solar photo­
sensitivity without any gastrointestinal involvement.
The biochemical picture in latency and remission is of 
minor increases in the urinary excretion of uroporphyrin and 
coproporphyrin with major elevations in faecal coProporphyrin, 
protoporphyrin and a characteristic porphyrin-peptide conjugate, 
(X-porphyrin) (Goldberg, 1971).
Acute attacks are invariably associated with increases in 
the excretion of ALA and PBG along with massive porphyrinuria. 
Severe bouts of photosensitivity have been reported, in which 
faecal excretion of porphyrins is reduced, with elevation of 
urinary uroporphyrin and coproporphyrin (Dean, 1965).
Dowdle et al (1967) have reported an increase in hepatic 
ALA.S in VP and the porphyrin excretion pattern would suggest a 
partial block in haem synthesis in conformity with the other 
acute porphyrias. Evidence for this has been provided by Becker 
et al (1977) who have shown a decreased activity of ferrochelatase 
in bone marrow lysates from patients with VP in agreement with 
earlier work in two subjects by Brodie et al (1976).
It is clear that VP can be provoked into an acute attack
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similar to those of AIP and HC (Lyberatos et al, 1976; Percy 
and Shanley, 1977) by misuse of certain drugs. However, the 
acute photosensitive bout, which is free from gastrointestinal 
features (Dean, 1965), may be associated with gross 
abnormalities in liver function and in that case be more 
similar to the non-acute type of porphyria, cutaneous hepatic 
porphyria (section 1.5.4.)*
1.5.4. CUTANEOUS HEPATIC PORPHYRIA (CHP)
Known also as porphyria cutanea tarda (PCT) or symptomatic 
porphyria, CHP is perhaps the most perplexing of the porphyrias. 
It is apparent that the disease can be caused by toxic liver 
damage as seen in an outbreak in Turkey following ingestion of 
hexachlorobenzene contaminated wheat (Schmid, I96O), or it may 
also be hereditary (Dehlin et al, 1973; Kushner et al, 1976).
The main biochemical findings are faecal excretion of 
coproporphyrin and protoporphyrin during remission and excretion 
of uroporphyrin and to a lesser extent coproporphyrin in the 
urine during acute phases.
The acute phases which present with solar photosensitive 
skin lesions are precipitated in the vast majority of cases 
by alcohol intake (Pimstone, 1975), although oral contraceptive 
steroids (Haberman et al, 1975) or barbiturates (Ziprkowsky, 
1966) have been implicated. Liver disease is invariably 
associated with the manifest disease as is siderosis which has
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been implicated in the derangement of haem biosynthesis 
(Kushner et al, 1975)*
Enzymatic studies have given inconsistent results.
However, Kushner et al (1976) and Elder and Tovey (1977) have 
demonstrated decreased hepatic activity of uroporphyrinogen 
decarboxylase which may account for the porphyrin excretion 
pattern in acute" phases. ALA.S has been shown to be raised (Moore 
et al, 1972) providing evidence in favour of a partial block 
as in the other hepatic porphyrias.
It remains clear that liver disease and siderosis- are 
important cofactors in the relapse of the disease involving 
diversion of formed porphyrins into the systemic circulation 
resulting in photosensitivity. Remission can be achieved by 
the treatment of the siderosis by venesection (ippen, 196I).
1.5,5. ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
EPP, the more common of the two erythropoietic porphyrias, 
is, like the hepatic porphyrias, transmitted as an autosomal 
dominant with variable penetrance.
The main biochemical findings are of raised faecal 
protoporphyrin excretion with high protoporphyrin content in 
circulating erythrocytes. The enzymatic defect has been traced 
to ferrochelatase, decreased activity being found in liver and 
cultured skin fibroblasts (Bonkowsky et al, 1975). More 
recently Becker et al (1977) have shown that ferrochelatase in
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bone marrow lysates is unstable, differentiating the abnormality 
from VP (section 1.3.5) where the ferrochelatase is probably 
inactive.
The main clinical feature is solar photosensitivity due to 
protoporphyrin in the blood (Piomelli et al, 1975) and hence 
skin. In later stages protoporphyrin deposition in the liver 
can result in progressive liver disease (Bames et al, 1968? 
Donaldson et al, 197%). The photosensitivity which is manifest 
as burning, local oedema, pruritus, and erythema in most cases, 
can also show skin pain and residual scarring (de Leo et al,
1976).
Experimental studies into the mechanism of the photoreaction 
have revealed that light of 400nm is most active, a wavelength 
close to the Soret maximum of porphyrin absorption (Magnus et al, 
1961). Laboratory models have shown that photosensitivity is an 
oxygen dependent process involving singlet oxygen (^Og)
(Pugimori et al, 1966); thus the effect is probably due to 
porphyrin sensitised photooxidation of cell components. This 
role of singlet oxygen is also suggested by the protection in 
experimental systems afforded by treatment with oc-tocopherol 
which quenches singlet oxygen (Moshell and Bjornson, 1977).
The treatment of choice in EPP is with 3-carotene which 
quenches singlet oxygen as well as absorbing light at 400nm.
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1.3.6. CONGENITAL PORPHYRIA (CP)
Congenital porphyria, mentioned for fullness, is the most 
rare of the porphyrias and, in contrast to the others, is 
transmitted in a recessive fashion. The characteristic finding 
of excessive excretion of the biologically inactive series I 
porphyrin isomers has led to the belief that the genetic 
abnormality in this condition is a deficiency or a relative 
deficiency of uroporphyrinogen cosynthetase (Miyagi et al,
1976; Brodie et al, 1977a).
28
1.4. MONOPYRROLES IN PORPHYRIA AND OTHER DISORDERS
Interest in the association of monopyrroles with acute 
porphyria arose with the discovery by Cookson and Rimington 
(1953) of the pyrrolic nature of one of the abnormal metabolites 
in AIP, namely porphobilinogen. The occurrence of PBG has been 
fully documented following the establishment of a quantitative 
assay for it (Mauzerall and Granick, 1956).
Evidence for the excretion of a second pyrrolic metabolite 
in AIP was provided in 1972 (Irvine and Vetterberg; Huszak et 
al). This metabolite, originally discovered by Irvine (196I), 
was termed "mauve factor" due to its colour reaction with 
Ehrlich’s reagent. The identification of "mauve factor" proved 
difficult due to its sensitivity to mild treatment. However, it 
was shown that it was not artifactual in origin (Schler et al,
1970).
Prior to its discovery in the urine of porphyric patients 
an association between "mauve factor" excretion and psychiatric 
illness had been made (O'Reilly et al, 1965; Ellman et al, 
1968). Typically the factor was shown to be present in up to 
50% of endogenous psychoses (Hoffer and Osmond, I963); 60 -
70% in acute schizophrenia (Schler et al, I967) and 60fo of 
schizophrenics who showed excessive porphyrin excretion (Huszak 
et al, 1972). As well as being found in AIP mauve factor 
excretion has also been shown in patients with CHP (Huszak et 
al, 1972) and VP (Irvine and Wilson, 1976).
As much of the work of this thesis is concerned with the
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quantitation of the mauve factor and with biochemical and 
pharmacological effects of this and related substances, 
work leading to its eventual identification will be covered 
in some detail here. Also covered will be previous 
pharmacological and behavioural studies which have been 
reviewed recently (Irvine, 1974).
1.4,1. IDENTIFICATION OF MAUVE FACTOR
Mauve factor was originally discovered by Irvine in the 
urine of schizophrenic patients using a chromatographic method 
that suggested it was an alkyl pyrrole. Using a more powerful 
chromatographic method following charcoal precipitation Irvine 
et al (1969) were able to resolve the mauve factor into five 
separate entities which if eluted and reprocessed would again 
give rise to all components. Mass spectrometric analysis of a 
single component spot showed a molecular ion that was suggestive 
of a mono-ethyl dimethyl pyrrole. This led to the processing of 
one such alkyl pyrrole, kryptopyrrole (2,4-dimethyl-3-ethyl- 
pyrrole) (Figure 7)» which produced a pattern of spots identical 
to that of the natural product. These findings led to the 
hypothesis that the "mauve factor" was essentially due to 
kryptopyrrole, an observation made independently by Sohler et
al (1970).
In an attempt to identify the component substances, the 
oxidation products of kryptopyrrole were synthesised (Lightner
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FIGURE 7 HETEROLOGOUS ALKYL PYRROLES
I 2,4-Dimethyl-3-ethylpyrrole (Kryptopyrrole)
II 2,3-Dimethyl-4-ethylpyrrole (Haemopyrrole)
III 4-Ethyl-2,5f5-trimethylpyrrole (Phyllopyrrole)
IV 3-Ethyl-4-methylpyrrole (Opsopyrrole)
and Crandall, 1973) (Figure 8). The chromatographic processing 
of these compounds showed that all of the five component spots 
could be produced from compounds II and III, and that inter­
conversion was due to acid used in the chromatographic 
separation (Irvine et al, 1973)* It was also shown that II 
could give rise to III when methanol was used for the extraction 
of the charcoal. This suggested that compound II, 4-ethyl-5- 
hvdroxv-3. S-dimethvl- -nvrrolin-2-one OHKPL was the primary 
compound and that the others were by-products produced during 
extraction or chromatography. This conclusion was supported by 
the work of Jacobson et al (1975) who were unable to demonstrate 
the presence of the parent pyrrole, kryptopyrrole, in the urine 
of schizophrenic patients using a sensitive gas-liquid chromato­
graphy - mass-spectrometry method.
As was said, however, the original mass spectrometric 
evidence suggested a mono-ethyl dimethyl pyrrole and, as has 
since been recognised, the subsequent methodology was not 
specific enough to differentiate between the oxidation products 
of kryptopyrrole and those of the (33’ isomer of kryptopyrrole, 
haemopyrrole (2,3-dimethy1-4-ethyl pyrrole) (Irvine and 
Wetterberg, 1972) (Figure 7).
It was not until recently that the development of improved 
extraction and chromatographic methods allowed unambiguous 
differentiation of the two isomeric forms (Irvine and Wilson, 
1976). Comparison of the synthetic oxidation products of
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FIGURE 8 KRYPTOPYRROLE AND ITS OXIDATION PRODUCTS
I 2,4-Dimethyl-3-ethylpyrrole (Kryptopyrrole)
II 4-3thyl-5-hydroxy-3,5-dimethyl-4^?-pyrrolin-2-one (OHKPL) 
III 4-Ethyl-5-methoxy-5,5-dimethyl-/\^_pyrrolin-2-one
rv 4-Ethyl-3-hydroxy-3,3-&imethyl-4^f-pyrrolin-2-one
kryptopyrrole and haemopyrrole and the natural product has 
allowed the final structural assignation to be made as
3-ethvT-S-hvdroxv-4.S-dimethvl-/\^-pyrrolin-2-one (Figure 9)» the 
oxidised form of haemopyrrole. In the work that is covered 
in this thesis this will be the substance referred to as 
the natural product usually abbreviated to OHHPL (see 
nomenclature section).
1.4.2. PHARMACOLOGY AND- BEHAVIOURAL PIL'^ EJiACOLOGY OF 
MONOPYRROLES RELATED TO 3-2THYL-5-HYDR0XY-4,5- 
DIMETHYL-/^-PYRR0LIN-2-0NE ( OHHPL)
It was not until recently that the mauve factor was finally 
identified and so most of the work in this area has been 
concerned with the effects of kryptopyrrole and, to a lesser 
extent, oxidation products of kryptopyrrole. There is a very 
close structural similarity between the oxidised forms of 
kryptopyrrole and the natural metabolite and it may not be 
unjustified in suggesting that they have properties in common. 
Furthermore, it has been shown that kryptopyrrole is metabolised 
oxidatively by microsomal enzymes in the rat, the sole product 
being the 33’isomer of OHHPL, namely OHKPL (Irvine, 1974)« This 
would imply that, where experiments are carried out with krypto­
pyrrole over an extended period using living animals, the 
possibility exists that the effects may be due to the metabolite 
and not the kryptopyrrole itself.
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FIGURE 9 HAMOPYRROLE AND ITS OXIMTION PRODUCTS
I 2,3-Dimethyl-4-ethylpyrrole (Haemopyrrole)
II 5-ethyl-5-hydroxy-4.5-dimethvl- -t>vrrolln-2-one (OHHPL)
III 3-ethyl-5-methoxy-4, S - d i m ethvl--pvrrolin-2-one
IV 3-ethyl-3-hydroxy-4,5~dimethyl-,^-pyrrolin-2-one
The toxicity of kryptopyrrole has been studied extensively 
and it has been found to be abnormally h i ^  among a series of 
related pyrroles (Moffett, 1968). Toxic effects were most 
obvious in the central nervous system, the lung and pleural 
cavity and the eye and orbital region. It has been found to 
have anticonvulsant properties in experimental animals, both 
in electrically provoked seizures in rats (Moffett, 1968) and 
in photically induced seizures in Fayoumi fowl, a species 
susceptible to seizures (Irvine et al, 1973)*
Neuroelectrical studies have shown that in non-toxic 
doses kryptopyrrole causes profound changes in electroence­
phalograph (EEG) patterns and activity, which bear resemblance 
to the EEG patterns seen with psychotomimetic agents such as 
LSD (Walker, 1975). -
One significant pharmacological effect of kryptopyrrole 
is its ability to induce hypothermia in experimental animals.
A recent study using the oxidised forms of kryptopyrrole, 
compounds III and IV (Figure 8) (Wetterberg and Formgren,
1976) showed that compound IV elicited a greater hypothermic 
effect than kryptopyrrole and was at least as toxic as 
kryptopyrrole, while compound III showed a lesser hypothermic 
effect and lower toxicity. The number of animals (mice) used 
in this study was, however, very small.
The behavioural effects shown with kryptopyrrole are a 
reduction in exploratory behaviour and general activity
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associated with huddling.
Other behavioural studies designed to look at the 
effects on established performance; fixed ratio responding 
to food reinforcement (Irvine and Zdanivsky, 1971) and 
discriminated avoidance (Zdanivsky and Irvine, 1972), 
revealed that kryptopyrrole showed effects similar to LSD 
in the former test, while in the latter showed effects 
intermediate between amine depletors (e.g. p-chorophenyl- 
alanine) and psychotoraimetics (e.g. LSD, mescaline). In 
long term studies using the second test, kryptopyrrole 
showed effects that were identical to psychotomimetics.
1.4.3. IMPLICATIONS OF THE EXCRETION OF OHHPL IN 
THE PORPHYRIAS. .
As has been discussed in the foregoing sections, the 
origin of the psychiatric syndrome of the acute porphyric 
attack is as yet unknown, although it is suspected that it 
is due to a lesion in the CNS, just as other features of the 
attack are due to lesions elsewhere in the nervous system. 
Attempts to relate the biochemical abnormalities to the 
clinical condition have all but failed. The only biochemical 
finding common to the three acute porphyrias during an attack 
is the excessive excretion of the porphyrin precursors ALA and 
PBG and up to date there have been no conclusive findings 
which would implicate either of these compounds in the
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generation of the neural lesion responsible for the psychiatric 
disturbance.
The finding that there is excessive excretion of a second 
monopyrrole in acute porphyria, a substance also excreted in a 
high percentage of cases of psychoses, presents the possibility 
that this substance is the materia peccans responsible for the 
clinical features of acute porphyria. As yet this is purely 
hypothetical as evidence in favour is completely lacking. In 
the past investigations have been carried out using related 
substances and extrapolation of results may prove fallacious.
As there has been no satisfactory method available for the 
quantitation of OHHPL, its role in the porphyrias remains to 
be determined. With this in mind the work covered in this 
thesis was designed with_two objectives
1. To develop a satisfactory method for the quantitation 
of OHHPL in biological material in order to investigate 
any relationships between these results and clinical 
findings.
2. To investigate selected biochemical and pharmacological 
effects of OHHPL and related compounds in experimental 
situations.
It is hoped that these studies will be able to give some 
insight into the possible role of OHHPL in the aetiology of 
the manifestations of the porphyrias and in particular of 
the psychiatric syndrome.
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C H A P T E R  2
MATERIALS -AND GENERAL METHODS
CHAPTER 2
MATERIALS AND GENERAL METHODS
2.1. MATERIALS
Radiolabelled chemicals, 4-^^C ALA and 2-^^C glycine were 
obtained from the Radiochemical Centre, Amersham, Bucks., 
England. ^^Fe was obtained from the radionuclide dispensary, 
Glasgow Western Infirmary, Glasgow, Scotland. Non-labelled 
ALA was supplied by Koch Light Laboratories Ltd., Colnbrook, 
Bucks., England. Kryptopyrrole was supplied by the Aldrich 
Chemical Company, Gillingham, Dorset, England. Silica gel 
from the Merck and Woelm ranges was obtained through BDH., 
Poole, Dorset and Koch Light Laboratories respectively.
A sample of OHHPL was a kind gift from Dr. D.G. Irvine, 
University Hospital, Saskatoon, Saskatchewan, Canada, while 
porphyrin standards were either obtained from the Sigma 
Chemical Company, London, England, or prepared and kindly 
donated by Mr. G.G. Thompson, Department of Materia Medica. 
University of Glasgow, Scotland.
Supplies of chemicals, packings, supports, spares etc. 
for the gas-liquid chromatography work were obtained from 
Field Instruments Ltd., Richmond, Surrey, England.
Enzymes and co-enzymes were obtained from BDH and other 
chemicals and reagents of the appropriate grade were obtained 
from BDH, Aldrich Chemical Company or Koch Light Laboratories.
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Experimental animals were supplied by the Tuck Animal 
Breeding Centre, Battlesbridge, Essex, England.
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2.2. NOMENCLATURE OF MONOPYRROLES
The systematic naming of the pyrroles encountered, in this 
thesis is, in most cases, long and unwieldy and unfortunately 
not all have well known trivial names.
One of the most important biological pyrroles, 2-amino- 
methyl-4-2’-carboxyethyl-3-carboxymethyl pyrrole, is 
universally known as porphobilinogen, a name created by 
Waldenstrom (Waldenstrom and Wahlquist, 1939) prior to the 
elucidation of its structure by Cookson and Rimington (1953)•
The four heterologous pyrroles (Figure 7), haemopyrrole, 
kryptopyrrole, phyllopyrrole and opsopyrrole, were all 
isolated as major reduction products of natural substances 
such as haemin, bilirubin or green chlorophyll (Sidgwick, 1966) 
The four trivial names-reflect their isolation from these 
substances.
Trivial names for the oxidised forms of kryptopyrrole and 
haemopyrrole (Figures 8 and 9 ) are not arrived at with such 
ease, but tend to reflect the expediency of normal usage.
Those oxidised forms with a ketone group at position 2 are 
essentially lactams as the adjacent secondary amine allows 
lactam - lactim tautomerism. Compounds II and IV in Figures 8 
and 9 are then hydroxy-lac tarns of kryptopyrrole and haemo­
pyrrole respectively. Compounds III are methoxy lactams. The 
5-hydroxy compounds, the compounds of interest, will thus be 
denoted as OHHPL and OHKPL (hydroxy-haemopyrrole lactam etc).
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Where the 3-bydroxy or 3-methoxy species arise in the text, it 
will be made clear to which compound reference is being made. 
This will be done using the serai-systematic forms 3-hydroxy- 
haemopyrrolin-2-one (OHHPL), 3-hydroxyhaemopyrrclin-2-one, 
5-methoxyhaeraopyrrolin-2-one etc. or by reference to Figures 
0 and 9»
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2.3. SYNTHESIS OF MONOPYRROLES
The unavailability of a suitable commercial supply for 
certain pyrroles, or in the case of porphobilinogen a suitable 
radioactive form, necessitated the production of such material 
by organic syntheses or biosynthetic methods.
2.3.1. BIOSYNTHETIC PREPARATION OF PORPHOBILINOGEN
Porphobilinogen was produced enzymically from ALA using a 
purified preparation of ALA.D from bovine liver.
The product was isolated, purified and crystallised from 
the assay mixture by the method of Cookson and Rimington (1954) 
Radiolabelled PBG was produced in an identical manner by 
spiking the substrate ALA with specifically labelled 4-^^C ALA.
Purification of ALA.D
A whole bovine liver was obtained from the abattoir as 
soon as possible following slaughter. Portions were diced and 
homogenised, using a domestic blender, in 0.15M potassium 
chloride buffered with 0.02M potassium phosphate (pH 6.8) 
containing ImM 2-mercaptoethanol. The homogenate was then 
spun at 2,500g for 45 minutes.
The supernatant was then heated to 60°C for five minutes 
with constant stirring, followed by rapid cooling on ice. The 
solution was then spun at 2,500g for 20 minutes and the 
resultant deep red supernatant retained.
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24.7g of ammonium sulphate was then added per 100ml and 
any resultant precipitate removed by centrifugation. A 
further 10.6g of ammonium sulphate was then added per 100ml 
and the resultant precipitate spun down and retained (may be 
stored at -25^0).
The precipitate was dissolved in 0.05M potassium phosphate 
(pH 6.8) containing ImM 2-mercaptoethanol to give a protein 
concentration of 20 - 30mg/ml. This solution was then heated 
to 72 - 74°C for 3 minutes, then chilled on ice. The super­
natant obtained following centrifugation (2,500g) was dialysed 
for 15 hours in O.O5M potassium phosphate (pH 6.8) containing 
ImM 2-mercaptoethanol. The inactive precipitate was then spun 
down (10 minutes, 2,500g) leaving a slightly turbid green 
enzyme solution.
Enzyme Incubation
The protein concentration of the purified enzyme prep­
aration was determined and adjusted to 20mg/ml with sodium 
phosphate buffer, pH 6.0,0.03M. 1.6ml of this solution was
then added to 6.6ral of sodium phosphate buffer, pH 6.8, O.IM, 
containing ALA and L-cysteine both in a final concentration 
of O.625M. The reaction mixture in a lead-free Thunberg 
tube was then degassed, the tube evacuated and the reaction 
incubated for 17 hours.
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Isolation of Porphobilinogen
The reaction mixtures were decanted into flasks containing 
mercuric acetate solution (l5% ^/v) and brought to ph 4 - 4*5 
with acetic acid. Further mercuric acetate was added until all 
porphobilinogen was precipitated (negative Ehrlich reaction of 
the supernatant)• The precipitate was collected on a Buchner 
funnel and washed with mercuric acetate (l% */v). The 
precipitate was then suspended in water and decomposed by- 
bubbling with hydrogen sulphide gas. After filtration and 
aeration, excess of lead acetate (lO^ ^/v) was added. The 
deeply pigmented precipitate was removed and washed repeatedly 
with lead acetate solution (l^ ^/v). Silver nitrate solution 
(20^ ^/v) was added to the combined filtrate and washings 
until precipitation was complete. After filtration and 
washing of the precipitate with silver nitrate solution (l%
^/v) the combined filtrate and washings were treated, without 
prior removal of lead or silver ions, with a slight excess of 
mercuric acetate solution (15^ */v). This mercury precipitate, 
almost white, was collected by centrifugation and decomposed by 
bubbling with hydrogen sulphide gas without the addition of 
further fluid. Mercuric sulphide was easily removed by 
centrifugation from the pale yellow supernatant, which was freed 
from hydrogen sulphide by aeration and then adjusted to pH 4 
with aqueous ammonia. PBG crystallised immediately in 
almost colourless, well formed, crystals. After chilling.
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the solution was filtered and the crystalline PBG washed first 
with water containing a little acetic acid, and then with 
acetone. Further quantities could usually be obtained by the 
same method by extracting the final mercuric sulphide 
precipitate with a little water. Yields were about 60^.
Radiolabelled Porphobilinogen
Radiolabelled labelled PBG was produced by the same method
except that 300^ iCi of ALA was added to 1.2g ALA over 40
reaction tubes. The product obtained (lOOmg; 56^) had a
specific activity of 2.08 x 10^ cpm/mg or 0.508 x 10^ cpm/pmol.
The purity was checked by paper chromatography on Whatman 3MN
paper using the upper layer of a butanol:acetic acid:water
(4:1:5) mixture for development. A second method of analysis
was the estimation of the PBG content of a solution of the
product by the standard PBG assay (section 2.4.2). In both
cases the purity was found to be greater than 96.5^*
*
2.3.2. PREPARATION OF ALKYL PYRROLES 
Haemopyrrole (2,3-dimethyl-4-ethylpyrrole)
Haeraopyrrole was synthesised essentially by the method of 
Rapoport (1976) following the scheme in Figure 10. The 
starting material ethyl propionylacetate was synthesised 
according to Ellis et al (1964).
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FIGURE 10 ORGANIC SYNTHESIS OF HAMOPYRROLE
1. HNO_; 2. Zn, HOAc; 3. CH,COCH^CO^
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Diethyl Prc-pionylmalonate - Magnesium turnings (67g), 
ethanol (67ml), carbon tetrachloride (3ml) and 80ml of a 
solution of diethyl malonate (410g) in ethanol (205ml) 
were warmed gently until the evolution of hydrogen began.
The remainder of the diethyl malonate was added slowly to 
maintain the reaction rate. 1550ml of dry ether was added 
when the reaction mixture had cooled and heating restarted 
till the magnesium had all dissolved. Propionyl chloride 
(250ml) in dry ether (270ml) was added slowly, then the 
mixture heated under reflux for 1 hour. The cooled 
magnesium complex was then decomposed carefully with excess 
ice-cold dilute sulphuric acid. Ether extraction and 
distillation gave diethyl propicnylmalonate (400g; 72%),
bp. 199°C/7é0mm.
Ethyl Propionylacetate (l) - Diethyl propicnylmalonate
(265g) was hydrolysed by boiling with water (655ml). 600ml
of water was then distilled off over 4*5 hours. The organic 
fraction in the residue was separated and the two aqueous 
fractions combined and extracted with ether (2 x 200ml).
The organic fractions were combined (with product) and 
washed with saturated sodium bicarbonate (50ml), water 
(4 X 50ml), saturated sodium carbonate (4 x 25ml), water 
(5 X 25ml), dilute sulphuric acid (2 x 25ml) and finally 
with water (4 x 50ml). Evaporation and distillation gave 
ethyl propionylacetate (l50g; 79%), bp. 100 - 120°C/20 - 30mm.
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Diethyl 5-ethyl-5-methyluyrrole-2,4-dicar'boxylate (ll) - 
Sodium nitrite (75g) in water (135ml) was added slowly to ethyl 
propionyl acetate (l50g) in acetic acid (380ml) with cooling so 
that the temperature was maintained below 5°C. When addition 
was complete the temperature was allowed to rise to room 
temperature overnight. This solution was then run slowly with 
stirring into ethyl acetoacetate (l35g) and acetic acid (380ml), 
a mixture of zinc dust (l75g) and anhydrous sodium acetate 
(l80g) being added simultaneously at 60 - 80°C. When addition 
was complete the temperature was raised to 100°C for an hour 
then the mixture was decanted into ice and water (lOL). The 
product was filtered, water washed and recrystallised as
needles from ethanol (l06g; 47%)» mp. 113 - 115°C.
Ethyl 3-ethyl-4-carboxy^5-methylpyrro1e-2-carboxylate (ill) - 
In a IL 3-necked flask fitted with a nitrogen bubbler-capped 
reflux condenser and magnetic stirring bar, were added 182ml of 
concentrated sulphuric acid (96 - 98%) and 40ml of 5^50^.20% 
SO^. When the temperature fell to 30°C diethyl 3-ethyl-5- 
methylpyrrole-2,4-dicarboxylate (llOg) was added .over 10 
minutes. The flask was then heated to 40°C for 20 minutes.
The contents were then decanted into ice (3L) and left over­
night. The resultant brown precipitate was purified by twice
boiling with IL of methanol giving 55g; (56%), mp. 250 - 255°C
(dec.).
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Ethyl 5-ethyl-4.5-dimethylpyrrole-2-carboxylate (IV) - 
To a IL 3-necked flask with a nitrogen bubbler capped precision 
addition funnel containing ca. 150ml redistilled diglyme was 
added 10.5g of sodium borohydride. The solution was stirred 
then cooled in an ice bath. Slowly over 3 hours 42.5g of methyl 
iodide was added and 30 minutes after the addition was complete 
22.5g of ethyl 3-ethyl-4-carboxy-5-methylpyrrole-2-carboxylate 
was added in one portion with ice cooling. After 120 minutes 
methanol was added to the reaction mixture till no more 
hydrogen was evolved. The solvent was then removed overnight 
by freeze drying. The residue obtained was partitioned 
between ether and water. The aqueous fraction was washed 
twice with ether (100ml) and the ether fractions combined, 
washed with water, dried with magnesium sulphate, filtered 
and evaporated to give crude product which was recrystallised 
from ethanol/water to give 7g (35%)» mp. $6 - 97°C.
2.3-Dimethyl-4-ethyTpyrrole (Haemopyrrole) (V) - To a 250ml
round bottomed flask with nitrogen bubbler capped reflux 
condenser was added 175ml triethylene glycol (trigol), 5*6g 
potassium hydroxide and 7g ethyl 3-ethyl-4,5-dimethylpyrrole-
2-carboxylate. The flask was heated at l65°C for 18 hours in 
the dark. When the reaction was complete the mixture was 
cooled on ice, extended with 75ml deoxygenated water, then 
extracted (x4) with 75ml diethyl ether under a safe light.
The combined ether extracts were washed with 30ml aliquots of
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deoxygenated water till neutral. The ether was evaporated 
under reduced pressure to ca. 10ml and the product 
crystallised at -25°C, (4g; 90%).
Phyllopyrrole (2.3.5-trimethyl-4-ethylpyrrole)
Phyllopyrrole was prepared by a method analogous to that 
for haemopyrrole. Acetylacetone was condensed with butanedione 
moncxime, in a reaction similar to the formation of II above 
(Knorr pyrrole condensation) giving 2,3,5-trimethyT-4-acetyl- 
pyrrcle. • The product was formed by the standard Huang-Minlon 
modification cf the Wolff-Kishner reduction (Vogel, 1970).
The pyrrole ketone was refluxed in digol with 5 equivalents 
of hydrazine hydrate for 1 hour to form the hydrazone. Water 
and excess hydrazine was then distilled off until a temperature 
of 170 - 190°C was attained and reflux continued for a further 
5 - 5  hours. The product was collected by ether extraction 
from the cooled reaction mixture.
Opsopyrrole (3-ethyl-4-methyluyrrole)
This was again prepared by a method similar to the 
preceding two. The product, however, proved rather unstable 
and was unsuitable for extended storage and subsequent animal 
experiments and was therefore omitted from the series.
2.3.3. SYNTHESIS OP OXIDISED ALKYL PYRROLES
The purposes of study required the synthesis of two oxidised
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pyrroles, oxidised forms of kryptopyrrole and haemopyrrole.
These compounds, the 2-ketc-5-hydroxy forms (OHKPL and 
OHHPL) were synthesised by photooxidation by methods based 
on those of Lightner and Crandall (1973) snd Lightner et 
al, 1974.
4-ethyl-5-hydroxy-3.5-dimethyl--pyrrolin-2-one (OHKPL)
A 0.1% C/v) solution of kryptopyrrole in methanol 
containing 3*5mg/l00ml Rose Bengal (^ i^g sensitizer) was 
illuminated in a glass cylinder maintained at 15°C by water 
cooling. The light source utilized was three lOOw tungsten 
bulbs situated at 10cm from the apparatus. A slow stream 
of oxygen was bubbled through the mixture during the oxidation 
procedure. The process was stopped when aliquots no longer 
gave a rapid positive reaction with an Ehrlich reagent 
(2% p-aminodimethylbenzaldehyde in methanol : HCl (9:l)).
At this point the solvent was removed by rotary evaporation 
below 40^0. The residue was taken up in a small volume cf 
chloroform and column chromatographed on silica gel, (column: 
2.5cm X 35cm; silica gel 40, E. Merck, Darmstadt, 70 - 230 
mesh ASTM) using chloroform, diethyl ether, ethyl acetate and 
acetone. A more complete separation of the eluted material 
in the ethyl acetate fraction was obtained by partition thin 
layer chromatography (tic) on silica gel (Silica gel P, M. Vcelm, 
Eschwege, 1mm, diethyl ether) to give three main components 
(Figure 8); II (R^ 0.11), III (R^ 0.45) and IT (R 0.32).
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These could be visualised if required by spraying with 
Ehrlich reagent and heating to 60°C. The required product 
was recovered from the tic plates by scraping off the 
required region, eluting it with acetone, evaporating the 
solvent and recrystallising from ethyl acetate.
The yields of products obtained were variable. However, 
OHKPL (ll) was always the major photo-product. Typical 
values were II 25 - 35%» III 8 - 12%, IV 5 - 15%»
The eluted fractions from the chromatography column 
were also analysed by gas-liquid chromatography. Five 
microlitres were injected on to the column and the fractions 
containing components II, III or IV retained for further 
purification. The purity of the final product was also 
checked by glc on the same column and found to be in excess 
of 9994.
3-ethyl-5-hydroxy-4.5-dlmethy1 - /v-nyrrolln-g-one (OHHPL)
This was produced essentially by the same method as used 
for OHKPL using haemopyrrole as starting material. The 
residue from photooxidation was taken up in a small volume of 
ethyl acetate for column chromatography on silica gel (column 
2.5 X 35cm; silica gel 70 - 230 mesh, M. Woelm, Eschwege) 
using ethyl acetate and ethyl acetate/acetone (60 : 40). The 
eluted fractions were again examined by glc for the main 
oxidation products (Figure 9; II, III and IV) and further 
purification carried out by partition thin layer chromatography
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(silica gel F, M. Woelm, Eschwege, 1mm, diethyl ether); II 
(R^ 0.09) III (R^ 0.25) and IV (R^ 0.43). Yields obtained 
were very similar to those obtained in the photooxidation 
of kryptopyrrole.
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2.4. PORPHYRIN PRECURSORS AND PORPHYRINS
2.4.1. 5-AHINOU BVULINIC ACID
ALA was measured in the urine by the method of Mauzerall . 
and Granick (1956).
ALA was removed from a PBG-free urine fraction by 
retention on an acidic cation exchange resin. After elution 
from the resin the ALA was condensed with acetylacetone and 
the resultant pyrrole complexed with p-dimethylaminobenzalde- 
hyde. The resultant coloured complex was measured spectro- 
photometrically.
Reagents
1. Dowex 2-X8, 200 - 400 mesh. Following the removal of fines 
by repeated suspension and sedimentation in water with removal 
of slow sediraenting particles, the resin was converted to the 
acetate form by washing on a column with 3M sodium acetate till 
chloride-free (as tested with silver nitrate). The resin was 
then washed with water until neutral (litmus paper). The resin 
in its acetate form could be stored for 3 - 4  months at room 
temperature in about twice its volume of water.
2. Dowex 50-X8, 200 - 400 mesh. Fines were removed as for 
Dowex 2. The resin was then converted to the sodium form by 
storage for 20 hours in twice its volume of 2M sodium hydroxide 
after which it was washed with water until neutral. It was then
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reconverted to the acid form by successive treatment with 1 
volume of 4M hydrochloric acid and 6 volumes of 2M hydro­
chloric acid. The resin was then stored for up to 4 months 
in twice its volume of IM hydrochloric acid.
3. Ehrlich reagent II - Ig of p-diraethylaminobenzaldehyde 
was dissolved in ca. 30ml of glacial acetic acid. 8ml of 
70% perchloric acid (specific gravity 1.7) were then added 
and the volume made up to 50ml with glacial acetic acid.
Method
For this analysis custom-made glass columns (icm x 20cm 
for Dowex 2, 1cm x 40cm for Dowex 50) plugged with cotton 
wool were packed by sedimentation with each ion exchange 
resin to a height previously found to be optimum (2 - 3cm).
Before use the columns were well flushed with water and 
kept wet at all times. 1ml of urine, adjusted to between pH4 
and 7 if necessary, was placed on a Dowex 2 column for the 
retention of PBG and the column washed after the passage of 
the urine with water (2 x 2ml). The total eluted material 
including the washings was quantitatively transferred to a 
Dowex 50 column and after passage was washed through with 30ml 
of water to remove urea. The column then was washed with 3ml 
sodium acetate solution (1M). A further 7ml of IM sodium 
acetate was then passed through the column and the eluate 
collected in a 10ml graduated test tube (with stopper) 0.2ml
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cf acetyl acetone was then added to the tube and the volume 
made up to 10ml with sodium acetate buffer, IM pH 4.6. The 
tube was then stoppered and placed in a heating block at 100°C 
for 10 minutes.
When cooled, 2ml of this solution was mixed with 2ml of 
Ehrlich reagent II and the extinction at 553mm read in a 1cm 
cell exactly 15 minutes later. The blank consisted of 7ml of 
IM sodium acetate treated in the same manner as the Dowex 50 
eluate.
A standard curve was constructed by the addition of known 
amounts of ALA to known volumes of urine. The standards were 
then analysed according to the method given.
Results were expressed as nmol AIA/L of urine.
2.4.2. PORPHOBILINOGEN
PBG was measured in urine by the method of Mauzerall and 
Granick (1956).
The PBG was removed from urine by retention on a Dowex 2 
anion exchange resin. After elution the PBG was complexed with 
p-dimethylaminobenzaldehyde and quantitated by a method similar 
to ALA (previous section).
Reagents
1. Dowex 2-X8, 200 - 400 mesh. See previous section.
2. Ehrlich reagent I. A 2% (^/v) solution of p-dimethylamino­
benzaldehyde in 6N hydrochloric acid.
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Method
The Dowex 2 resin containing the PBG (see previous section) 
was eluted successively with 2ml IM acetic acid and 2ml 0.2M 
acetic acid. The total eluate was collected and diluted to 10ml
with distilled water. 2ml of this was mixed with 2ml Ehrlich
reagent I and the extinction read at 555nm after 5 minutes. The 
blank was 2ml distilled water plus 2ml Ehrlich reagent I.
Results were calculated by a method analagous to that for
ALA and expressed as nmol PBG/L of urine.
2.4.3. PORPHYRINS IN URINE
The main porphyrins in urine are uroporphyrin and copro­
porphyrin, although in certain cases the intermediate penta-, 
hexa- and hepta- carboxylic porphyrins are also found. 
Porphyrinogens which also occur were oxidised to the 
corresponding porphyrin before estimation.
Porphyrins were measured by one of two methods.
1. Solvent extraction followed by fluorimetric or spectro-
photometric quantitation. This method, based on that of
Rimington (l97l), has drawbacks in that hexa- and hepta-
carboxylic porphyrins are measured with uroporphyrin and
penta-carboxylic porphyrin is measured with ooproporphyrin.
2. High performance liquid chromatography (HPLC). This has the 
advantage of being less time consuming and has the ability to
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measure the intermediate porphyrins individually. Based on the 
method of Gray et al (1976), this method will be covered in a 
separate section.
Method (solvent extraction)
25ml of urine were placed in a separating funnel and 
extracted twice with a mixture of 10ml glacial acetic acid and 
100ml diethyl ether. The ether extracts were combined and 
washed with successive 25ml portions of sodium acetate solution 
(5% ^/v hydrated salt) until the aqueous phase no longer 
showed red fluorescence under ultra violet (UV) light. The 
organic phase was used for the extraction of coproporphyrin 
while the combined aqueous phases contained the uroporphyrin.
Ooproporphyrin; The combined organic phase was washed firstly 
by shaking for one minute with 20ml of iodine solution 
(0.005%,freshly prepared) and secondly with 25ml of distilled 
water. Coproporphyrin was then extracted, by shaking; from the 
ethereal solution,with successive 5ml portions of 5% hydro­
chloric acid until the extract no longer showed red fluorescence 
under UV light. The total volume of these extracts was 
recorded, the solution filtered and the fluorescence measured 
in a broad-band fluorimeter (Locarte Company Ltd.).
Uroporphyrin: The combined aqueous phases were adjusted to
pH 1.5 - 2.0 and then extracted twice with 25ml of cyclohexanone.
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The combined cyclohexanone fractions were then thoroughly 
mixed with 100ml diethyl ether and an aqueous phase allowed 
to separate. This fraction was removed, volumed and mixed 
with an equal volume of 10% hydrochloric acid. The organic 
phase was then extracted with successive 5ml portions of 5% 
hydrochloric acid until no fluorescence showed under the UV 
light. The acid extracts were combined, volumed auid the 
extinction measured in a 1cm cell at 380 and 430nm and at 
the Soret maximum (about 406nm).
Calculations
The coproporphyrin concentration in urine was given by :
[(F.O. X 0.717) - 0.031] X fél I  ^  •
= nmol coproporphyrin/24hrs or /L 
where F.U. = Fluorimetry units
A.V s= Acid volume
V =s 24hr urine volume (lOOO gives results
as per litre)
V = volume of urine extracted
O.7I7) = Factors relating to standard graph
0.031) (gradient and intercept)
0.654 = Conversion factor for S.I. units
Uroporphyrin concentration was given by :
2 X Emax - (E43O + E58O)
= nmol uroporphyrin/24hrs or /L
[ X 0.832 X A.V X 1.205 X Ç
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where Emax = Extinction at Soret maximum 
E43O = Extinction at 430iun 
E58O = Extinction at 380^
A.V = Acid volume
V = 24hr urine volume (lOOO gives results
as per litre)
V = Volume of urine extracted 
0.832 = "Extinction coefficient"
1.205 = Conversion factor for S.I. units
2.4.4. PORPHYRINS IN FAECES
The main porphyrins found in faeces are protoporphyrin and 
coproporphyrin. However, in certain pathological conditions 
the excretion of other porphyrins may become substantial (Gray 
et al, 1976). As with urinary porphyrins, HPLC has become the 
method of choice for the measurement of the excretion of 
individual porphyrin species. Solvent extraction methods, 
however, provide useful screening tests for excessive porphyrin 
excretion.
The solvent extraction method for the estimation of 
coproporphyrin and protoporphyrin is very similar to that for 
uroporphyrin and coproporphyrin in urine, and is described 
below. The HPLC method will be covered in a separate section.
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Method (solvent extraction)
0.5g and Ig of faeces were taken for estimation of 
porphyrin and faecal dry weight respectively. The faecal 
sample for porphyrin estimation was homogenised in ca. 10 
ml of glacial acetic acid and then 30 - 40ml of diethyl ether 
was added and mixed thoroughly. The suspension was then 
centrifuged at 400g for 3 - 4  minutes, then the supernatant 
was removed and viewed under U.V light. The extraction was 
repeated until no fluorescence was seen in the supernatant.
The combined ether-acetic fractions were extracted twice
with sodium acetate solution (3% ^/v hydrated salt) to remove
traces of uroporphyrin, then with 20ml iodine solution (0.005% 
w/ V
v), then 20ml of distilled water. The resultant organic 
phase contains the coproporphyrin and protoporphyrin.
Coproporphyrint The organic phase was extracted with successive 
5ml portions of 0.1% hydrochloric acid until no fluorescence was 
present in the aqueous fraction. The acid fractions were 
combined, volumed and filtered and a portion used for fluorescence 
estimation of coproporphyrin.
Protoporphyrin; The protoporphyrin was extracted with successive 
5ml portions of 5% hydrochloric acid and the acid fractions 
combined and treated as for coproporphyrin.
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Calculations
The coproporphyrin concentration in terms of faecal dry 
weight was given by ;
(P.U. X 0,65) + 0.065
= n moles coproporphyrin/g dry wt. 
where P.U. = Fluorimetry units 
A.V = Acid volume 
w.w = Wet weight of faeces 
d.w = Dry weight of faeces 
W = Weight of faeces used for estimation 
0.63) = Factors relating to standard graph
O.O63)
1.529 = Conversion factor for S.I. units
for protoporphyrin ;
['(P.ÏÏ. X 1.42) - 0.175
= n moles protoporphyrin/g dry wt.
Abbreviations are as for coproporphyrin above.
2.4.5. MEASUREMENT OF PORPHYRINS BY HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY 
Porphyrins extracted from urine and faeces were quantitated 
by HPLC on a p-Porasil column (3.9mm (i.d.) x 30cm) (Waters 
Associates Inc., U.S.A.). Solvent delivery was made by a dual 
head reciprocating pump (Model M 6OOOA, Waters Associates Inc.) 
capable of delivering 10ml per minute at up to 6OOO psi.
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Porphyrin esters were detected and quantitated using a variable 
wavelength U.V. monitor (model CE212 Cecil Instruments Ltd., 
U.K.) in conjunction with a flatbed pen recorder (model P.M. 
E.202, Philips). Porphyrin concentrations were estimated by a 
peak height method or by peak areas as calculated by a digital 
integrator. Porphyrins in liver tissues were measured by the 
method for faecal porphyrins following homogenisation of the 
tissue in the estérification mixture.
Method - Urinary Porphyrins
25ml of urine was mixed with 300ml of a mixture of 
methanol and sulphuric acid (specific gravity I.84) (95:5) to 
esterify the porphyrins. This was left in the dark at room 
temperature for 24 hours. 2.5 nmoles of mesoporphyrin-IX- 
dimethyl ester were then added in chloroform to each sample 
as internal standard and the porphyrin methyl esters extracted 
with chloroform until no fluorescence showed under U.V. light.
The chloroform extract was then evaporated to dryness 
under a stream of nitrogen gas (below 40°C). The residue was 
taken up in 1 - 2ml of chloroform and filtered through a O.Tum 
glass microfibre filter and the filtrate blown down to small 
volume ( ca. 0.1ml). About 30p^ of this was then taken for 
chromatography.
The solvent used for the separation of urinary porphyrins 
was a mixture cf 2,2,4-trimethyl pentane (isooctane) and methyl 
acetate (2:1). The solvent mixture was filtered and degassed
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prier to use by passing through a 0.3pm glass microfibre filter 
under vacuum. It was found that a solvent flow rate of 4ml/ 
minute gave the best separation of porphyrin esters in the 
shortest time possible (Figure ll).
Calculations
Porphyrin concentrations were calculated from the ratio of 
peak height (or peak area) with respeot to the internal standard. 
Response factors were obtained from a standard injection 
containing porphyrins in known concentrations.
Results for individual porphyrins were given by the 
equation
n-ol IS ^ ^  X ^ 3  (std) X fleetest)
= nmol porphyrin/L or /24 hours
where IS = Internal standard mesoporphyrin ester 
PH X= Peak height of individual porphyrin 
V = Volume of urine extracted 
24h = 24 hour urine volume
Method - Faecal Porphyrins
The porphyrin in 0.5g (wet wt.) of faeces was esterified 
overnight in 50ml of methanol/sulphuric acid mixture (95:5).
2.5 nmoles of protoporphyrin-IX-diethyl ester was added as 
internal standard and the porphyrin esters extracted with 
chloroform. Protoporphyrin diethyl ester was produced by
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FIGTJEE 11 SEPARATION OF PORPHYRIN ESTERS BY HPLC
1. Protoporphyrin diethyl ester
2. Protoporphyrin dimethyl ester
3. Mesoporphyrin dimethyl ester
4* Coproporphyrin tetramethy1 ester
5. Penta-carboxylic porphytin methyl ester
6. Hexa-carboxylic porphyrin methyl ester
7. Hepta-carboxylic porphyrin methyl ester
8. Uroporphyrin octa methyl ester
hydrolysis ( 6M HCl, 16 hrs) and re-esterification (ethanol/ 
sulphuric acid (95:5)» 16 hrs) of protoporphyrin dimethyl 
ester •
The combined chloroform extracts were evaporated to 
dryness and the residue taken up in 1ml dichloromethane for 
preparative column chromatography. Columns (0.8 cm i.d. x 
10cm) were packed with silica gel (Woelm 70 - 250 mesh) 
suspended in dichloromethane/methanol (96:4)» flushed with 
50ml of the same solvent mixture and the porphyrin extract 
applied. The porphyrins were then quantitatively eluted 
using the above solvent. The porphyrins in a fast moving 
band were identified under UV light and were collected in 
the first 20ml of eluate. Dark brown contaminating pigments 
remained on the column..- The porphyrin containing eluate was 
evaporated to 0.5ml and a portion of this used for HPLC 
without prefiltering.
The solvent system used for this separation was 
n-heptane/methyl acetate (80 ; 45) with a solvent flow of 
1.5ml/min. A typical chromatogram is shown in Figure 11.
Calculations
Calculation of individual porphyrin concentrations was 
performed as for urinary porphyrins.
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2.5. ENZYMES OF HA EM BIOSYNTHESIS
The enzymes of haera biosynthesis were assayed in rat liver 
homogenates prepared from livers which had been perfused, in 
situ, via the portal vein with 25ml ice cold saline (0.15M 
sodium chloride) prior to excision. Homogenates were prepared 
in saline using an ultrasonic-mechanical homogeniser (Polytron) 
at strengths described in the methods for each assay.
2.5.1. &-AMINOLAEVULINIC ACID SYNTHASE
Assay of the activity of ALA.S was performed by a modifi­
cation of the methods of Dowdle et al (l9é?) and Freshney and 
Paul (1970).
Reagents
Reaction mixture: Phosphate buffer (0.05M, pH 6.8)
containing glycine (0.5mM), sodium malate (0.5mM), magnesium 
chloride (2mM) and pyridoxal phosphate (0.4mM).
Homogenisation mixture: Phosphate buffer (0.12M, pH 7.0)
containing glycine (imM), sucrose (0.5M), magnesium chloride 
(0.04M), mercaptoethanol (8mM) and EDTA (0.02M).
Method
0.1ml of liver homogenate (l:1 in saline) was mixed with
0.1ml of homogenisation mixture, then 0.2ml of reaction mixture 
added containing 2-^^C glycine (l2.5jiCi/ml). This was then 
incubated, stoppered,at 37 C for 1 hour on a shaking water bath.
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The reaction was stopped by adding 0.2ml of the total 
reaction mixture to 40^1 carrier ALA. solution (I.5N trichloro­
acetic acid containing ALA (I.9N)). Precipitated protein was 
spun down at 4°C and lO^ il of the resultant clear supernatant 
spotted on Whatman 3^  paper for electrophoresis.
The ALA and glycine were then separated by electro­
phoresis in phthalate buffer (O.O5M, pH4) run at 54v/cm for 
2 hours in water-cooled high voltage electrophoresis apparatus 
(Locarte).
After electrophoresis the ALA spot was visualised with 
ninhydrin spray (5% in butanol), excised and burnt in a sample 
cxidiser (intertechnique) prior to (3 counting in a liquid 
scintillation counter (Packard). Enzyme activity was 
calculated from the amount of ALA produced and expressed as 
nmol/ALA produced/g protein/hour.
2.5.2. &-AMINOLAEVULINIC ACID DEHYDRATASE
This was measured by modification of the standardised EEC 
method for blood (Berlin and Schaller, 1974).
Reagent
Special Ehrlich reagent: 2.5g p-dimethylaminobenzaldehyde
was dissolved in 50ml of glacial acetic acid and 24.5ml of 
perchloric acid (specific gravity 1.7) added. When cooled the 
volume was made up to 100ml with glacial acetic acid.
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Method
0,2ml of homogenate (1:3 in saline) was diluted with 
1.5ml of water and placed in a water bath at 37^C along with 
an ALA solution (O.OIM in sodium phosphate buffer, O.IM, 
pH 7.4) for 10 minutes to equilibrate. After the equilibration 
time 1ml of the ALA solution was added to each reaction tube, 
the tubes stoppered, mixed and replaced in the bath in total 
darkness. The assays were run in duplicate with a zero time 
that was stopped with 1ml of 10^ trichloroacetic acid.
After an incubation of 1 hour each tube was stopped with 
1ml trichloroacetic acid and the tubes centrifuged to remove 
the protein precipitate. The supernatant was decanted and 
respun then 2ml removed and added to 2ml of special Ehrlich 
reagent. The extinction of the sample was then read after 5 
minutes at 555nm against a blank of 2ml trichloroacetic acid 
and 2ml special Ehrlich reagent.
Results were calculated by using an extinction coefficient 
of 113mM ^ cm ^ for the PBG-Ehrlich complex and results 
expressed as nmol PBG formed/g protein/hour*
2.5.3. UROPORPHYRIHOGSH-I-SYNTHASE
This was assayed by a modification of the method of 
Prydman and Feinstein (1974).
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Method
1ml of homogenate (1:3 saline or 0.15M potassium chloride) 
was incubated with 0.1ml of PBG solution (0.82niM in sodium 
phosphate buffer 83mM, pH 7*65) and 1ml of reduced glutathione 
(3.2mM in phosphate buffer). This mixture we.s incubated for 1 
hour at 37^C in the dark and the reaction stopped by the 
addition of 9ml of an ethyl acetate/glacial acetic acid mixture 
(2:1). This was centrifuged at 2000g to remove the precipitate 
which was then re-extracted with 5ml aliquots of ethyl acetate/ 
glacial acetic acid until no more porphyrin fluorescence was 
observed. The total volume of extract was noted and 0.4ml mixed 
with 5ml of 0.5N hydrochloric acid. The fluorescence of this 
mixture was measured spectrofluorimetrically to measure the 
formation of uroporphyrin. Uroporphyrin was estimated as for 
urinary uroporphyrin (section 2.4*3) and the results expressed 
as nmol uroporphyrin formed/g protein/hour.
«
2.5.4. UROPORPHYRINOGEN DECARBOXYLASE
This assay was carried out essentially by the method of 
Prydman and Feinstein (1974) which involves production of 
uroporphyrinogen substrate in situ, for further conversion to 
coproporphyrin.
Method
The assay was set up as for URO.S and the incubation carried 
out for 1 hour. Thereafter 0,2ml of potassium dihydrogen
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orthophosphate solution (0.4M) was added. This changed the 
pH of the reaction mixture halting the URO.S reaction and 
allowing the URO.D reaction, which had previously been 
inhibited, to proceed. The reaction was then allowed to 
continue for a further hour when it was stopped with 9ml of 
the ethyl acetate/glacial acetic mixture (2:1) and extractions 
continued as before until no further porphyrin fluorescence 
could be extracted from the precipitate. The combined extract 
was then back-extracted with a saturated solution of sodium 
acetate until all the uroporphyrin had been extracted into the 
aqueous phase. The ethyl acetate/glacial acetic acid phase 
containing the synthesised ccproporphyrin was then treated as 
for the faecal ccproporphyrin estimation described earlier 
(section 2.4.3). The results of the assay were expressed as 
nmol ccproporphyrin produced/g protein/hr.
2.5.5. COPROPORPHYRINOGEN OXIDASE
This assay was performed using a modification of the method 
of Battle et al (1965).
Method
Coproporphyrinogen was prepared from ccproporphyrin by 
reduction with sodium amalgam (3^  'Vv) under nitrogen in the 
dark. The coproporphyrinogen was then separated by filtration 
through a sintered tube into a Buchner flask containing 0.13ml
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sodium thioglycollate (2M) and subsequently brought to pH 7.4 
with phosphoric acid (40^ ^/v). Before use, this solution 
was diluted 1 : 1 with Tris buffer (O.OIM, pH 7.4)* 0.2ml of
this solution of coproporphyrinogen were added with 2.5ml of 
Tris buffer and 1ml of the liver homogenate (l : 5 in saline 
or 0.15M potassium chloride) to a 25ml Erlenmeyer flask which 
was closed with a cotton wool stopper. This was incubated 
with shaking at 37^C in the dark for 1 hour. The reaction 
was stopped with 10ml of ethyl acetate/glacial acetic acid 
mixture (4 : l)$ mixed and left to stand in daylight for 3P 
minutes to convert the residue of coproporphyrinogen to 
coproporphyrin. Protoporphyrin produced by this reaction was 
extracted as before and quantified by the method described 
earlier for protoporphyrin estimation. Results were expressed 
as nmol protoporphyrin produced/g protein/hour.
2.5.6. PSRROCHEUTASE
FERRO.C was assayed by the method of Goldberg et al (1956).
Method
A solution of protoporphyrin dimethyl ester was made 
up (1.7 Jimol in 2ml of 7M hydrochloric acid) and left for 18 hours 
in the dark to hydrolyse. The resulting solution of protopor­
phyrin was freeze dried and redissolved immediately before use in 
10ml sodium hydrogen carbonate solution (0.I4M). Incubation was
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carried out in Thunberg tubes "in vacuo" at 37°C for 1 hour. 
Into each tube was placed 0,2ml of reduced glutathione 
solution (lOmM) in Tris buffer (0,45M, pH 8.2) and 0.2ml of 
ferric chloride solution (l6pM) also in Tris buffer, contain­
ing (2^Ci), The reaction was started by the addition
of 0.2ml of homogenate (l ; 3 in saline or 0.15M potassium 
chloride) and stopped by the addition of 4ml of haem carrier, 
prepared by the haemolysis of packed red cells which had been 
centrifuged to remove cell debris. The whole solution was 
carefully mixed and the protein and haem precipitated and 
water removed by the addition of 10ml anhydrous acetone. The 
mixture was then centrifuged and the supernatant discarded.
Haem was then extracted from the precipitate by successive 
extraction with 4 x 20ml portions of acetone/glacial acetic 
acid solution (4 : l). The combined solutions of haem were 
heated in a water bath at 90°C until all the acetone had 
evaporated and the resultant solution was left overnight for 
haem to crystallise. The haem crystals were washed twice with 
glacial acetic acid, water, absolute ethanol and ether in 
succession. The crystals were then dried in hot-block at 100°C, 
weighed and counted in a y counter. The recovery of haem was 
calculated from the known haemoglobin concentration and the 
results expressed as % ^^Fe incorporation into haem/mg protein/ 
hour.
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2.6 QUALITATIVE DETECTION OF "KRYPTQPYRROLE"
This method is based on the method of Irvine (196I) for 
the detection of what was then thought to be kryptopyrrole but 
as has been stated (section 1,4.1.) is now known to be OHHPL. 
As will be seen the method is very non-specific and is of 
little use other than as a screening test.
Fresh urine (100ml) was mixed with 2g of activated char­
coal, allowed to stand for 2 hours and then filtered in a 
Buchner funnel. After the charcoal was washed with 80ml of 
distilled water the "kryptopyrrole" was eluted with 100ml of 
acetone, which was evaporated in vacuo at 30°C. The residue 
was taken up in water and extracted three times with 3#5ml 
of peroxide-free diethyl ether. Acetone (2.2ml) was then 
added and the mixture- extracted twice with 6.6ml of ether.
Both ether fractions were flash-evaporated at 30°C, the 
residue being dissolved in 2ml of acetone and then applied to 
Whatman 3MM chromatography paper. A standard of synthetic 
kryptopyrrole (4OO nmol) was applied at the same time and 
ascending chromatography run for 12 hours in the solvent 
system prcpan-2-ol/water/ammonia solution (sp. gr. 0.88)
(20:2:1). The chroma to grams were dried in cool air and the 
"kryptopyrrole" was visualized as a purple-blue spot (R^ 
value 0.9) by development in Ehrlich's reagent (ig of p- 
dimethylaminobenzaldehyde dissolved in hydrochloric acid/ 
methanol, 1:9» ^/v) followed by heating at 55°C.
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The gas-liquid chromatography method for the quantitation 
of OHHPL will be covered in a later section.
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2.7* MICROSOMES AND MICROSOMAL HA2M AND CYTOCHROMES
2.7.1.. PREPARATION OF MICROSOMES
Tissue for the preparation of microsomes was kept on ice 
after removal until it was homogenised in a l:l(^/w) volume 
of ice cold O.I5M potassium chloride using an ultrasonic 
mechanical homogeniser (Polytron). All further procedures 
were carried out at 4°C. Cell debris, nuclei etc. were first 
removed by centrifugation for 15 minutes at 900g. The 
resulting supernatant was then spun at 17,500g for 15 minutes 
on a preparative ultracentrifuge to remove mitochondria. The 
post-mitochondrial supernatant was spun at 105,000g for 1 hour 
to remove the microsomes, the supernatant being discarded.
The microsomal pellet was washed and resuspended in 0.15M 
potassium chloride using a Potter-Elvehjem homogeniser and 
again centrifuged at 105»000g for 1 hour. The final washed 
microsomal pellet was resuspended in 0.15M potassium chloride 
( ca. 7ml) and a protein estimation carried out on the 
suspension. This suspension was then used for the estimation 
of microsomal haem and cytochromes.
2.7,2. ESTIMATION OF MICROSOMAL HAEM
Microsomal haem was measured by the pyridine haemo chromo gen 
method of Paul et al (1953).
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Method
2ml of the final microsomal suspension was taken and to 
it was added 1ml pyridine and 2ml sodium hydroxide solution 
(0.25M) and the mixture shaken thoroughly. The resultant 
solution was then divided equally between two glass cuvettes 
and 5mg of sodium dithionite added to the test cuvette and 
mixed. The difference spectrum was then recorded in a dual 
beam spectrophotometer (SP 8000, Pye Unicam Ltd.) between 550 
and 575nm«
Calculation
The haem concentration is calculated using an extinction 
-1 -1
coefficient of 32.4mM cm as follows
A e  X 77.16 . / . . ----- -------- = nmol/rag protein
= difference in extinction between 557 
and 575nm
a = protein concentration of microsomal suspension
2.7 .3. ESTIMATION OF MICROSOMAL CYTOCHROME P-450 AND 
CYTOCHROME b_
Cytochrome P-450 and Cytochrome b^ were measured by the 
method of Omura and Sato (1964).
Method
4ml of potassium phosphate buffer (0.15M, pH 7.0) was added to
2ml of microsomal suspension to give a final protein concentration
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of approximately 2mg/ml. This mixture was then split equally 
between two glass cuvettes.
50pl of a 12mM NADH solution in phosphate buffer was then
added to the test cell to reduce cytochrome b^ and the
difference spectrum recorded in the range 400 - 500nm.
Using the same cells, carbon monoxide was bubbled through 
the test cell for 15 seconds. 5mg of sodium dithionite was then 
added to both the test and reference cells and carbon monoxide 
again bubbled through the test cell for 15 seconds. The cyto­
chrome P-450 difference spectrum was then recorded in the range 
400 - 500nm.
Calculation
Cytochrome b- concentration was expressed in terms of the
difference in extinction between 423 and 500nm per unit of
protein :-
A e (42? - 410) -1
protein concentration
Cytochrome P-450 concentration was expressed as follows ;-
^ 2.902 nmol Cyt.P-450/mg microsomal protein
£  X  d X c
where = difference in extinction between 450 and 490nm 
of the difference spectrum.
£ = molar extinction coefficient of cytochrome 
P-450 between 450 and 490nm on the difference 
spectrum = 91cm*^ mM*”^
d = light path = 1cm
c = protein concentration of microsomal suspension
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2.8. MICROSOMAL OXYGENASES
2.8.1. PORPHOBILINOGEN OXYGENASE
The oxidation of PBG by microsomal enzymes was measured 
essentially by the method of Prydman et al (1975) and Tomaro 
et al (1973) using an unpurified enzyme preparation.
Reagent
Reaction mixture; This was O.IM sodium phosphate buffer, pH 7.4 
containing porphobilinogen (0.26raM) and either sodium dithionite 
(2mM) or NADPH (0.8mM) plus a NADPH-regenerating system (nicotin­
amide (O.IM), glucose-6-phosphate (lOmM), glucose-6-phosphate 
dehydrogenase (5ng/ml) and magnesium chloride (20mM)).
Method
The final microsomal pellet was resuspended in sodium 
phosphate buffer (O.IM, pH 7*4) to give a final protein concen­
tration of 10 - 20mg/ml. 1ml of this suspension was mixed with 
1ml of reaction mixture and the incubation performed at 37°C for 
1 hour. When NADPH plus the regenerating system was used the 
reaction mixture was preincubated for 10 minutes before the 
addition of microsomal suspension. Blanks were run simultaneously 
omitting dithionite or microsomal suspension.
The reaction was stopped by the addition of 1ml of 0.3M 
trichloroacetic acid and the precipitated protein spun down.
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Substrate consumption was assayed by the addition of 1ml 
of Ehrlich reagent II followed by measurement of the extinction 
at 553^^ 15 minutes later. Porphobilinogen was estimated with 
reference to a standard graph drawn up with known PBG concen­
trations and results were expressed as nmoles PBG utilised/g 
protein/hour.
When the radiochemical assay was used the unlabelled sub­
strate PBG was substituted with the radiolabelled PBG described 
in section 2.3.1. The assay was incubated and stopped as before 
but on removal of the protein precipitate the pH of the reaction 
mixture was adjusted to between 4 and 7 using saturated sodium 
bicarbonate solution. The PBG and reaction products were then 
removed from the reaction mixture by retention on Dowex 2 ion 
exchange resin as for urine samples. The eluted material was 
then frozen and lyophylised.
The dried material was then taken up in a small volume of 
ethanol : acetone (l;l) and applied to thin layer chromato­
graphy plates (precoated microcrystalline cellulose, 0.5mm) and 
run using the upper layer of a butanol : acetic acid ; water 
mixture (4:1:5) as developer. PBG and reaction products 
(Figure 12 ) were visualised by spraying with an Ehrlich reagent 
(2%  p-diraethylaminobenzaldehyde in methanol ; HCl (9:1)). PBG, 
purple 0.63; 2-keto-PBG, orange R^ 0.51; 5-hydroxy-2-keto- 
PBG, yellow R^ 0.39- The formation of each product could be 
quantitated as follows. For each compound the area of the plate
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FIGDRE 12 POHPHOBILIMOGEH AND ITS OXIDATION PRODUCTS
1. Porphobilinogen
2. 2-ketoporphobilinogen
3. 2-keto-5-hydroxyporphobilinogen
was removed, placed in a polycarbonate combustion capsule 
and burnt in a sample oxidiser followed by P-counting.
The amount of product could be calculated from the ratio 
of counts in the product and PBG spots knowing the original 
PBG concentration*
2.8.2. HAEM OXYGENASE
The activity of haem oxygenase was measured by a modification 
of the method of Naines and Kappas (1975)*
Method
Reaction mixture: Potassium phosphate buffer (O.llM,
pH 7*4) containing glucose-6-phosphate (l.3mM) magnesium
chloride (3mM), glucose-6-phosphate dehydrogenase (7*5^&/rol)
and haem (25pM).
The final microsomal pellet was resuspended in phosphate
buffer (O.IM, pH 7*4) to give a final protein concentration of 
»
10 - 20mg/ml. 4ml of reaction mixture and 1ml of microsomal 
suspension were preincubated for 5 minutes at 37°C. Thereafter 
the mixture was divided into two equal aliquots. To the test 
aliquot NABP (final concentration O.SmM) in bicarbonate solution 
(lÿ ^/v) was added whilst to the reference incubation mixture 
sodium bicarbonate alone was added. The incubations were 
carried out for 15 minutes after which period the reaction was 
stopped by the addition of 2ml of the reaction mixture to a
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tube containing 2ml of 0.25M NaOH and 1ml of pyridine. Haem 
consumption was then measured by the method of Paul et al 
(1953) (section 2.7.2).
The results were expressed as nmol haem oxidised/mg 
microsomal protein/hour.
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2.9. THYROID FUITCTIQN TESTS
Serum total thyroxine (T4) and triiodothyronine (T3) were 
determined by semi-automated radioimmunoassay methods (Challand 
et al, 1975) employing a second antibody separation (Ratcliffe 
et al, 1974). The free thyroxine index (FTl) was calculated 
from the result of the total T4 and the thyroid hormone binding 
capacity (Thyopac-3, Radiochemical Centre, Amersham, U.K.)
(Clark and Brown, 1970). 3>3*»5’-triiodothyronine (reverse T3)
was assayed in unextracted serum (Ratcliffe et al, 1976) while 
serum thyroid stimulating hormone (TSH) was measured by a method 
based on that of Hall et al (l97l). Free thyroid hormone levels 
(FT3, FT4) were measured directly by radioimmunoassay of a serum 
dialysable fraction (Yeo et al, 1977a). Normal values of these 
parameters are listed in Table 2. Free thyroid hormone concen­
trations in pregnancy were taken from Yeo et al (1977b). A 
standard thyrotrophin releasing hormone (TRH) test was employed 
(Ormston et al, 1971).
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2.10. ADDITIONAL METHODS
2.10.1. PROTEIN ESTIMATION
Protein estimations were made by the method of Lowry et 
al (1951).
2.10.2. PRIMARY CREATIHIHE
Urinary creatinine was determined by routine auto-analysis.
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2.11. STATISTICAL METHODS
Where applicable the results were calculated and expressed
as mean ± standard deviation (S.D.), the standard deviation
being calculated from the expression
S.D. = I Z(x - x)^
M  N - 1
where x was any of the values measured, x the mean value, atnd N 
the number of observations.
The significance of the results was calculated by Students 
t test using the formula 
t =
S
Ji + i\ K i n.
where s was an estimate, of the combined standard deviation of 
both groups calculated from
S % X - + Z(x - =2)
+ %2 - 2
the degrees of freedom P = - 2
x^ and Xg were the means of both groups and and the number 
of observations in each group.
In some studies where a normal distribution was not assumed 
the non-parametric Nann-Whitney U test was used to examine 
significance. This test was based on the formula 
Ü = + 1) -
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or + Ng(Ng + l) -
where R^ = the sum of the ranks assigned to the group whose 
sample size was and R^ = the sum of the ranks assigned to 
the group whose sample size was . Of the two values obtained
from these equations it was the smaller value of U that was 
used to test significance.
The parametric least squares regression analysis of Pearson 
was used to analyse linear relationships. With n pairs of 
associated observations represented by (x, y) the true 
regression line for the regression of y on x is 
y = A + Bx
B = Z(x - x) (y - ÿ)
Z(x - xf
A = ÿ - X B
and the correlation coefficient r
r = (x - x) (y - y)
 ^[Z(x - x)^] [X(y - ÿ)^]
Non-parametric correlation analysis was carried out using the 
two ranking tests of Spearman and Kendall.
In both tests the values of x and the values of y were ranked 
separately. In the Spearman test the difference in the value of 
the ranks of x and y (d) for each of the N x, y pair was summed 
( %  d). Thus the equation for the Spearman rank correlation
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coefficient was as follows
,2
r
s
1 - 6 I d‘
-  N
In the Kendall rank correlation test the ranks of x were
arranged in natural order (i.e. 1, 2, 3 .N). The values
of the ranks of y were arranged under their corresponding 
value of X. The value of S was then determined by starting at 
the first value of the rank of y on the left and counting the 
number of ranks to its right which were larger and subtracting 
the number of ranks to its right which were smaller. This was 
done for all ranks of y and the sum of the results corresponded 
to S, Given S the value of the Kendall rank correlation 
coefficient was
T - B _____
Ô.5N (N - 1)
The probability associated with rg could be found directly 
from tables. However for T values for N > 10, Z was calculated 
as follows
2(2N + 5) 
9N (N - 1)
and the probability associated with values of Z obtained from 
the appropriate tables.
Significance was assumed in both of these tests if the 
probability of an event occurring on the basis of the null 
hypothesis was less than 5 in 100 (p < 0.05).
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V/here analyses involved large numbers of observations the 
ranking tests, Mann-Whitney U, Spearman and Kendall, were 
carried out on the Northumbrian Universities Multiple Access 
Computer (NUMAC). Examples of each are shown in Appendix 1.
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C H A P T E R  5
QUANTITATIVE DETERMINATION OF 3-ETHYL- 
5-HYDROXY-4,3-DIMETHYL - A^-PYRROLIN-2-ONE 
BY GAS-LIQUID CHROMATOGRAPHY
CHAPTER 5
QUANTITATIVE DETERMINATION OF 3-ETHYL-5-HYDROXY-4.5- 
DIMETHYL-A^-PYRROLIN-2-ONE b y GAS-LIQUID CHROMATOGRAPHY
3.1. INTRODUCTION
Since the discovery of the mauve factor, even before its 
unequivocal identification, attempts have been made to quantitate 
it. Most of these previous attempts have involved reaotion of 
the pyrrolic metabolites with Ehrlich’s aldehyde reagent. Irvine 
in 1971 made semiquantitative estimations of eaoh of the oxidised 
components after reaotion with Ehrlich reagent, using integrating 
densitometry. This method was applied after two dimensional 
chromatography, a process which itself did not maintain the 
integrity of the urinary metabolite (see section 1.4.1.).
Other attempts have involved integrating ion current mass 
spectral quantitation (Boulton and Majer, 1970) and the 
complexing of "kryptopyrrole** with Ehrlich's aldehyde or ^^C- 
formaldehyde (Wetterberg and Formgren, 1976). Neither of these 
methods have provided consistent results.
It was obvious that the successful establishment of a 
suitable method for the quantitation of OHHPL would allow, and 
was essential for, a greater in-depth investigation into the 
natural occurrence than had before been possible.
The method of quantitation chosen, gas-liquid chromato­
graphy (glc) reflects the availability of apparatus as well as
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suitability considering the physio-chemical properties of the 
compounds in question. It combines the required sensitivity 
and specificity with proven capability and precision.
A method is described for the quantitation of OHHPL in the 
urine of human subjects using a simple solvent extraction method. 
This method was found to be inadequate for plasma. However, a 
similar method was used for the quantitation of OHHPL in the 
serum and plasma of experimental animals treated with OHHPL 
and consequently had very high levels. In addition OHKPL could 
be measured using OHHPL as am internal standard also in experimental 
animals.
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5.2. METHOD
3,2.1. APPARATUS
Gas liquid chromatography was performed on a Pye 104 series, 
dual channel gas chromatograph (Pye Unicam Ltd., Cambridge, U.K.) 
equipped with dual flame ionisation detectors and injection port 
heaters.
Output from the glc amplifier was connected to a Philips 
PM 8000 flatbed recorder.
The carrier gas used was oxygen-free nitrogen, used without 
pre-treatment and the detectors were supplied with high purity 
hydrogen and compressed air.
Glass columns either 1.7m or 2.8m long x 4mm i.d. were 
supplied by Pye Unicam"and injections were made with a standard 
5iil glass syringe (S.G.E. Ltd., Melbourne, Australia).
Packing of Columns
The stationary phase chosen for chromatography was 
Carbowax 20M (polyethylene glycol 20M) and the support was Gas 
Chrom. Q, 100 - 120 mesh. Column packings were either bought 
pre-coated or prepared as follows : For the coating of 25g
support 100ml (4 x 25) of a solution of Carbowax in chloroform 
was prepared at the same concentration required on the final 
packing. The support was then rapidly added to the solution 
and dispersed with a minimum of stirring. The mixture was then
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vacuum filtered cn a Buchner funnel and the coated support 
removed and oven dried.
Columns were pre-treated with dimethyldichlorosilane in 
toluene (5^ ^/v) for 24 hours. Prior to packing they were 
washed with methanol and air dried. This process ensured the 
removal of 'active sites' on the interior glass surface that 
might otherwise reduce the efficiency of the column. The 
column was packed under suction and the packing settled with 
a vibrating spatula (Mettler). The open column end was then 
plugged with glass wool which had been previously acid washed 
and silanised.
Before use the columns were conditioned by heating to 
250°C for 24 hours in the chromatograph without connection of 
the distal end to the detector. This ensured the removal of 
volatiles that may have otherwise contaminated the detector.
3.2.2. STANDARDS
As a safeguard against variable recovery during extraction 
and to eliminate the need for accurate aliquot measurement 
during the extraction procedure, use was made of an internal 
standard added to the urine or plasma before extraction. For 
this purpose one of two compounds was used.
Standard A: OHKPL. This was produced and purified as in
section 2.3.3*
Standard B: 5»5-iimethyloxazolidine-2,4-dione (DM0) (Figure I3).
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This was produced and kindly dcnated by Dr. F. Rcwell 
(Sunderland Polytechnic, Sunderland).
Both of these compounds fulfilled the requirements 
necessary for use as an internal standard. These were
1. Linearity of detector response over the range used.
2. Conservation of internal standard/OHHPL concentration 
ratio throughout the extraction.
5. Ease of separation from OHHPL by glc.
. 4. Absence cf contaminating peaks cn glc.
5. Similarity of structure to OHHPL.
The obvious choice for internal standard was OHKPL 
(standard A) the 33* isomer of the natural metabolite. The 
likeness in structure that ensured the identical behaviour 
during the extraction also however made the separation of the 
two compounds by glc difficult. Separation could, however, be 
effected using lower temperatures and longer columns. This 
inevitably resulted in cycle times of around 30 minutes.
Cycle times could be reduced by the use of DM0 (Standard 
B) as internal standard. This was resolved using shorter 
columns and higher temperatures, with cycle times of about 10 - 
12 minutes. For this reason the majority of urine analyses were 
performed using DM0 as internal standard. Occasional urines 
were encountered with interference in the region of the 
chromatogram at which DM0 was eluted. These could usually be 
analysed if required using OHKPL as standard. Plasma assays 
all required the use of OHKPL as internal standard.
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3.2.3. STABILITY
The stability cf OHHPL in urine was found to be poor 
although this was pH dependent. The half-life of the 
compound in urine was found to be in the order of 1 0 - 1 2  
hours.
The variability of stability of OHHPL in urine precluded 
the use of 24 hour specimens and spot samples were used.
Degradation of OHHPL or either of the internal standards 
during the assay procedure was negligible.
3.2.4. EXTRACTION PROCEDURE 
Urines
Fresh urine was used immediately or deep frozen (-25°C) 
until use, when 10ml were taken and thoroughly mixed with 
10ml of ethyl acetate containing the internal standard 
(25 nmol standard A, or 700 nmol standard B). The samples 
were then extracted twice with 20ml of peroxide free diethyl 
ether, and the combined organic phases evaporated to dryness 
(below 40°C, under nitrogen). The residue was taken up in 
50pl of ethanol for chromatography.
Experimental Plasmas and Serum
These were samples from animals which had been treated 
with OHHPL and had large amcunts of OHHPL in the plasma. 
Serum or plasma was de-proteinised with an equal volume of
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propanol containing OHKPL as internal standard, the samples 
centrifuged to remove the precipitate and the supernatant 
lyophylised. The residue was extracted with a small volume 
of ethanol and a portion taken for glc.
5.2.5. CHROMATOGRAPHY
For chromatography 1 - 5 ^1 of the final ethanolic 
extract was injected on to the glc columns.
The optimum conditions for sensitivity and resolution 
of standards were as follows
i) For Standard A (2.8m column), column temperature 
190°C (isothermal); injection port temperature 
230°C; carrier gas flow rate lOOml/min.
ii) For Standard B (l.7m column), column temperature 
230°C (isothermal); injection port temperature 
250°C; flow rate of carrier gas (oxygen-free 
nitrogen) 50ml/rain.
For both, detector gas flow-rates: air 360ml/min, hydrogen
75ml/min.
The amplifier attenuation setting usually employed was 
X 200 (detector response of 2 x 10 amp f.s.d.), although 
this could be altered instantaneously as conditions required.
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3.2.6. CALCULATION
From standard chromatograms the response factor (peak 
height/quantity injected) of OHHPL and the internal standard 
were calculated.
The concentration of OHHPL in each test is then given by
(t-t) X X  f X  Igo =
where PH IS = Peak height of the internal standard
RF = Response factor
a = Amount of internal standard added (pg)
V = Volume of urine or plasma extracted
Results for urines were expressed in terms of creatinine 
concentration by dividing the above result by the creatinine 
result (mol/litre). . ...
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3.3. EVALUATION OF THE METHOD
Prior to the use of the assay for the determination of 
OHHPL in biological fluids an evaluation of its reliability 
was made. It had to be shown that the requirements made of 
the choice of internal standard (section 3*2.2) were ful­
filled and also that in its final form the assay had adequate 
specificity, precision and accuracy for the purposes for which 
it was intended.
3.3,1. ASSESSMENT OF INTERNAL STANDARDS
Similarity in Structure
The structures of OHKPL and OHHPL are shown in Figures 8 
and 9 respectively and that of DM0 is shown in Figure 13.
The similarity between the two pyrroles is obvious but the 
similarity between DM0 and OHHPL is not so readily so. The 
two compounds do, however, have certain features in common.
They are both heterocyclic with a ring nitrogen. They also 
have two substituent oxygen functions and substituent alkyl 
groups. The DM0 has am extra ring oxygen not present in the 
pyrroles.
Linearity of Detector Responses
This was checked by the injection of varying amounts of 
each compound, amounts extending far beyond the range expected 
to be encountered. The detector response, guaged as peak height,
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FIGURE 13 5 » 5-Dimethyloxazolidine~2.4-dione,
INTERNAL STANDARD FOR GLC
was shown to he linear over the range used for all three 
compounds (Figure I4). As would he expected the responses 
to OHHPL and OHKPL were very similar while that to M O D  
was ahout 30-fold less. This was partly due to the peak 
shape of DM0■, which for equivalent injections was hroader 
and thus for equivalent area responses should he shorter.
This, however, was not enough to account for the large 
differences observed in this parameter.
Conservation of OHHPL/lnternal Standard Ratio
The extraction procedure for urines, basically a single 
solvent extraction, make the requirements placed upon the 
internal standard less stringent due to its simplicity. As 
hoth DM0 and OHHPL are extracted in excess of 95% the errors 
arising from variations in the ratio at this stage are minimal. 
The extraction properties of OHHPL and OHKPL in all systems 
used are essentially identical.
Ease of Separation
Figure 15 shows the separation achieved for hoth OHKPL 
and DM0 . In hoth cases are these adequate.
Absence of Contamination
This was assessed by the same methods used to test the 
specificity of the assay (section 3.3.2). Occasional samples 
were encountered with interference at the points interest on
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the chromatogram. For the most part this could he avoided 
by the use of the alternative internal standard.
5.3.2. SPECIFICITY
The specificity of the method depends on the extraction 
of OHHPL and standards free from compounds of similar chrom­
atographic behaviour. Evidence for the lack of interference 
from solvents and reagents was obtained by the analysis of . 
distilled water containing added OHHPL. The final glc traces 
of these extracts showed no extraneous peaks either from 
solvent or from breakdown of standards during the procedure.
The absence of peaks interfering with the OHHPL on the 
test chromatograms was checked by on-column méthylation of 
these components, observing quantitative migration of the 
test peak. When OHHPL was added to a specimen which showed 
an OHHPL peak no new peaks were found, only an increase in 
the OHHPL peak height was observed. Omission of internal 
standards failed to show any other components with identical 
retention times.
Occasional samples were encountered with unknown peaks 
incompletely resolved from the OHHPL or standards. In the 
case of interference with internal standard, the sample could 
be re-analysed using the alternative standard. If this 
occurred with the OHHPL pesdc the estimation had to be discounted, 
The occurrence of this was low and could not be correlated with
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any group of patients. The random occurrence of this allowed 
the omission of the subject from any investigative series.
3.3.3. PRECISION
The overall precision of the method was determined by the 
replicate extractions (lO)of the same blank urine or plasma 
(i.e. urine in which OHHPL was undetectable or plasma from 
control animals) to which synthetic OHHPL had been added. The 
coefficients cf variation for the assays for each standard are 
shown in Table 3*
The same assays allowed calculations of recovery of each 
of the compounds from urine or plasma. Results of these are 
also shown in Table 3*
3.3.4. SENSITIVITY
The sensitivity of the assays as they stand was 0.1 pmol/L 
for urine and 25 ^imol/L for experimental plasma. This was 
gauged from the peak height twice the background noise.
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TABLE 3 PRECISION AND RECOVERY OF OHHPL ASSAY 
FOR URINE AND PLASMA (EXPERIMENTAL)
Internal
OHKPL
standard used 
DM0
Urine Coefficient of 
variation
5.1# 7.4#
Recovery 94-97# 92-95.5#
Plasma Coefficient of 
variation
5.4# -
Recovery 84-93# -
5.4. NORMAL VALUES
The evaluation of the assay was followed by a study of 
normal subjects. These were either healthy members of 
laboratory or ward staff, or normal siblings of porphyric 
patients.
A total of 82 subjects were studied of whom 16 were 
rejected because of administration of the contraceptive pill. 
Although mean values or urinary OHHPL excretion in these 
subjects was greater than matched controls (0.59 ± O.46pmol/L 
compared with 0.34 ± O.33pmol/L) the difference was not 
statistically significant. The remaining 66 were made up of 
38 females (age 17 - 59) and 28 males (age 22 - 64).
Urinary excretion of OHHPL in these subjects is shown in 
Figure I6. Values were expressed in terms of creatinine 
concentration because of the use of spot urine samples. The 
distribution found by plotting OHHPL concentrations in terms 
of urine volume was almost identical. The group, 0 - 35^mol/ 
mol creatinine, (32 subjects) includes 15 subjects in whose 
urine OHHPL was undetectable.
The normal range of OHHPL excretion taken as 95% of the 
normal distribution was 0 - 1.7^mol/L or 0 - 217pmol/mol 
creatinine.
There were no significant sex-related or age differences 
in excretion, although group numbers in the latter analysis 
were small and there was some variation in mean values (Table 4).
97
nT
O
lO
I
§
a
o
CO 8
I
O
8
CO
CO
CO
%M
COA
H
ÈA
A
È
W0
Ac
& CO0 EhC5
63
1-30M
Eh COA
AM A
A
E-tCOM 0A S
(gg = u) dnojSu|*ou |c;o; 40
VÛr4
M
p«4
0
03
1
5
CO
-p
0 
0)
w
ITSrH
8•H
c
§
rf\hf\
1
0
1
I
§
M
g
S
I
&
M
W
g
M
E"<
M
I
Sm
H
O
Spq
S
<N
CM CM
CM
LT\lf\
CMm
ir\
CM
ONmir\
CM
O
3.5. DISCUSSION
The major problem encountered in the development of the 
assay for urine was the instability of OHHPL under certain 
conditions. Extraction procedures had to avoid acidic 
conditions or the presence of methanol with which the OHHPL 
could be methylated. Cold storage (-20°C) overcame any 
instability in urine while the solvent extraction method 
reduced the possibility of losses through degradation. The 
simplicity of the extraction methods, however, limit the 
sensitivity which can be attained by the assay. Gas liquid 
chromatography has the potential for much greater sensitivity 
than that used in the assays. Increased sensitivity in this 
case would require a much greater purification of the substances 
of interest. This was" particularly true in the case of the 
plasma assay. When human plasma was extracted there was gross 
contamination at the areas of interest on the chromatogram.
This could not be overcome by variations in the chromatographic 
conditions such as temperature programming and any other 
purification procedures have the attendant risks of degradation.
It may be that a method with more specific detection capabilities 
such as glc with nitrogen detection or glc coupled to mass 
spectrometry may be required to achieve the required sensitivity 
and specificity.
The method used for serum or plasma from experimental 
animals had low sensitivity because there was little concentration
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of OHHPL during extraction. This however meant that there 
was little interference from other substances. It allowed 
satisfactory quantitation of OHHPL and OHKPL in animals given 
relatively high doses of these substances.
As it stands, the urine method allows, for the first time, 
the absolute quantitation of OHHPL and is suitable for 
investigation into those pathological conditions in which its 
excretion is abnormally raised.
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C H A P T E R  4
3-ETHYL-5-HTDR0XY-4.5-DIMETHYL-A^-PYRR0LIN~2~0NE 
IN PORPHYRIA- AND RELATED DISORDERS
CHAPTER 4
5-ETHYL-5-HTDROXY-4.5-DIMETHYL-A^-PYKROLIN-2-ONE IN 
PORPHYRIA AND RELATED DISORDERS
4.1. INTRODUCTION
The acute porphyrias exhibit certain similarities to some 
overt psychiatric disorders. The psychiatric syndrome of the 
porphyrias is invariably associated with the expression of the 
genetically defined biochemical abnormality but no gross 
abnormalities in haem biosynthesis have been shown in psychiatric 
illness. A proportion of schizophrenics, however, do show mild 
disturbances in porphyrin metabolism. The demonstration of 
excretion of OHHPL in both the porphyrias and some psychiatric 
disorders was the common factor that was the basis of the 
suggestion that OHHPL played a role in the aetiology of the 
psychiatric syndrome of the porphyrias. Pharmacological and 
behavioural studies carried out using like substances, 
especially kryptopyrrole, did not provide evidence contrary to 
this view.
The failure of previous attempts to quantitate OHHPL has 
hindered attempts to investigate this association further. The 
following chapter deals with the quantitation of OHHPL in 
porphyria, although the first sections cover earlier studies 
using a qualitative method.
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OHHPL excretion has also been studied in several other 
disorders because they exhibit certain common features.
These are psychiatric illness, lead poisoning and liver disease
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4.2. QUALITATIVE INVESTIGATION OF MONOPYRROLE EXCRETION 
IN HEPATIC PORPHYRIA
Prior to the development of the glc method for the 
quantitation of OHHPL, a qualitative survey was undertaken using 
a modification of Irvine's method (section 2.6). Using this 
method excretion of OHHPL, then thought to he kryptopyrrole, could 
only be assessed as positive or negative.
It was originally puzzling that two such compounds, krypto­
pyrrole and OHHPL, differing as they do in polarity and hence 
chromatographic properties, could possibly be confused. The 
matter however was resolved by the following findings.
1. When OHHPL was run in the chromatographic system it 
migrated to a position with an R^ of 0.9, identical to that 
of the kryptopyrrole standard. Development of colour with 
Ehrlich reagent required heating to 50 - 60°C.
2. When a kryptopyrrole standard was run and Ehrlich reagent 
applied there was an immediate colour reaction of a 
component with R^ 0.95 with a more reddish colour than 
that of the OHHPL complex. Heating of the chromatogram 
to 50 - 60°C resulted in the visualisation of a second 
component, R^ 0.9, an identical colour to the OHHPL 
complex, with concomitant fading of the kryptopyrrole 
spot. An example of a test chromatogram is shown in 
Figure 17.
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These results indicated that the chromatographic system 
was unable to adequately resolve kryptopyrrole from its 
oxidation products or in fact from these of haemopyrrole. 
Processing of kryptopyrrole in this system causes oxidation 
of a large proportion of the applied sample producing the 
component with 0.9. Development of colour with test urine 
samples required heating indicating that it was an oxidised 
pyrrclic species. The unequivocal identification of this is 
described in the introductory section 1,4.1.
In this section the presence or absence of the mauve 
spot only will be described.
4.2.1. PATIENTS
■ A group of seventeen patients with the three acute forms 
of porphyria (AIP, HC, VG) were studied. Of these four were 
in attack, four in remission and nine were latent for the 
conditions. Urine from ten healthy volunteers was also 
screened.
Urine specimens were first morning samples analysed 
within an hour of voiding and full porphyrin and precursor 
analyses were carried out.
4.2.2. RESULTS
The age, sex, type of porphyria, porphyric status, 
porphyrin and precursor excretion and the result of the krypto­
pyrrole test are outlined in Table 5.
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In all patients in attack and remission ''kryptopyrrole*' 
could be demonstrated in the urine while a negative test 
result was obtained in urine from latent subjects. No 
"kryptopyrrole" could be detected in the urine from any of 
the normal subjects.
The detection limit of the test was difficult to estimate 
The lower limit of detection of the Ehrlich test for krypto­
pyrrole itself is approximately ^nmoles. However, for the 
oxidised pyrrolic forms which were originally thought not to 
react with Ehrlich*s aldehyde, and do so only with heating, 
the detection limit is about 100-fold less. Assuming 100% 
recovery from urine, the lower level of detection was about 
3pmol/L, although this is a very rough estimate.
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4.3. HEPATIC PORPHYRIA
4.3.1. PATIENTS
Eighteen carriers of the A IP gene defect were studied of 
whom 10 were latent (5 male, 7 female). All of the remaining 
patients (all female) were studied when totally asymptomatic 
and four were studied during am acute episode. A brief resume 
of the history of the non-latent porphyries is given in Table 
6, while fuller case histories of those studied in attack are 
given in Appendix 2.
Two patients with hereditary coproporphyria (HC) (both 
female) and four with cutaneous hepatic porphyria (CH), (3 
male, 1 female) were also studied. The patients with HC were 
asymptomatic at the time of study and those with CHP were 
undergoing monthly venesection. None of these patients showed 
overt signs of porphyria at the time of study.
4.3.2. RESULTS
When urinary OHHPL was measured, estimation of urinary ALA, 
PBG and creatinine was also made. It was not possible, however, 
to perform porphyrin estimations in all of the samples but 
estimations were carried out on 24 hour specimens from some of 
the patients using solvent extraction methods.
Where appropriate, statistical evaluation of differences in 
OHHPL concentrations has been made using the non-parametric
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Mann-V/hitney U test while non-parametric correlations were 
made using the Spearman or Kendall ranking tests.
Where possible urinary estimations were performed on 
early morning spot samples. However, there was no consistent 
diurnal variation observed in in-patients. Control values 
used were those of age and sex matched normals chosen at 
random from the normal group.
Urinary excretion of OHHPL in the patients with AIP in 
attack, remission and latency is shown in Figure 18. Where 
multiple estimations have been carried out on a single 
patient median values have been used. Compared with control 
values excretion is significantly raised in all three groups 
(latents p < 0.05» remission p = 0.001, attack p < 0.05). 
Expression of the results in terms of creatinine concentration 
(Figure 19) did not alter the significance of these findings. 
There was no significant difference in the excretion of OHHPL 
in the three test groups. OHHPL excretion in the patients 
with HC and CHP is shown in Table 7. Except for the values 
indicated these lie within the normal range.
OHHPL excretion was followed in patient 3 through an 
acute attack (see case history). Daily OHHPL, ALA. and PBG 
excretion during the attack is shown in Figure 20. There was 
little apparent correlation between the clinical condition 
and OHHPL excretion, while that of ALA and PBG showed reasonably 
good correlation including rebound excretion after the discon­
tinuation of laevulose therapy.
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FIGURE 18 URINARY OHEPL EXCRETION IN AIP
Excrétion is shown in terms of urine volume
O  = subjects with AIP 
#  = age and sex matched control values
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FIGURE 19 URINARY OHHPL EXCRETION IN AIP
Excretion is shown in terms of urinary 
creatinine concentration.
□  = subjects with AIP
■  = age and sex matched control values
TABLE 7 URINARY OHHPL EXCRETION IN PATIENTS WITH 
HEREDITARY COPROPORPHYRIA AND CUTANEOUS 
HEPATIC PORPHYRIA
HEREDITARY COPROPORPHYRIA
Case Date OHHPL |imol/L
1 A.M. 27.5.77 . 0.81
2 J.B. 27.5.77 2.1 *
CUTANEOUS HEPATIC PORPHYRIA
1 C.B. 5.8.77 0.17
2 W.V. . 15.4.77 2.9 *
2.9.77 0.97
18.5.77 1.5
5 J.W. 20.5.77 ND
5.8.77 ND
2.9.77 0.45
ND = Not detectable * Outwith normal range
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Two patients (cases 3 and 5) suffered from frequent severe 
attacks. OHHPL estimations were carried out on several 
occasions on each patient. Results of these estimations are 
shown, along with the patient's condition in Table 8.
A significant association was found in all subjects with 
AIP between the excretion of OHHPL and ALA (Figure 21) (p < O.Ol) 
and an almost identical correlation between PBG and OHHPL 
(Figure 22) (p < 0.05). The similarity of these associations 
was not surprising in the light of the demonstration of a 
highly significant linear correlation (p < O.OOl) between 
urinary ALA and PBG (Figure 23). There was no such correlation 
in normal"subjects.
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TABLE 8 MULTIPLE ESTIMATION OP URINARY OHHPL
IN TWO PATIENTS WITH AIP
Date OHHPL (fimol/L) Condition
Case 3 4.11.76 26.6 Asymptomatic
18.3.77
29.4.77
36.8
2.68
Mild abdominal pain
30.4.77
1.5.77
15.3
4.2 Acute attack
2.5.77 12.1
(see also Figure 20 
and text)
3.5.77 17.3
28.6.77 1.8 Abdominal pain, constipation
29.6.77 2.3 Mild abdominal pain, postural 
hypotension
13.9.77 5.2 Tachycardia, postural 
hypotension
20.9.77 9.3 Abdominal and limb pain, 
tachycardia, agitation
Case 5 11.3.77 12.9 Mild abdominal pain
15.4.77 6.9 Asymptomatic
27.5.77 3.85 Intermittent abdominal pain
12.7.77 8.4 Asymptomatic
3.8.77 1.05 Asymptomatic
30.8.77 2.7 Abdominal pain
31.8.77 1.8 Abdominal pain
•  •
uOuoo idH H O
Ph
M
<
tc
E-4
M
CO
Eh
o
H
"D
PQ
r4
CO o
o
s
1— 1 V
Pi
3
C
g
o o
' C
•H
hQ 6
•H
E m
o
r*4
r4
(d
« Ü
< •H
4->
1— t
•H
4->
(tJ
+>
R M
W W
•H
w C
m O
•H
-P
% nJ
o •H
M u
E-i o
< M
M m
O rt
o
CO (D
CO x:
< Eh
1-4
C\J
o
M
P4
Pi
T- r-
9JÎ!l/loujri u^uoQ IdHHO
w
EhM
COEhO
W
•“5
PP
CO
O
g
1-3I
>H
«
I
§M
ë
I— I O 
O co co 
<
C\J
CM
H
Ü
M
m
O
O
\/
Pi
o
•H(M
•H
&
•H
n
!>i
cd
u
•H
-P
U
•H
-P
(d-p
m
u
•H
Co
•H
-P
■2O
Owm
cd
Eh
M
<
O U O Q  VIV
o
e
a
<
i
cr;
K>
C\J
H
oM
8
0 
V
A
1U•H
(M•H
&•H
CQ
nSo
•H
•P
CO
•H+»
a
CO
A•H
I
Iti
1
I
4.4. PSYCHIATRIC DISORDERS
OHHPL was measured in the urine of patients with various 
psychiatric disorders as an extension of previous studies by 
other workers who had shown increased inoidence of OHHPL in 
certain types of psychiatric illnesses.
4.4 .1. PATIENTS
The major difficulty encountered in this study was in 
accumulating adequate numbers of patients within the various 
classifications of psychiatric disease. There were also large 
variations in the clinical status of patients within a 
particular group. The clinical diagnosis of each patient was 
made by the consultant psychiatrist and in some cases Feighner 
criteria (Feighner et al, 1972) were used for confirmation. 
V/here a quantitative assessment of the severity of a patient’s 
condition was made the patients were rated using the Hamilton- 
Lorr rating scale (Hamilton et al, I96O). An example of this 
is shown in Appendix 5*
Initially classifications were made broadly to give larger 
samples for analysis. These were
1. Psychosis; schizophrenia, endogenous depression, 
manic depression.
2. Neurosis: neurotic depression, anxiety depression,
obsessional neurosis.
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5. Organic brain disorder; This was principally 
organic brain damage resulting from alcoholism, 
syphilis or physical trauma.
There were gross variations in clinical conditions even 
within the sub-groups, and it was virtually impossible to obtain 
homogeneity with significant numbers.
The group of patients studied initially was a group of in­
patients from the psychiatric wards of Stobhill General Hospital 
and of the Southern General Hospital, Glasgow. These patients 
fell mainly into the schizophrenia or endogenous depression 
groups. There were 24 subjects (l9 female, 5 male) aged 
between 24 and 78 years old, of whom 22 could be broadly classed 
as psychotic (5 schizophrenia, 17 endogenous depression). At 
the time of study all of these patients were undergoing drug 
therapy for their psychiatric condition and/or non-associated 
illnesses. Table 9 shows the drugs in use with these patients.
I
Liver function tests were carried out in all of the patients 
from the Southern General Hospital. In every case these were 
normal.
The possibility of drug-mediated alterations in OHHPL 
excretion made it desirable to obtain a similar group of 
patients not on drugs. This group of patients was obtained 
from the Gartnaval Royal Hospital, Glasgow, and consisted 
of 22 patients (all male) of whom 8 were psychotic (7 schizo­
phrenia) and 9 had an organic brain syndrome almost always
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TABLE 9 THERAPEUTIC AGENTS GIVEN TO PSYCHOTIC 
SUBJECTS STUDIED
NEUROLEPTICS
Thioridazine
Perphenazine
Haloperidol
Trifluoperazine
Chlorpromazine
Fluphenazine
MINOR TRANQUILLISERS 
Nitrazepam 
Chlordiazepoxide
Lorazepam Pimozide
ANTIDEPRESSANTS
Imipramine
(L-Tryptophan)
Phenelzine 
Lithium Carbonate
Amitryptyline
MISCELLANEOUS
Propranolol
Carbimazole
Aminophylline
Dextropropoxyphene Frusemide 
Oxprenolol Digoxin
Orphenadine Alcohol
associated with alcoholism. Liver function tests were carried 
out on the patients with alcoholism. Most of the patients had 
a raised serum alkaline phosphatase; one had raised bilirubin 
and one had raised alanine transaminase (ALT) activity. None 
of these patients had been on drug therapy for at least four 
months.
Three patients were studied with an organic brain syndrome 
not related to alcoholism and 6 others with miscellaneous 
disorders were also studied.
4.4.2. RESULTS
The results of OHHPL estimations in the urine of psychotic 
patients on drugs is shown in Figure 24. Although a number of 
the values are within the normal range when treated as a group, 
excretion is significantly greater than that of the age and sex 
matched control values (p < 0,01). There was no significant 
difference between the schizophrenic patients and those with 
endogenous depression. Furthermore no correlation could be shown 
between OHHPL levels and the urinary excretion of ALA and PBG. 
Elevated excretion showed no association with any particular drug 
being prescribed for the patients and the large variety of drugs 
involved meant that analysis of the effect of single drugs could 
not be looked at.
OHHPL estimations in patients with schizophrenia and alcoholic 
organic brain syndrome who were not on drugs showed differences
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when expressed in terms of creatinine or urine volume (Figure 
25). The significance of this could not he determined. It is 
clear, however, that several of the patients in each group 
showed raised OHHPL excretion. In all cases urinary ALA. and 
PBG levels were within the normal range and there were no 
correlations or associations with OHHPL levels. The Hamilton 
rating scores of the patients with schizophrenia are shown in 
Table 10. The scores in each of the P and N sub-scales are 
shown as well as the total score. OHHPL levels in terms of 
creatinine and urine volume are also shown. Table 11 shows 
the results of statistical analyses of possible correlations 
between each of the Hamilton rating scores and OHHPL levels.
When expressed in terms of urine volume there is a tendency 
towards a negative correlation. However, when levels are 
expressed in terms of urinary creatinine, there are significant 
negative correlations between OHHPL and the HRS(T) and HRS(P) 
values.
HRS values were not obtained for the patients with organic 
brain disorders. Abnormal OHHPL excretion showed no statistical 
correlation with abnormal liver function tests.
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TABLE 10 HAMILTON RATING SCORES (HRS) AND URINARY
OHHPL LEVELS IN SCHIZOPHRENIC PATIENTS
The values of 
on the P and N
the total 
subscales
score (T) and the scores 
are given (see Appendix 3)
OHHPL
Case HRS(T) HRS(P) HRS(N) umol/L umol/mol creat.
1 25 25 0 . 5.5 443
2 2 2 0 1.26 851
3 49 45 6 0.46 36.5
4 0 - 0 0 0.78
5 26 12 14 1.46 198
6 32 28 4 0.55 102
7 5 3 2 0.69 259
TABLE 11 SPEARMAN RANK CORRELATION COEFFICIENTS
FOR THE DATA SHOWN IN TABLE 10
Significance of results: * p < 0.05 ** p < 0.01
OHHPL
jimol/L umol/mol creat.
h r s (t ) -0.43 -0.94
HRS(P) -0 .39 - -0.83 *:
HRS(N) -0 .32 -0.77
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4.5. LEAD POISONING
Lead poisoning was included in the series because it has 
long been known that lead burden causes disruption of haem 
biosynthesis (Garrod, 1892). Lead has been shown to affect 
the activities of several of the enzymes of haem biosynthesis 
and in fact inhibition of ALA.D by lead (Hemberg and Nikkanen, 
1972) has been used in the past as an index of the severity of 
lead poisoning. Lead also causes a decrease in FERRO.C and 
TJRO.D activities (Boyett and Butterworth, 1962; Schmidt et 
al, 1973) and. a concomitant increase in the activity of ALA.S 
(Maxwell and Meyer, 1976). Accompanying these enzyme changes 
is increased urinary excretion of ALA and porphyrins but not 
of PBG (Haeger, 1957).
4.5.1. SUBJECTS
Frank lead poisoning is now a rare occurrence. The study 
was thus limited to subjects with sub-clinical lead toxicity. 
The subjects studied were a group of industrial lead workers 
none of whom showed any outward signs or symptoms of lead 
poisoning, although all had blood lead levels outwith the 
normal ranges.
4.5.2. RESULTS
Urinary OHHPL, urinary ALA and PBG, blood lead levels and 
erythrocyte ALA.D activity were measured in 15 subjects. The
112
results are shown in Table 12. All subjects had blood lead 
levels (BPb) outwith the normal range and all had depressed 
erythrocyte ALA.D activity. ALA excretion was raised in a high 
percentage of the cases but urinary OHHPL and PBG were within 
normal ranges.
It was noticed that high ALA excretion was associated with 
lower OHHPL values and non-parametric analysis revealed a 
significant negative association between OHHPL and ALA (p < O.O5) 
(Figure 26) and also between OHHPL and ALA.D (p < 0.05). There 
were also significant correlations between the parameters of lead 
poisoning, ALA, ALA.D and BPb (p < 0.001 in all cases).
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TABLE 12 OHHPL. ALA AND PBG IN URINE, ERYTHROCYTE
ALA.D ACTIVITY AND BLOOD LEAD (BPb) LEVELS
IN INDUSTRIAL LEAD WORKERS
AU.D
OHHPL ALA PBG BPb nmol ALA/min/
Case umol/L umol/L umol/L umol/L ml rbc
1 1.2 31.3 8.4 2.3 11.3
2 1.26 27.8 5.5 3.4 6.8
3 1.84 47.3 6.3 3.3 4.2
4 0.21 30.5 8.3 2.1 13.2
5 0.12 199.0 7.2 4.4 0.9
6 0.01 50.6 5.5 4.3 1.8
7 0.59 78.7 20.4 3.9 0.7
8 0.41 61.8 4.9 3.7 8.4
9 0.22 193.0 7.2 4.8 1.3
10 0.22 28.1 3.3 3.2 8.6
11 0.84 33.1 3.8 3.5 7.0
12 0.75 85.2 0.01 3.9 2.8
13 0.66 35.5 2.7 3.9 2.9
14 0.13 60.1 5.0 3.3 8.1
15 0.01 210.0 0.55 5.0 0.7
Normal
range 0—1.7 0-43 0-25 0-2 16-38
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4.6. LIVER DISEASE
In hepatic porphyria there can be changes in liver function 
that varies from near normality in AIP to gross dysfunction in 
CHP and in each porphyria the degree of dysfunction bears some 
relationship to the activity of the disease. On the other hand 
porphyrinuria has been associated with abnormal liver function 
of origin other than porphyria. Excessive urinary excretion of 
coproporphyrin has been found in hepatitis, cirrhosis, jaundice 
and alcoholic liver disease, (Lamon, 1977)* In the case of 
cirrhosis depressed ALA.D activities have also been found 
(Allain et al, 1977).
This tentative connection between liver disease and 
porphyria suggested that it may have been worthwhile to look at 
the excretion of OHHPL in- a group of patients with liver disease. 
The following sections describe such a study.
4.6.1. PATIENTS
The patients studied were all attending the out-patient 
clinic of Stobhill General Hospital. They fell into two main 
groups: chronic active hepatitis and cirrhosis. Of the patients
with cirrhosis, 5 had primary biliary cirrhosis, 5 had alcoholic 
cirrhosis and 1 patient had cirrhosis of unknown origin 
(cryptogenic).
All of the patients with hepatitis were undergoing steroid 
therapy at the time of study while the patients with cirrhosis
114
were receiving various regimens consisting mainly of vitamin 
supplementation.
4.6.2. RESULTS
Relevant clinical data, liver function tests and urinary 
OHHPL, ALA. and PB G in the patients studied are shown in 
Tables 13 and 14. In all cases of hepatitis, urinary ALA and 
PEG were normal as were OHHPL levels, except for one patient 
with accompanying^ cirrhosis. Likewise in the cirrhosis group 
porphyrin precursor excretion was largely normal but several 
cases showed increased OHHPL excretion. This latter finding 
could not be correlated with liver function tests, the severity 
of their clinical condition or ALA and PEG levels.
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4.7. DISCUSSION
Qualitative chromatographie methods have been used to show 
an assooiation between the exoretion of OHHPL and psyohosis and 
various forms of porphyria (CHP, VP and AIP) (irvine and Wilson, 
1976). The same workers were also able to demonstrate the 
exoretion of OHHPL in 12% of normal subjects. The results 
presented in this chapter also show that OHHPL is excreted in 
HC.
One interesting feature arising from the qualitative study 
(section 4*2.) was the absence of chromatographic evidence for 
the excretion by latent porphyria oases. Although this is most 
certainly due to the insensitivity of the method, it provided 
some clues to excretion levels in each of the porphyrias studied. 
The main shortcoming of the study was the lack of numbers in each 
group and it may be erroneous to try and draw too many conclusions 
from it.
The establishment of the quantitative method has allowed the 
measurement of OHHPL in all but 22% of normals and from the 
normal distribution some estimate of the sensitivity of the 
qualitative methods can be gained. The maximum sensitivity of 
the method described in section 2.6., which could not detect 
OHHPL in normals, is about 2.1 pmol/l while that of the method 
used by Irvine and Wilson (1976) is greater than 1.5 pmol/l.
The results of the quantitative assay on urine from the 
patients with AIP are similar to earlier studies which were able to
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shew excretion in up to 90% of the cases (Irvine and Wilson,
1976).
No significant differences were found in attack, remission 
or latency. This, along with the findings in repeated analyses 
in single patients in attack and remission would appear to oast 
doubt on a possible role for OHHPL in the aetiology of any of 
the manifestations of AIP. Any attempt to correlate OHHPL with 
the psychiatric status of patients with acute porphyria was 
frustrated by the lack of patients presenting with a psychiatric 
syndrome.
It may be that urinary excretion does not provide a good 
enough index of plasma or tissue levels and variations in plasma 
levels may be masked by gross disturbances in urinary levels.
This is also probably the- case with ALA and PBG exoretion and 
plasma levels, where again it is much easier to measure urinary 
concentrations of ALA and PBG than plasma levels and significant 
changes in plasma levels may never be reflected in urine.
One interesting finding was the assooiation between OHHPL 
and ALA and PBG levels. The linear relationship between ALA 
and PBG requires that OHHPL exoretion be related to only one of 
ALA and PBG for both of the above associations to arise. That is, 
if for example OHHPL excretion was a factor of PBG exoretion, the 
assooiation of ALA with OHHPL would arise automatically. The 
findings in lead workers may shed some light on this. The absence 
of any correlation between the raised ALA levels seen in these
117
subjects would suggest that in AIP the ALA-OHEPL assooiation is a 
secondary result.
This finding in turn raises the obvious question, ’is OHHPL 
formed from PBG ?’. Figure 27 shows a comparison between OHHPL 
and PBG and it can be seen that decarboxylation (x 2) and deamination 
of PBG would give the required carbon skeleton while PBG.O has 
been shown to insert the required oxygen functions (Frydman et al,
1973).
There are other compounds which could theoretically give rise 
to OHHPL. Reviewed recently by Irvine and Wilson (1976), these 
include dicarboxylio porphyrins with the correct ’haemo’ 
configuration in the D ring, tetrapyrrolic bile pigments of the 
IX-cc on IX-3 series, again with the’haemo’ configuration or 
certain bilirubic acids or propentdyopents. Irvine and Wilson 
have proposed that the most likely of these are certain porphyrins 
of the isoooproporphyrin series which are produced in excess in 
CHP but this would not account for OHHPL excretion in AIP, where 
these porphyrins do not occur, unless all of the isoooproporphyrin 
produced in AIP is metabolised via OHHPL. It would thus appear 
that PBG may be the most likely precursor of OHHPL.
The findings in the psychiatric patients again reinforce 
earlier results by other workers. There are significant increases 
in urinary OHHPL levels in patients with schizophrenia, endogenous 
depression and alcoholic dementia (organic brain syndrome) but 
again there was no positive correlation with excretion and 
patient’s condition. The negative correlation between the Hamilton
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rating scores of the schizophrenics and OHHPL would in fact 
suggest that exacerbation of the psychiatric illness is 
connected with a decrease in OHHPL excretion. However, 
verification of this finding would require the accumulation 
of greater numbers and again plasma levels.
Increased excretion in patients with alcohol induced 
organic brain syndrome may be a result of abnormal liver 
function, although abnormalities shown in liver function tests 
were not great. There may be some similarity in these cases 
to cirrhotic liver disease (including alcohol induced) where 
some patients showed increased excretion. The fact that both 
in the psychotic patients and those with liver disease, OHHPL 
excretion is increased in the absence of PBG, may be contrary 
to the hypothesis of PBG" as a precursor. It may be that, in 
these cases, increased activity of the OHHPL synthesising enzyme 
system (if there is one) is due to deranged liver metabolism as 
compared to substrate induction in the porphyrias.
So, in none of the conditions studied can raised OHHPL 
excretion be associated with exacerbation of the clinical 
condition and these findings must cast doubt on any role for 
OHHPL in the aetiology of the manifestations in these disorders. 
It may be that knowledge of plasma levels will allow a definite 
statement to be made in this respect.
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C H A P T E R  5 
MONOPYRROLES AND HAEM BIOSYNTHESIS
CHAPTER 3
MONOPYRRQLES AND HAEM BIOSYNTHESIS
5.1. INTRODUCTION
Qualitative studies, following the discovery of OHHPL 
excretion in schizophrenics, showed that excretion of OHHPL 
was also found in two porphyrin producing disorders; 
porphyria (Irvine and Wilson, 1976) and porphyrin producing 
psychotic states (Huszak et al, 1972). Qualitative work 
described in section 4*2. was suggestive of a role for OHHPL 
in the precipitation of the acute porphyric attack, but the 
more recent quantitative studies proved contradictory in this 
respect. These studies did provide evidence, however, that 
OHHPL excretion was directly associated with the abnormalities 
in haem biosynthesis seen in the porphyrias.
The following studies were prompted by the earlier work 
and were designed to investigate the possibility that OHHPL 
excretion was not the result of abnormal porphyrin metabolism 
but was a factor in the aetiology of such abnormalities. It 
was known that the haem biosynthetic pathway is sensitive to 
treatment with a wide variety of agents and this work was 
designed to investigate a possible direct effect of OHHPL and 
related compounds on haem biosynthesis.
The substances used in the study were those originally
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thought to be the natural product; kryptopyrrole and OHKPL, 
as well as OHHPL itself. For comparison, three other 
pyrrole species were used. These were
1. Haemopyrrole: The synthetic precursor of OHHPL and pp*
isomer of kryptopyrrole.
2. Phyllopyrrole: An alkyl pyrrole with the same substituents
as kryptopyrrole and haemopyrrole but with a methyl group 
on the reactive 5-position.
3# Ethyl 3-acetyl-2,4-&imethylpyrrole-5-carboxylate (EADC), an 
intermediate in the synthesis of kryptopyrrole with carboxy- 
ethyl and acetyl substituents replacing the a-raethyl and 
P-ethyl groups of phyllopyrrole.
The latter two compounds were found to lack the extreme 
toxicity of kryptopyrrole and haemopyrrole.
Biochemical studies were designed to look at the effects 
of OHHPL, the natural compound, in particular, although 
selected properties of the other compounds were studied.
Effects on the following aspects of haem metabolism were 
looked at
1. In vivo porphyrin and precursor excretion.
2. The activities of the enzymes of haem biosynthesis in vivo 
and in vitro.
3. Hepatic porphyrin levels.
To guage the effects on haem utilisation and breakdown, 
the activity of hepatic haem oxygenase (HAEM.O), the haem
121
degrading enzyme, and microsomal haem and cytochromes P-450 
and were also measured.
Attempts were also made to assay porphobilinogen 
oxygenase (PBG.O) one of an ill-defined group of oxygenases 
capable of oxidising monopyrroles such as PBG and krypto­
pyrrole. Although not described in humans, induction of 
this enzyme has been shown to reverse experimentally 
produced porphyria in animals (Frydman et al, 1975)»
122
5.2. PORPHYRIN SYNTHESIS AND EXCRETION
The following set of experiments were designed as a 
preliminary investigation into the effects of monopyrroles 
on porphyrin excretion in rats. Hepatic levels were also 
measured to monitor synthesis. In one set of experiments 
ALA supplementation was given to look at the effects of 
these compounds on an already overloaded pathway.
Dose responses were studied using EADC which was in 
plentiful supply and was non-toxic and thus allowed 
administration in increased doses.
5.2.1. METHODS
In all experiments Sprague-Dawley rats weighing between 
150 - 200g were used. Animals were housed in metabolic 
cages and given food and water ad libitum.
Animals were injected (intraperitoneally) with the 
compounds of interest. The doses of kryptopyrrole and 
haemopyrrole were limited by their extreme toxicity. Table 
15 shows the doses normally employed: for kryptopyrrole and
haemopyrrole these were the maximal non-lethal doses, for 
OHHPL and OHKPL these were the minimum effective doses and 
for EADC and phyllopyrrole arbitrary non-toxic effective 
doses.
Compounds were dissolved either in propylene glycol or 
50% C'/y) ethanol and control animals received propylene glycol
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TABLE 13 DAILY BOSES OF MONOPYRRQLES AND 
ALA FOR in vivo STUDIES
Unless stated otherwise these were the 
daily doses used
DOSE
mmol/kg mg/kg
Kryptopyrrole 0.65 80
OHKPL 0.65 100
Haemopyrrole 0.41 50
OHHPL 0.65 100
Phyllopyrrole 0.65 90
EADC 0.96 200
ALA (HCl) 0.60 100
or 50% ethanol alone. Where AIA supplements were added these 
were dissolved in saline and the pH of solution brought to 
pH7 with saturated sodium bicarbonate.
Urine and faeces collections were made daily and on 
sacrifice livers were removed for porphyrin estimation.
Normally porphyrin estimations were made by solvent extraction 
methods, although HPLC analyses of the porphyrin products of 
some experiments were carried out to verify the identity of the 
extracted porphyrin and to gain information on the individual 
porphyrin species present.
Urinary porphyrin and precursor excretion were expressed as 
nmol/rat/24h while faecal excretion and hepatic concentrations 
were given as nmol/g dry wt. and nmol/g wet wt. respectively.
5.2.2. RESULTS
Using the doses of monopyrroles shown in Table 15 all of 
the compounds were found to increase porphyrin excretion and 
hepatic porphyrin levels. ALA and PBG excretion was unaltered 
by treatment in all cases.
Urinary excretion and faecal levels are shown in Table 16. 
In all cases total urinary excretion of porphyrins is raised, 
and in each case, except EADC, coproporphyrin is by far the 
major fraction. HPLC analyses of the individual porphyrins 
in the urine of animals treated with OHHPL, haemopyrrole and 
EADC are shown in Figure 28.
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There is no apparent consistent change in the proportion 
of each porphyrin. Honopyrrole treatment caused a decrease in 
the proportion of coproporphyrin while EADC also reduced the 
proportion of penta. OHHPL and haemopyrrole increased the 
proportion of uroporphyrin and penta while EADC increased 
uroporphyrin and hepta. Treatment with OHHPL only marginally 
changed the proportion of each porphyrin.
Faecal levels show little change from control values 
although EADC treatment causes a decrease in faecal porphyrin 
excretion. HPLC analysis revealed no major change in the 
proportional make-up of the total porphyrin. The coproporphyrin 
contained a small percentage of penta and this was uniform 
throughout.
Hepatic levels are shown in Table 17. In all cases proto­
porphyrin concentration is significantly raised. However, 
treatment with OHHPL and OHKPL results in no significant elevation 
of coproporphyrin levels.
HPLC analysis of the hepatic porphyrins showed that penta 
was only present in one case (haemopyrrole) and then as a very 
small percentage of the total porphyrin.
Tv/o experiments were carried out to study the effects of 
ALf. loading in pyrrole treated animals. For this, OHKPL and 
OHHPL were used. The results with both pyrroles were almost 
identical. Those for OHKPL are shown in Figures 29, 30 and 31* 
Treatment with ALA alone increased urinary excretion of ALA,
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TABLE 17 HEPATIC PORPHYRIN CONCENTRATIONS IN
RATS TREATED WITH MONOPYRRQLES
n = 6 in test groups and n = 24 in the 
control group
Significance of difference from control 
values :
* p < 0.005 ** p < 0.001
Group
Hepatic concentrations (nmol/g wet wt)
Coproporphyrin Protoporphyrin
Control 0.15 ± 0.07 0.37 ± 0.13
Kryptopyrrole 0.27 ± 0.06** 0.72 ± 0.23*
OHKPL 0.18 ± 0.07 0.76 ± 0.22**
Haemopyrrole 0.58 ± 0.18* 1.47 ± 0.39**
OHHPL 0.17 ± 0.09 0.97 ± 0.35**
Phyllopyrrole 0.48 ± 0.13** 3.51 ± 0.7**
EADC 0.33 ± 0.11** 1.81 ± 0.52**
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PBG, coproporphyrin and uroporphyrin, faecal levels of copro­
porphyrin and protoporphyrin and hepatic levels of coproporphyrin 
and protoporphyrin. OHHPL treatment alone had no effect on ALA 
or PBG excretion but increased urinary and hepatic porphyrins. 
When given together the effects appeared to be synergistic with 
most parameters being increased above those of ALA treated 
animals.
The dose response of porphyrin excretion to increasing 
monopyrrole dosage was studied using EADC. Total daily excretion 
in animals given daily doses of 0.48, 0.96, 1.44 and 1.92 mmol/kg 
is shown in Figure 32. The maximum response was shown at 1.44 
mmol/kg. Peak excretion was on either the second or third day, 
although the animals at the lowest dose showed no peak of 
excretion over the period studied.
Animals receiving the three highest doses showed a marked 
diuresis which was also greatest at 1.44 mmol/kg and at the peak 
urine volumes were up to four times that of control animals.
The increased excretion of porphyrin was not entirely due to the 
diuresis as porphyrin levels in the urine were also raised.
Figure 33 shows the individual porphyrins in the urine of 
each group of animals at the peak excretion point (day 2 or 3)» 
With increasing dosage there is a decrease in the proportion of 
coproporphyrin with a concomitant increase in the formation of 
hepta then uroporphyrin.
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5.5. ENZYMES OF HA EM BIOSYNTHESIS
This set of experiments were carried out with OHKPL and 
OHHPL only. The effects of these compounds on each enzyme 
activity was measured in vivo and in vitro.
5.5.1. METHODS
In the in vitro study assays of each of the haem enzymes 
were carried out in the presence of OHHPL or OHKPL at differing 
doses calculated to span the projected plasma levels in 
animals given the porphyrinogenic dose of each compound and 
maximal plasma levels in humans. The final concentration of 
OHHPL and OHKPL in the assay mixtures was I6I, 52, 6.5 and 1.3 
Umol/L. Assays were carried out as described in the method 
section and OHHPL or OHKPL were added in one component of the 
assay mixture to give these final concentrations. Pooled liver 
homogenate from 3 rats was used.
For the in vivo experiment animals were treated as in the 
preceding section and were killed at the time of m a-rinruni 
porphyrin excretion (normally 48 hours after the first injection) 
Livers were perfused in situ with ice cold saline, excised and 
homogenates used for enzyme assay.
5.3.2. RESULTS
The results of the enzyme assays with added OHHPL are shown 
in Table 18. In no case was there a significant difference in
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TABLE 18 IN VITRO ENZYME ACTIVITIES IN THE 
PRESENCE OF OHHPL
All enzyme activities are expressed as 
nmol product formed/g protein/hour
Enzyme I6l
Final OHHPL conc. (^imol/L) 
52 6.5 1.3 0
ALA.S 32 28 31 29 33
ALA.D 2.81 2.81 2.85 3.48 3.35
URO.S 11.28 13.29 14.05 15.05 12.06
URO.D 2.68 5.98 2.64 0.16 1.55
COPRO.0 57.2 61.6 59.0 58.5 55.0
FERRO.C 0.42 0.49 0.49 0.47 0.46
any of the treated groups. This was also found for OHKPL.
In vivo results are shown in Table 19* With OHKPL the 
only significant difference was in the raised activity of 
ALA.S There was very large variation in the activities of 
ITRO.D and COPRO.0 and these were not assayed in the animals 
treated with OHHPL. In these animals raised ALA.S was again 
the only difference.
In a separate experiment haemopyrrole also was shown to 
cause an increase in ALA.S activity in rat liver.
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TABLE 19 ENZYME ACTIVITIES IN ANIMALS TREATED 
WITH OHKPL AND OHHPL
* Significantly different from control 
p < 0.005
-j- As percentage of ^^Fe into haem/mg of 
protein/hour incorporation
Enzyme
Activity (nmol product formed/hour per g protein)
Control OHKPL Control OHHPL
ALA.S 72.2 ± 16.5 195.8 ± 65.6* 79.5 ± 10.4 132.4 ± 24.1*
ALA.D 10.1 ± 2.4 8,9 ± 2.1 14.3 ± 3.7 15.2 ± 4.2
URO.S 21.9 ± 7.7 -26.1 ± 7.9 37.8 ± 2.5 41.5 ± 2.9
URO.D 16.5 ± 24.2 6.5 ± 6.4 - -
COPRO.0 92.2 ± 10.0 194 ± 89.0 - -
FERRO.cf 1.81 ± 0.95 1.7 ± 0.66 2.6 ± 0.19 2.6 ± 0.358
5.4. MICROSOMAL HAEM AND CYTOCHROMES
To investigate further the increased activity of ALA.S 
described in the foregoing section, microsomal levels of 
haem and cytochrome P-450 and b^ were measured in the livers 
of animals treated with OHKPL and OHHPL.
5.4.1. METHOD
Animals were treated with OHHPL and OHKPL as before. 
Microsemes were prepared and cytochromes measured by the 
methods described in section 2.7.
5.4.2. RESULTS
The results are shown in Table 20.
Both OHHPL and OHKPL cause a significant decrease in the 
hepatic microsomal levels of haem and cytochrome P-450. In 
neither case do the observed changes in cytochrome b^ levels 
achieve significance.
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5.5. HAEM OXYGENASE
Haem oxygenase (HAEM.O) the haem degrading enzyme was 
assayed in animals treated with OHHPL in an attempt to explain 
the haem deficiency that results from treatment with these 
compounds. Tic of a chloroform extract of whole liver after 
méthylation was also carried out to look for the formation of 
green pigments which have been associated with apparently non- 
enzymic loss of liver haem (Unseld and De Natteis, 197^;
De Natteis and Unseld, 1976). In vitro effects of OHHPL were 
also studied using a microsomal preparation from animals 
treated with stannous chloride to induce HAEM.O as the basal 
level was too low to detect any depression of activity by the 
method employed.
5.5.1. METHODS
In the in vivo studies rats were injected with OHHPL at 
two dose levels: 0.65 mmol/kg and 1.3 mmol/kg. Groups of six
animals were killed at 16 and 40 hours and the livers removed 
without perfusing.
On removal a macroscopic examination of the livers was 
made for green discolouration. A portion was then taken for 
the preparation of microsomes and the remainder was pooled in 
test and control groups and esterified overnight in a methanol/ 
sulphuric acid mixture (95:5). The methanolic mixture was 
extracted with chloroform, the chloroform fractions evaporated
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and the residue applied to silica gel plates and chromato­
graphed in a system consisting of chloroform/kerosene/ 
methanol (20:5:5). On development examination was carried 
cut for the appearance of green bands at positions below 
that of a haem standard.
Microsomal pellets were also examined for green 
colouration before resuspension for the assay of HAEM.O 
(Section 2.8.2),
The in vitro effects of OHHPL were studied using a high 
activity preparation of HAEM.O obtained by treating animals 
with stannous chloride (0.25 mmol/kg in saline) 16 hours before 
the preparation of the microsomal fraction. This produced an 
HAEM.O activity of 40 - 50 times basal. The effects of OHHPL 
were measured by adding-OHHPL to the reaction mixture as for 
the haem enzyme although higher concentrations were used.
5.5.2. RESULTS
All attempts to demonstrate the presence of green pigments 
proved fruitless. Colourations of the microsomal pellets and 
esterified liver extracts from test animals were indistinguish­
able from those from control animals. Tic of the liver extract 
showed no green fractions.
Microsomal HAEM.O activity in animals treated with OHHPL 
is shown in Table 21. There was no significant difference in 
haem oxygenase in any of the groups.
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TABLE 21 MICROSOMAL HAEM.O ACTIVITY IN THE LIVER
OF OHHPL TREATED ANIMALS
Haem.O activity was measured in microsomal 
preparations at 16 hours following a single 
injection or at 40.hours following injections 
of OHHPL at 0 and 24 hours.
Haem.O activity (nmol haem used/ 
mg protein/hour)
Group 16 hours 40 hours
Control 1.58 ± 0.55 1.49 ± 0.72
OHHPL (0.65 mmol/kg) 1.47 ± 0.75 1.61 ± 0.87
OHHPL (1,3 mmol/kg) 1.45 ± 0.58 1.51 ± 0.75
The effect of OHHPL on. HAEM.O from pooled induced livers 
is shown in Figure 34. It can be seen that at the highest 
concentration used (l6pM) there was a $0^ decrease in the 
activity of HAEM.O.
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5.6. PBG OXYGMASE .
Measurement of PBG.O by the method in section 2.8.1 
proved extremely problematical. The activity in the 
microsomes from control animals was so low that it could not 
be measured using the colorimetric method. It has been 
suggested that this low activity is due to the presence of 
an inhibitor of the enzyme under normal circumstances.
Using the radiochemical method the reaction products 
2-keto-PBG and 5-hydroxy-2-keto-PBG (Figure 12) could be 
isolated and quantitated. However, it was found that 
identical processing of blank reaction mixtures also yielded 
both of the reaction products indicating that autooxidation 
of the PBG was occurring during the extraction process.
Processing of PBG solutions in the same way showed that 
the extent of autooxidation was extremely variable and could 
not be eliminated by alteration of the extraction procedure 
without drastically affecting the yield of enzymatically 
produced oxidation products.
Using the enzyme assay, as described, the enzymic 
production of oxidation products was about 2C^ of non- 
enzymically produced material and it was impossible to detect 
any alteration in activity following treatment with haemo­
pyrrole reported as substrate for the same or a similar enzyme 
(Irvine, 1974). Animals treated with either kryptopyrrole or 
haemopyrrole showed the appropriate oxidation products in their
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urine but it is conceivable that these also could be produced 
non-enzymically.
Human placental tissue was used to produce microsomes in 
which the activity of PBG.O could be detected. However, the 
poor quality of the assay precluded any comparative studies 
although the findings were indicative of the presence of this 
system in human tissue.
Purification of the enzyme from any of the sources was 
not carried out as a quantitative assay of the activity of 
the enzyme could not then be obtained. A more sensitive assay 
will probably be required before comparative experiments are 
possible, although it may be that levels are very low in the 
uninduced state.
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5.7. DISCUSSION
Prier to the initiation of these studies the sole report 
of porphyrinogenesis due to a monopyrrole was the report by 
De Matteis that the pyrrole derivative 4-methyl-2-methoxymethyl- 
5-carbethoxypyrrole-3“propionic acid methyl ester could cause 
porphyrin accumulation in chick embryo liver cell cultures 
(De Natteis, I968). The ability of other pyrroles, reported in 
the foregoing chapter, to cause increases in porphyrin synthesis 
and excretion in rats is suggestive that this may be a property 
of pyrroles as a class of compounds.
It is extremely unlikely, considering the structures of the 
pyrroles involved, that the increased porphyrin formation caused 
by administration of these compounds is due to direct incorpor­
ation of the compounds into porphyrins. Evidence in support 
of this has been obtained in bacterial systems. Kryptopyrrole, 
which causes increased porphyrin accumulation in the medium of 
Bacillus subtilis cultures, cannot support the growth of mutant 
strains of the bacteria lacking the initial enzymes of haem 
biosynthesis, ALA.S and ALA.D (Berek et al, 1975)*
It is also equally unlikely that each of the pyrroles used 
is metabolised to a common intermediate, although it is feasible 
that haemopyrrole and kryptopyrrole exert their porphyrin inducing 
effects through the oxidised forms OHHPL and OHKPL. Thus using 
bacterial cultures Durko et al (1975) have shown that the effects 
of kryptopyrrole are enhanced if oxidation products are present
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although these inolude compounds other than OHKPL.
The mechanism of action of the compounds in this study is not 
clear although it is probable that in each case the mechanism is 
the same as that of OHHPL and OHKPL the compounds studied in 
greatest depth. It is clear that the increased porphyrin synthesis 
is due to elevated ALA.S activity and that this is probably due to 
derepression resulting from a decrease in a regulatory haem pool 
as evidenced by decreased microsomal haem levels.
Depletion of the regulatory haem pool, or free haem, could 
occur by one of several mechanisms. Increased enzymic or chemical 
degradation, increased utilisation, or decreased formation could 
all lead to depletion of free haem levels. In liver the major 
fraction of haem is utilised in cytochrome P-450 formation and 
as microsomal cytochromes are also depleted there would appear to 
be no increase in utilisation. There is also no evidence of 
increased degradation of haem. No green pigments, indicative of 
abnormal haem breaikdown, were found nor was there any change in 
HAEM.O activity in vivo.
Oxidised forms of kryptopyrrole have been found to bind to 
haem in vitro (Durko et al, 1976) and this effect may be responsible 
for the inhibition of haem oxygenase at high OHHPL concentrations.
It is unlikely that in vivo concentrations become great enough to 
cause any significant effect on the enzyme.
The most likely reason for the decrease in haem formation is 
an inhibition at some point in the biosynthetic pathway. Evidence
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fer this is given by the accumulation of porphyrins in the 
liver and increased excretion of porphyrins. It is feasible 
that pyrroles, due to their similarity in structure to the 
porphyrins, could cause competitive inhibition in the pathway 
enzymes or transport processes. No effect was shown, however, 
in the enzymes of the pathway studied, in vivo or in vitro, 
although the assays of URO.D and COPRO.0 may have lacked the 
necessary sensitivity or precision to detect any changes.
Little is known of the processes involved in the transport 
of pathway intermediates between the cytoplasm and the mito­
chondria and it is possible that the inhibition occurs there 
or in the penultimate enzyme of haem biosynthesis, protopor­
phyrinogen oxidase for which there is no established assay.
One final possibility is that the monopyrroles exert their 
effects by altering the availability of cofactors or secondary 
substrates for the pathway enzymes such as the iron required 
for the ferrochelatase reaction. The latter may be possible 
if like kryptopyrrole the other monopyrroles are able to complex 
iron (Fischer and Orth, 1934)• No evidence in favour of this
was obtained from the studies with FERRO.C, but it is not incon­
ceivable that the situation in vivo is quite different to that 
in the in vitro assay and that in the in vivo situation the 
concentration and availability of iron are critical.
Although no reports have been made of inhibition of haem
biosynthesis in this manner, the porphyrin excretion pattern is
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not inconsistent with this. At lower doses the main finding 
is of increased coproporphyrin in the urine with increased 
hepatic levels of coproporphyrin and protoporphyrin. This 
is consistent with the findings of Durko et al (1975) who 
found increased coproporphyrin,penta and uroporphyrin (all 
III isomer) in culture medium of B. suhtilis given krypto­
pyrrole.
The effect of EADC in increasing doses is similar to the 
findings in rats treated with hexachlorohenzene (HCB)(Doss et 
al, 1976). Prolonged treatment with HCB results in uroporph­
yrin and hepta being the major urinary porphyrins with copro­
porphyrin next. With EADC the effect was much more rapid.
The relative increase in the proportion of these two porphyrins 
at the higher doses may.reflect progressively greater liver 
dysfunction and the associated diuresis may be also due to this 
or renal damage.
The effects of these compounds were not entirely related 
to their toxicity, although the most toxic, haemopyrrole, was 
the most effective in increasing porphyrin excretion. The 
extreme toxicity of haemopyrrole and kryptopyrrole appeared to 
be associated with the vacant oc-position as substitution with 
an oxygen function or methyl group greatly reduced the toxicity, 
In addition, increasing the number of oxygen functions and thus 
polarity and water solubility, decreased the toxicity without 
abolishing the effects on porphyrin metabolism.
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It would appear then that further investigations are 
required before fuller understanding of the properties and 
mechanism of action of this group of compounds is obtained 
and it may be that the use of the non-toxic EADC may provide 
a model system for the action of the others.
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C H A P T E R  6
BEHAVIOURAL EFFECTS OF 3-ETHYL-5-HYBR0XY-4, 
5-DINETHYL- A^-FYRROLIN-2-ONE
CHAPTER 6
BEHAVIOURAL EFFECTS OF 3-ETHYL-5-HYDR0XY-4.5- 
DIMETHYL-A^-PYRROLIN-2-ONB
6.1. INTRODUCTION
In attempts to investigate further the possibility that the 
porphyrin precursors ALA and PBG were involved in the aetiology 
of the manifestations of the acute porphyrias, a large number of 
pharmacological studies have been carried out. This is especially 
true of ALA the more readily available compound. Recent work 
reviewed by Becker and Kramer (1977) has shown that ALA and PBG 
both have potent pharmacological effects on the nervous system. 
However, the physiological significance of these findings is 
uncertain.
As well as pharmacological activity,ALA has been shown to 
exert behavioural effects including impairment of voluntary 
movement (McGillicn et al, 1973; NcGillion, 1975) and effects 
on social behaviour in mice (Cutler and Moore, 1978).
The association of the excretion of OHHPL with porphyria 
and psychiatric disorders has led to the testing of the 
pharmacological and behavioural effects of certain pyrroles, 
especially kryptopyrrole originally thought to be the natural 
metabolite. Although kryptopyrrole and its oxidised form 
(OHKPL) were found to have both pharmacological and behavioural 
properties (see Section 1.4.2.) OHHPL has not been tested in any
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system* The following sections describe experiments designed 
to look at the effects of OHHPL in two systems in which ALA. 
was found to be active. These were designed to look at 
spontaneous voluntary activity in rats and social behaviour 
in mice. Both of the methods allow quantitation of any changes 
in behaviour.
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6.2. METHODS
The spontaneous voluntary activity of rats treated with 
OHHPL was measured by the method of NcGillion et al (1973)*
A group of six adult male rats were injected with OHHPL 
(0.65 mmol/kg in ethanol (50% ^/v))and six control animals 
received 50% ethanol alone 7 minutes later. Ten minutes 
following the injection each group of animals was placed in 
an activity monitoring box and the activity registered for 
five minutes.
The activity monitoring system comprised a wooden glass- 
fronted box (60cm X  60om x 60cm) into the roof of which two 
ultrasonic pressure transducers were mounted. One of the 
transducers, acting as a transmitting element, was driven by 
an oscillator unit at 4O.KH2, setting up a standing wave 
pattern within the test area. The second transducer acted 
as a receiver and changes in the standing wave pattern caused 
by the movement of animals within the box produced the output 
of the unit. The demodulated and amplified output from the 
receiver was used to drive a mechanical counter and the count 
registered on it was proportional to the activity monitored by 
the receiver.
By using a pair of counter/amplifiers both attached to the 
same receiver it was possible to differentiate between gross 
and fine movements by manipulating the sensitivity of each.
The counter set at greater sensitivity picked up fine and gross
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movements while that at lower sensitivity picked up grçss 
movements only, A measure of fine movement could be 
obtained from the difference of the two values.
The spontaneous activity of each group of animals was 
measured for 5 minutes every 15 minutes and measurements were 
continued for 1.5 hours. The whole experiment was carried 
out under a 'safelight' and the animals were observed for any 
gross abnormalities in behaviour.
The second set of experiments involved the direct 
observation of the behavioural acts and postures during 
social interaction between mice. The method entailed the 
placing of two unfamiliar mice together and recording the 
acts and postures during the ensuing encounter. The postural 
elements and behavioural acts forming the basis of the study 
were outlined by Grant and Mackintosh (1963) and were grouped 
into the categories of non-sooial behaviour, social investi­
gation, aggression and flight. The subdivisions of each 
category are shown in Table 22.
In practice, adult male mice of the CWF strain were 
injected with OHHPL in trigcl/saline (l:8) at two dose levels 
(0.975 mmol/kg and 1.95 mmol/kg). Control animals received 
trigol/saline. Each treatment group was divided in two with 
animals in each half drawn from different stock cages. At 50 
minutes to 1 hour after injection two mice, one from each half 
of the same treatment group, were placed in a clear transparent
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TABLE 22 BEHAVIOURAL CATEGORIES AND INDIVIDUAL 
ELEMENTS OBSERVED IN THE ETHOLQGICAL 
STUDY OF THE EFFECT OF OHHPL IN MICE 
(Grant and MacKintosh, 1965)
1. NON-SOCIAL BEHAVIOUR
Explore Dig
Scan Push-dig
Wash Eat
Self-groom Jump
Scratch
Crawl-over
on-bars
off-bars
2. SOCIAL INVESTIGATION
Attend Nose
Investigate Follow
Sniff Push-under
Groom
Stretch-attend
Crouch
3. FLIGHT
Flag
Evade
Upright posture Defensive sideways
Defensive upright Retreat
4. AGGRESSION 
Bite
5. IMMOBILITY (No individual elements)
cage between two observers. The behaviour shown by each animal 
was recorded by the observers for five minutes and the frequency 
and duration of each category listed. Following observation 
animals receiving the higher dose level were anaesthetised with 
ether and blood removed by heart puncture for estimation of 
plasma OHHPL levels. They were then killed before recovery.
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6.3. RESULTS
The results of the spontaneous activity measurements are 
shown in Table 25. When summed over the times of the experiment 
each day there was no significant differences between test and 
control group. Within each group and category there was a large 
variation in values and this may reflect an effect of the 
injection itself.
In the ethological study there were no apparent differences 
in any of the categories in either of the test groups. The 
combined results are shown in Tables 24, 25 and 26. In no 
category was there any significant difference in mean frequency 
cf any of the elements in each category or the sum of the 
individual elements of a category. The total mean duration of 
all elements of each category showed no differences between 
groups.
The mean plasma OEHPL level in the test group receiving 
OHHPL at 1.95 mmol/kg was 0,31 ± O.llmmol/L.
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TABLE 23 SPONTANEOUS ACTIVITY IN ANIMALS GIVEN" 
OHHPL AND CONTROLS
Activity was measured every 15 minutes and 
the animals were injected on two consecutive 
days.
Total counts in each category 
Test (n = 6) Control (n = 6)
DAY 1 Gross Gross+Pine Fine Gross Gross+Fine Fine
lOmin 10076 12801 1725 5554 11427 5873
.25min 5412 10485 5075 6110 11029 4919
40min 3238 7658 4420 4403 8696 4293
55min 2968 6594 5526 4032 8689 4646
TOrain 2337 4581 2244 2900 6435 5535
85min 2895 10298 4403 6357 10595 4258
Mean 4987 8736 3490 4889 9478 4587
S.D. ±2865 ±3001 ±1460 ±1558 ±1895 ±748
DAY 2
lOmin 4311 7795 3484 5988 7786 5799
25min 5323 6960 5637 2842 6490 5648
40min 4415 8550 4135 5401 10383 4982
55min 1460 5582 1922 2271 5563 5292
Mean 5377 6671 5295 5625 7556 5950
S.D. ±1369 ±2287 ±956 ±1382 ±2093 ±755
TABLE 24 RESULTS OF OBSERVATIONS OF NON-SOCIAL
BEHAVIOUR IN ANIMALS TREATED WITH OHHPL
NON-SOCIAL BEHAVIOUR Mean frequency of individual elements
Explore
Scan
Wash
Self-groom
Dig
Push dig
Eat
Jump
Scratch
Crawl-over
on-hars
off-hars
Overall mean frequency 
Overall mean duration
Control 
(n = 28)
57.2
48.9
5.5
2.57
7.50
2.50 
1.55 
1.47 
0.57 
0.04 
0.47
0
126.57
227.23
Test.
(n = 32)
55.69
49.34
2.25
1.88
6.63
5.54
1.10
0.75
0.41
0
0.12
0.06
121.5
224.75
TABLE 25 RESULTS OF OBSERVATIONS OF SOCIAL
INVESTIGATION IN ANIMALS TREATED
WITH OHHPL
SOCIAL INVESTIGATION Mean frequency of individual elements 
Control Test
(n = 28) (n = 32)
Attend 18.18 16.1
Investigate 6.39 7.88
Nose 6.04 4.97
Sniff 0.75 1.81
Follow 0.75 0.91
Push under 1.0 1.0
Groom 0.29 0.13
Stretch-attend 0.04 0
Crouch 0.43 0.28
Overall mean frequency 33.9 33.1
Overall mean duration 46.3 49.3
TABLE 26 RESULTS OF OBSERVATIONS OF FLIGHT.
AGGRESSION AND IMMOBILITY IN ANIMALS
TREATED WITH OHHPL
Mean frequency of individual elements
FLIGHT
Flag
Evade
Upright posture 
Defensive upright 
Defensive sideways 
Retreat
Overall mean frequency 
Overall mean duration
Control (n=28) 
0.61 
0.07 
0 
0
0.04
0
0.71 
0.75
Test (n=52) 
0.38 
0.06 
0.03 
0.1 
0.07 
0.03
0.67
1.4
AGGRESSION
Bite 0.07
Overall mean frequency 
Overall mean duration
0.07
0.21
IMMOBILITY 
Mean frequency 
Mean duration
5.55
25.26
5.38
23.9
6.4. DISCUSSION
Methods which involve observation or measurement cf changes 
in the behaviour cf laboratory animals have been used in 
the past to look at the pharmacological properties of certain 
compounds. Section 1.2.4 outlines experiments carried out in 
the past to test the behavioural activity of certain monopyrroles, 
either thought at the time to be the natural excretion product in 
psychoses and porphyria or structurally related to such compounds. 
The work described in this chapter was designed to investigate 
the properties of OHHPL, the natural product, in two experimental 
systems which had already been used to show behavioural properties 
of ALA.
The first method, that of McGillion et al (1973)» was used to 
show that ALA treatment-caused changes in the spontaneous activity 
of mice. In an identical system, using rats, OHHPL caused no 
significant changes in activity although the dose used was 
sufficient to cause increased hepatic pcrphyrin synthesis and 
porphyrinuria. Temporal variations were observed in both treated 
and untreated animals but these may just reflect changes due to 
the trauma of the injection procedure or to disturbances in the 
surrounding environment.
The second experiment utilised a technique which has been 
shown to provide an highly sensitive index of drug induced 
behavioural changes (Chance and Silverman, 1964). It has also 
been shown that certain drugs can elicit quantitative dose- 
dependent changes in some of the behavioural categories (Cutler
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et al, 1975). Cutler and Nccre (1978) have shown using this 
system that there is an increase in immobility in mice treated 
with ALA with a concomitant decrease in non-social behaviour. 
OHHPL was found to be totally inactive in this system at each 
of the doses used.
Contrary to the above findings of Cutler et al (1975) it 
has been shown that certain categories of behaviour only 
undergo drug-induced changes in a narrow dose range (Krsiak,
1974) and the lack of activity shown by OHHPL at the two doses 
used may not preclude activity at lower, or even higher 
concentrations. EADC, for example (used in porphyrinogenicity 
testing) was found to have sedative and hypnotic effects at 
doses of 0,96, 1,44 and 1.92 mmol/kg.
The behavioural effects elicited by ALA are probably 
direct effects cn the central nervous system as ALA has been 
shown to cross the blood brain barrier (BBB) at the concen­
trations used. However, no information is available on the 
ability of OHHPL to cross the BBB although it is clear that 
high plasma levels are attained following injection.
As was said above, it may be that the failure to show 
effects of OHHPL may reflect the inadequacy of the dose range 
used. It is, however, difficult to project doses in animals 
equivalent to the human situation. The maximum human plasma 
level was estimated to be 10^ of the maximum urinary level, i.e.
4 umol/l and the plasma level encountered in the final experiment
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was many times this. It is recognised however that in the case 
of certain drags (e.g. barbiturates) the effective dose in 
rodents oan be at least forty times the dose for humans.
It remains to be seen therefore whether the dose levels 
of OHHPL and OHKPL bear any relationship to the human situation 
but it must be said that the doses used produced plasma levels 
probably far in excess of those in man. These experiments 
therefore provide no evidence cf a behavioural activity of 
OHHPL of physiological significance.
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C H A P T E R  7 
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CHAPTER 7
THYROID FUNCTION AND PORPHYRIA
7.1. INTRODUCTION
The clinical suspicion and later biochemical confirmation 
of thyrotoxicosis in a patient (Appendix 2, Case 5) during an 
acute attack of AIP led to this study of thyroid function in 
AIP.
The acute porphyric attack shows many common features with 
acute thyrotoxicosis including tachycardia, vomiting, weight 
loss and a neuropsychiatrie syndrome (Hall et al, 1974).
Although only one case of hyperthyroidism associated with AIP 
has been reported (Mann and de Nardo, I965), serum protein- 
bound iodine (PBl) (Heilman et al, 1963) and. total thyroxine 
may also be raised in AIP (Hollander et al, I967). These 
latter findings may be related to a rise in thyroxine-binding 
globulin (TBG) (Hollander et al, 1967). The rise in total 
thyroxine was thought to be independent of the clinical status 
of the patient (Hollander et al I967).
Biochemical studies on the effects of thyroid hormone on 
haera biosynthesis have shown that in rats T3 can potentiate the 
induction effects of allylisopropylacetamide (AIA) on hepatic 
ALA.S (Matsuoka et al, I960). More recently Morgan et al (1976) 
have demonstrated that although inactive by themselves T3 and T4 
can also stimulate AIA induced porphyrin biosynthesis in serum- 
free chick embryo liver cell cultures.
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As well as looking at thyroid function in AIP this study 
locks at some possible effects of thyroid hormone on porphyrin 
synthesis and also at thyroid hormone levels in experimentally 
produced porphyria.
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7.2. CLINICAL STUDIES
7.2.1. PATIENTS
Thyroid function of a group of patients with AIP was studied. 
Four patients were studied during an acute attack (Appendix 2: 
Cases 3» 5, 7 and 9) and in three of these (Cases 3» 5 and 7) 
sequential measurements of thyroid function were made during 
further acute attacks. Seven patients in remission and six 
latent for the disease were also studied.
7.2.2. RESULTS
Methods employed are outlined in Section 2.9 and normal 
values of thyroid function tests are shown in Table 2.
In all patients with AIP in remission or latency, T3, T4,
FTI, T3 and TSH values were within the normal range. In two 
patients in remission TSH response to the standard TRH test was 
normal. Serum T3, T4, FTI in patients 3» 5 and 7 are shown in 
Figures 35, 36 and 37. Where levels of free T3 and T4 were 
measured, these are also shown.
In Case 3» with one exception, acute attack was accompanied 
by a rise in T3, T4 and FTI (Figure 35) and on one occasion T3 
was outwith the normal limits. Basal rT3 and TSH in attack and 
remission were normal.
Case 7 showed similar trends (Figure 36) and on one occasion 
T4 was above the upper limit of normal. Again basal rT3 and TSH 
were normal throughout as were TRH tests.
151
150
100
50
20
150
100
50
100 20
FIGURE 35
Weeks
SEQUENTIAL MEASUREKENTS OF TOTAL (T3, T4) 
AND FREE (FT3, FT4) THYROID HORMONE 
CONCENTRATIONS AND FREE THYROXINE INDEX 
(FTI) IN CASE 3
Normal ranges are denoted by the solid lines
V =  FTI
■  = T4 nmol/litre 
#  = T3 nmol/litre
A = Acute attack 
□  = FT4 pmol/litre 
O  = FT3 pmol /litre
150
100
50
150
100
50
FTI ^ T
A
A
A Â.y— A/'
A
FT4
. k
a
i
□
0
FT3
1
#
0
o
I
10
Weeks
20
15
10
5
15
10
20
FIGURE 56 SEQUENTIAL MEASUREMENTS OF TOTAL (T3, T4) 
AND FREE (FT3. FT4) THYROID HORMONE 
CONCENTRATIONS AND FREE THYROXINE INDEX 
(FTI) IN CASE 7
Normal ranges are denoted by the solid lines
▼  = FTI
g  = T4 nmol/litre 
#  = T3 nmol/litre
A =s Acute attack 
□  = FT4 pmol/litre 
O  = FT3 pmo] /litre
A A A  A del i very
1 1 1  T ▼
3 0 0
200
100
4 0 0
30
3 0 0
20
200
100
100 150
Days from Admission
50 200 250
FIGURE 57 SEQUENTIAL MEASUREMENTS OF TOTAL (T3, T4) 
AND FREE (FT5, FT4) THYROID HORMONE
CONCENTRATIONS AND FREE THYROXINE INDEX 
(FTI) IN CASE 5
Normal ranges are denoted by the solid lines
▼  = FTI A = Acute attack
H  = T4 nmol/litre D = FT4 pmol/litre
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Case 5 was followed throughout her pregnancy (Figure 37)•
There was a marked, consistent increase in T3, T4 and FTI 
throughout the pregnancy, the levels being higher when she was 
symptomatic (p < 0,025). rT3 values were also raised but 
showed no correlation with clinical condition. Levels of T3,
T4, rT3 and the FTI fell to normal levels on delivery. Free 
T4 levels were above the upper limit of normal for pregnant 
women (Yeo et al, 1977a.) and T3 levels were outwith the normal 
range on all but one occasion, TSH values were normal through­
out and did not vary with clinical condition.
Thyroid function tests were normal in cord serum and in 
the baby at three days.
Case 9» when studied in attack showed a raised T4 (l65 nmol/L) 
and FTI (147) with a normal T3, These parameters were all within 
the normal range one month later when the subject was asymptomatic.
In all four subjects urinary ALA and PBG levels were raised 
and showed little correlation with acute episodes. Similarly in 
cases 3» 5 smd 7 urinary OHHPL levels, when measured, showed no 
correlation with clinical condition or thyroid hormone levels.
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7.3. BIOCHEMICAL STUDIES
These studies fell into two sections. Firstly in an 
attempt to assess the possible effects of porphyria, or more 
specifically the metabolites produced in porphyria, rats were 
made "porphyric” by the administration of ALA or OHKPL and 
thyroid hormone measurements carried out. Secondly, following 
the report of the potentiating effects of T3 and T4 on drug- 
induced porphyrinogenesis, the effect of T3 on the induction 
of ALA.S by OEHPL was investigated.
7.3.1. METHODS
Groups of 8 and 6 Sprague-Dawley rats were treated with ALA 
and OHKPL respectively. Dosage was as described in Table 13.
The animals given ALA were housed in metabolic cages and urine 
and faeces collected for porphyrin precursor and porphyrin 
measurements. After 48 hours both groups of animals were killed 
by stunning followed by exsanguination. In all animals serum 
total T4 measurements were performed and in the OHKPL group 
hepatic ALA.S activity was measured.
In the second experiment six groups of 6 animals were treated 
as follows: group 1, control (iml 50% ethanol); group 2, OHHPL 
0.13mmol/kg; group 3, OHHPL 0.13ramol/kg + T3 0.77umcl/kg; group 
4, OHHPL O.65mmol/kg; group 5, OHHPL O.65mmol/kg + T3 O.77^imol/kg; 
group 6, T3 0.77^imol/kg. Animals were injected at 0 and 24 hours 
and killed at 48 hours for the estimation of hepatic ALA.S activity.
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7.5.2. RESULTS
The results of T4 estimations in animals treated with 
ALA. and OHKPL are shown in Table 27 along with porphyrin 
precursor and porphyrin results for the ALA group and ALA.S 
activities in the OHKPL group.
Treatment with ALA caused large increases in the 
excretion of porphyrins and porphyrin precursors and 
presumably circulating levels of ALA, PBG and to a lesser 
extent coproporphyrin as seen in the urinary excretion. 
Treatment, however, had no effect on serum T4 levels in these 
animals.
In the OHKPL group, treatment markedly raised hepatic 
ALA.S activity but again there was no effect on serum T4 
levels. ■
ALA.S activities in the second set of experimental animals 
are shown in Table 28. Treatment with OHHPL was only effective 
in raising ALA.S activity at the higher dose and in none of 
these groups did T3 have an effect on ALA.S activity.
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TABLE 28 THE EFFECT OF OHHPL AT T3 ON 
ALA.S ACTIVITY
* Significantly different from control 
values p < 0.001
Group
(n=6) Treatment
ALA.S 
nmol/g protein/hour
1 Control 58.2 ± 6.9
2 OHHPL 0.13 mmol/Kg 65.8 ± 7.2
3 OHHPL 0.15 mmol/kg 
T3 0.77 jimol/kg
63.1 ± 5.2
4 OHHPL 0.65 mmol/kg 158.7 ± 27.2*
5 OHHPL 0.65 mmol/kg 
T3 0.77 ^mol/kg
148.2 ± 25.0 *
6 T5 0.77 nmol/kg 59.6 ± 6.1
7.4. DISCUSSION
A single case of AIP has been reported with associated 
hyperthyroidism which was thought to have a deleterious effect 
on the porphyric neuropathy (Mann and de Nardo, 1965). In. 
this patient the signs of both diseases improved with propyl­
thiouracil therapy. Other studies have shown increased PBI 
(Heilman et al, 1963)» total thyroxine and TBG (Hollander et 
al, 1967), although in these studies no correlation was drawn 
with clinical condition.
In the present study TBG was found to be raised only during 
an attack. In the three patients in whom sequential sampling 
was possible, total serum T4 levels and the PTI was increased in 
the acute attack. In patients 3 and 7» who presented regularly 
with mild pre-menstrual-attacks, T4 levels were raised on 5 ont 
of 6 occasions (Figures 35 and 36), although levels were within 
the normal limits. On the other hand there is little doubt that 
patient 5 became acutely thyrotoxic during an attack (Figure 37 ). 
Raised free hormone levels correlated well with attacks, although 
total hormone levels were difficult to interpret because of the 
pregnancy.
Any mechanism proposed for the increases in thyroid hormone 
levels can only be hypothetical. Abnormal synthesis and 
metabolism of other hormonal agents, for example steroid 
hormones, have been shown to be associated with the acute 
porphyric attack (Moore et al, 1973» Bradlow et al, 1976) and
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carrier proteins other than TBG have been found to be raised 
in AIP (stein and Tschudy, 1970). Although there have been 
reports of abnormal hypothalamic function in AIP (Perlroth et 
al, 1967; Stein and Tschudy, 1970) consistently low TSH 
levels suggest that pituitary driven thyroid stimulation is 
unlikely and no evidence obtained from TRH tests would indicate 
abnormalities in the hypothalamic-pituitary axis. It would seem 
then that the increased thyroid activity must be the result of 
a direct effect on the thyroid or reduced hormone clearance, 
although this would require that feedback mechanisms also be 
altered. Present knowledge does not allow unequivocal 
differentiation of these possibilities. There is an accumulating 
body of evidence of direct neural stimulation of the thyroid in 
man (Melander et al, 1976). Direct stimulation of sympathetic 
input to the thyroid has been shown to increase thyroid hormone 
secretion without affecting TSH levels (Melander et al, 1976).
As the major clinical features of AIP can be explained on the 
basis of a generalised autonomic neuropathy (Goldberg, 1959)» 
it may be that the hyperthyroidism seen in the patients with AIP 
may be neurogenic in origin.
The neuropathy in the acute porphyrias is probably due to 
neural demyelination itself due either to a haem deficiency or 
excessive metabolite production. As no animal model has yet been 
found that mimics the pathological changes found in AIP, it is 
not surprising to find normal thyroid function in the simplistic
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animal systems studied. The experiments with ALA and OHKPL would, 
however, appear to rule out the possibility of a direct pharma­
cological effect of these or other metabolites on the thyroid in 
the rat. However, extrapolation to the human may not be valid.
It has been proposed (Matsuoka et al, I968; Morgan et al, 
1970) that the effects of T3 and T4 on AIA-induced porphyrin 
synthesis may be of physiological significance in AIP where 
there may be increased levels of these hormones. The possibility 
arises of a cyclical effect whereby the porphyric neuropathy 
increases free thyroid hormone levels which in turn may 
potentiate the induction of ALA.S,
AIA is thought to act primarily by destruction of the haem 
moiety of cytochromeP-450 following conversion of its allyl 
group to an epoxide group (Doedens, 1971).T4 has been shovm to 
increase microsomal oxidases (Kato and Gillette, 1965) and it 
is possible that T3 and T4 enhance the effect of AIA by increasing 
the rate of epoxide formation. If this was so it would be 
expected tlmt these hormones would also enhance the effects of 
other porphyrinogenic allyl compounds such as allyl-containing 
barbiturates, or other compounds requiring oxidative activation.
The lack of any effect, found in these studies of T5 on 
OHHPL induction of ALA.S suggests that OHHPL acts by another 
mechanism and does not require prior oxidation.
It has also been suggested that thyroid hormones act by 
increasing AIA.S-specific messenger RNA (Matsuoka et al, I968).
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If this was the case treatments which decrease intracellular 
haera, thought to repress ALA.S at a translational level (Sassa 
and Granick, 1970), would he expected to be enhanced by T3 or 
T4 treatment. In this case both AIA and OHHPL effects would 
be enhanced.
It is obvious that greater knowledge of the mechanism of 
action of thyroid hormones is required before a full evaluation 
of the consequences of increased thyroid hormone levels in AIP 
can be made.
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C H A P T E R  8
GENERAL DISCUSSION
CHAPTER 8
GENERAL DISCUSSION
Insight into the biochemical abnormalities in disease can 
be gained -using analytical techniques to quantitate body 
substituents and it has been stated in the past,
”It seems reasonable to assume that if one were 
able to identify and determine the concen­
trations of all compounds (of interest) inside 
the human body including high and low molecular 
weight substances, one would probably find that 
almost every known dise&se would result in 
characteristic changes of the biochemical 
composition of the cells and body fluids."
(Jellum et al, 1973)
Although this view.is futuristic, its relevance in the 
porphyrias is obvious. In the porphyrias, in particular, 
knowledge of the fundamental defect and of plasma metabolite 
levels has not as yet allowed unambiguous identification of 
the cause of the acute manifestations. There is little doubt 
that such complete knowledge would soon result in the under­
standing of the disease process.
Part of the work contained in this thesis is an extension 
of present knowledge of the occurrence of OHHPL, a metabolite 
of interest in the porphyrias. It was designed to investigate 
the possibility that OHHPL may play a role in the manifestations 
of acute porphyria.
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Restriction of the quantitation of OHHPL to urine means 
that certain assumptions must he made in any discussion of 
plasma levels or of the effects of this compound. It may he 
erroneous to project plasma levels from urinary levels but 
the use of urinary creatinine levels for ’normalising' the 
urinary concentration of OHHPL may allow better comparison 
of results. If it is assumed that these levels to some extent 
reflect plasma levels (a totally random relationship between 
urine and plasma would be unexpected) then the results of 
quantitations provide no evidence for an acute role for OHHPL 
in the acute porphyrias. However, it may be that the urinary 
levels do not adequately reflect the plasma levels and that 
these in turn do not adequately reflect the tissue levels.
This also holds true for.,the other metabolites which could 
arguably be the peccant substances in the acute porphyrias.
The finding and quantitation of OHHPL in psychoses is in 
confirmation of earlier studies by other workers. Again there 
was no evidence of a direct role for OHHPL in the generation 
of any of the clinical features of these disorders, although 
there was some evidence that OHHPL excretion was in some way 
related to the remission of symptoms in patients with schizo­
phrenia .
The excretion of OHHPL in porphyria and psychoses may be 
unrelated but knowledge of the biosynthetic mechanism for form­
ation of OHHPL is required for clarification of this point. It is
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unlikely that OHHPL production in psychoses is a fundamental 
defect and it is more likely that it is a result of generally 
deranged metabolism. Other abnormalities that have been 
found in psychoses, schizophrenia in particular, include 
abnormalities in carbohydrate, amino acid and steroid meta­
bolism (Tourney and Hatfield, 1972; Benjafield and Rut1er, 
1973).
The evidence from the patients with liver disease and 
industrial workers, taken along with the other results, is 
suggestive of an hepatic origin for OHHPL and that PBG could 
be a likely precursor. Both these possibilities require 
substantiation. Determination of plasma levels and of the 
biosynthetic origin of OHHPL should provide much greater 
insight-into the possible roles of OHHPL in these disorders.
Determination of plasma levels will also allow a better 
assessment of the possible physiological significance of the 
finding that the group of monopyrroles studied, including 
OHHPL, were all porphyrinogenic. Most significantly these 
compounds caused a decrease in microsomal haem and an increase 
in the activity of ALA..S in rats.
Under normal circumstances any increased demand for haem 
can be met by a modest increase in ALA.S activity (De Matteis 
and Gibbs, 1972). However, in the porphyrias, the partial 
block in haem biosynthesis results in diminished haem 
formation and concomitant induction of ALA.S. Without the
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superimpositicn of other factors a steady state is reached 
whereby the metabolic block is partially compensated by a 
raised ALA.S activity in turn maintained by a decreased haem 
level. A direct result of this is that any mechanism which 
puts an extra demand on haem will have a greater effect on 
this partially induced system than on a normal uninduced one. 
Such an example is the precipitation of acute porphyric 
attacks by drugs which are innocuous in this respect in 
normal subjects.
It would be impossible to predict the physiological 
significance of these results. If it is accepted that OHHPL 
is a direct product of PBG or any of the subsequent pathway 
products it would be extremely rare and unusual for a 
biological substance to.cause an increase in the activity of 
the pathway forming it. The reverse is almost always the case. 
With this in mind it would be expected that any effect of OHHPL 
on patients with porphyria must be minimal although OHHPL may 
play a role in the maintenance of raised ALA.S activity.
More significant perhaps is the finding of raised thyroid 
hormone levels in patients in attack. The biochemical studies 
suggest that the raised hormone levels per se may not affect 
haem biosynthesis and any effect shown previously is due to 
the increased formation of active metabolite (for example 
activation of AIA). It is clear, however, that in one case 
studied the patient became thyrotoxic and there is little
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doubt that her clinical condition suffered adversely. 
Considering the similarities between thyrotoxicosis and the 
acute porphyric attack, it is possible that in patients in 
attack raised thyroid hormone levels may be detrimental where 
the neuropathy of the attack pre-exists. This of course is 
purely hypothetical.
In conclusion then it can be said that, although OHHPL 
and related compounds have been found to have certain 
interesting effects on haem biosynthesis, no evidence has 
been obtained which points directly to OHHPL as the offending 
metabolite in either porphyria or psychosis. It is clear 
that further studies on its natural occurrence and pharmaco­
logical properties are required before any definitive 
conclusions are arrived at. These studies will certainly be 
expedited by the recent synthetic method ( Wooldridge and 
Lightner, 1977) for its preparation. It will hopefully not be 
long before a ‘conclusion can be reached on the role of this 
interesting compound, which for so long has frustrated 
researchers and ironically was originally misidentified as 
kryptopyrrole - ’the hidden pyrrole'.
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A P P E N D I C E S
APPENDIX 1. Computer printouts of typical non-parametrical 
analyses of results using the Mann-Whitney TJ 
test and the Spearman and Kendall correlation 
analyses.
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JU13ER GF TAPI ALLES T3 READ I J .....................................  2
JT-'IBFR OF VARIABLES ALLED :3Y TiAJSPGRlATIG.IS. . 0
TOTAL JUIbER OF Ti-JTIALLES............................................... 2
OlOBER jP  CASES TO :& 3 L  I.J ............................................... 44
CASE LFiSELI JG \A H L L I .E S .....................................................
L I.U T S  A IL  U ISSIJG  V i^U E  CUECUED BEFORE TFAJSFOIUATIOJS
BLAJRS ARE.......................................................................................  OEiÜS
I I P I T  M J I T  l U I B E i . ..............................................................................................  E
RE. : I . J D I.J PUT i; JI T PRI0 H TO RE^ALI J G. . DATA. . . 30
I JPUT FOR lAT
(F 3 . /i> 16-L P3. Q)
D\r;IiAI:LES TO BE USED
1 OUIPL 2 G1U31P
GROl.PIJG TAAR I/eLE .....................................................................G R jlP
PERFORI KRUSKAL-VIALLIS U TEST
.JUIBER OF CASES READ...............................................................  44
iURlSKiAL-vA'ELIS G JE WAS A JÆYSI S OP TKRIAJ.CE TEST RLSILTS
TARIfETLE 1 OURPL 
GROUP PRZuUEJCY FùAJU
JJ. Ja IE  SUi
1 PSYOFPLR 22 524. C
2 PSYO.ILH 22 466 .0
APT SRaL -L T L L : S TEST STATISTIC = 0. 46345
LEVLL OP SIG.JIFICAJCE = 0. 4960 ASSUII.JG CTI-SGUa RE L IS TR IB U TIJJ 
l.TTR 1 DEGREES OF FREEDG-i
.lAJ.J-WRIT JET TEST STATISTIC = 271
LE’ 'EL OF SIG JIFICAJCE = 0 .2430  ASSUII JG TOE.lAL DISTRIBUTIO J
^ E\FCUTI0. J TER II. JATES.
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sraii
/rlXEC lT IO  J BEGI JS 
b-ILP3S
PR] G ?J\ i GO I T?ijL I . J J ?. lATIOJ
i-COJTI JUE " IT U  L'GDCC l , 9 )  + LG D JU :S (S ^2 4 ) + (2 6 , 36) + (3& , 40) + ( 4 2 , 44) 
P P jbLE I T ITLE  IS  'Ü.TIPL-/4LÂ-PBG CO PR. S P D 'C yU E JE './
I JPUT VARL'C=3.
CASE=19.
FOR I AT IS  ' ( F3. /J  F8. 4, F8. 4) ' .  /
UARIAB .JAIES iY^E 'O U iP LD  'P 3 G ', ' Æ A ' . /
TEST T ITuE  IS  'SPDAjyKEJD CurR. ' .
SPEAR.
K E J D iL ./
E JD ./
FROELEI T IT L E .............................. G iL ilL-ALA-PLG  CGRR. SPLYyREJD
JUIBER GF VARIABLES TG READ I J ...................  3
JUIBER GF v a r ia b l e s  ADDED BY TRAJSFJRIa T Il JS . . Û
TOTAL .JlMBFFi OF V iLR R LiLES ............................................ ...  3
JUIBER OF CASES TO READ I J .............................  19
Ca s e  LABELIJG VARIABLES .....................................................
L IJ IT S  AJD .IIS S IJG  V/O.UE CJLCilED BEFORE TR:iJSFOAlr:.TIOJS
BE A JUS W E .............................................................................................ZEiÜS
I'JPUT U I IT  J U ID E T i................................................  5
REOIJD I JPUT U J IT  PRIOR TO RDADI JG. . DATA. . . JO
I JPUT FOR I AT
(F 8 . 4, F3. 4, F3. 4)
lA R IW LE S  TO BE USED
1 O R EL 2 PBG 3 W a
CO-IPUTE KEJDU.L PAJR CORRSLATI 0 J COEFFI Cl EJT( S)
CO IPUTE SPDiRIAJ RAJK COPRSLATIOJ COEFFI Cl EJT( S)
JUIBLR OF CASES READ............................................................... 19
KEJD/ÎLL PAJK CORRELATIOJ COEFFICILJTS
01 DIPL PBG ALA
1 2 3
O.LIPL 1 1. 0000
PBG 2 -  3. 0 539 1. 0 000
W A 3 - 0 .  2242 0. 1934 1. 0000
SPEAFJAJ Fu-iJR CO-RRSLATiaJ COEFFIClEJTS
OiDiPL PBG W A
1 2 3
OiLIPL 1 1.0000
PcG 2 - 0 .  0019 1.0000
ALA 3 - 0 .  3224 0. 3131 1. 0000
‘ EvECUTIOJ TER 11 GATES.
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APPENDIX 2. Case histories of patients with acute 
intermittent porphyria studied during 
an acute attack.
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CASE 3 J.C. B o m  1955 Diagnosed 1976
This 21 year old woman was admitted to Stobhill General 
Hospital in March 1976 with intermittent epigastric and limb 
pain, constipation and severe depression of six weeks duration. 
Her urinary porphyrins had been estimated on 21 separate 
occasions in an investigation of abdominal pain in view of a 
strong family history of porphyria. All of these estimations 
were within normal limits. Prior to her admission she had been 
prescribed pentazocine for dysmenorrhoea, discontinued because 
of nausea, and amitryptyline in view of her depression. Two 
weeks prior to admission she was begun on an oral contraceptive 
agent.
On admission she was anxious and tremulous and there was 
slight epigastric tenderness. Pulse and blood pressure were 
normal and there were no abnormal motor or sensory signs. 
Urinary porphyrin excretion was consistent with an acute 
porphyric attack. Urinary OHHPL levels were followed in this 
patient throughout the acute phase of this attack and were also 
measured on several subsequent occasions.
Abdominal pain was treated with pethidine; constipation 
with neostigmine and bizarre behavioural states controlled 
with promazine. Laevulose infusion was started to increase 
caloric intake and was discontinued after four days when the 
patient was asymptomatic. Rebound epigastric pain was 
controlled with dihydrocodeine and she was discharged 16 days 
after admission.
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In July she had a mild attack with transient abdominal 
pain and depression associated with menstruation and a 
further mild attack some months later due to caloric 
restriction.
Throughout 1977 she had several minor attacks usually 
associated with menstruation, with abdominal pain, postural 
hypotension and tachycardia. In October 1977 she was 
admitted suffering from severe hypotension and nausea and 
was diagnosed as suffering from an acute attack of which 
these were the only symptoms. She responded slowly to 
therapy and since then has remained well.
CASE 4 M.McA. B o m  1950 Diagnosed 1976
This lady was admitted as an emergency to the surgical 
wards of Glasgow Royal Infirmary suffering from colicky lower 
abdominal pain of two days duration which was increasing in 
severity and accompanied by vomiting.
Prior to admission she had developed an urticarial 
eruption that was treated with mebhydrolin.
On examination it was decided that she required an 
exploratory laparotomy and a normal appendix was removed 
under anaesthesia induced using thiopentone sodium. Following 
surgery her pain was very severe and unrelieved with morphine. 
Consequently the diagnosis of porphyria was suggested and 
confirmed.
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She was then transferred to Stobhill General Hospital 
where she was found to be suffering from abdominal pain and 
constipation. There was however no evidence of tachycardia, 
hypertension or neuropsychiatrie upset. Urinary OHHPL 
measurement was made at this time.
Her recovery was uneventful and she has remained well 
save for occasional postural hypotension. OHHPL estimations 
were repeated when she was asymptomatic.
CASE 5 J.McM. Born 1955 Diagnosed 1976
This 20 year old married woman was admitted to Stobhill 
General Hospital in April 1976 with a 3 week history of 
abdominal and joint pain, generalised weakness and anorexia. 
She had been amenorrhoeic for three months. In the previous 
year prescription of an oral contraceptive agent was discon­
tinued after four months because of severe abdominal pain.
On examination she was thin and looked pale and unwell. 
Her eyes were prominent and hyperthyroidism was suspected. 
There was slight abdominal pain, tachycardia and hypertension. 
Early pregnancy was confirmed by pelvic examination.
Biochemical and haematological examinations revealed 
abnormal liver function tests (raised alkaline phosphatase, 
aspartate transaminase (AST) and alanine transaminase (ALT)), 
raised serum urea and deficient serum iron with low serum 
iron saturation. Haemoglobin was decreased with a raised
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E.S.R. ALA and PBG levels in urine were greatly elevated 
consistent with an acute attack of porphyria.
Her condition progressively deteriorated and she was 
transferred to the intensive care unit. Limb weakness 
increased to almost complete paralysis with a loss of tendon 
reflexes and muscle wasting. She also developed difficulty 
in swallowing and a diaphragmatic palsy. She became 
incontinent of urine and aphonic.
Therapy was initiated with 20% laevulose; hypertension 
and tachycardia were treated with propranolol and oral 
prednisolone was given empirically. Obstipation was treated 
with neostigmine and restlessness with promazine. In addition 
she received high tension oxygen therapy for 3 days. A week 
after admission she was transfused four units of packed red 
cells because of persistent anaemia.
Improvement was slow but consistent. A right basal 
bronchopneumonia was treated with ampicillin. She had an 
isolated grand mal seizure two weeks after admission. As 
soon as swallowing improved a high protein and carbohydrate 
diet was begun. Muscle power and tendon reflexes gradually 
improved and laevulose therapy was discontinued three weeks 
after admission. Eight weeks after admission there was some 
return of voice power, full urinary retention, normal ability 
to swallow and she was able to walk unaided. The pregnancy 
progressed uneventfully and she was discharged 12 weeks after 
admission.
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A mild attack precipitated by a urinary tract infection 
responded to laevulose, propranolol and promazine. Despite 
this muscle power improved continuously and she delivered a 
healthy male child after induction of labour with intravenous 
sintocinon.
Since then she has suffered several attacks usually 
associated with menstruation and urinary OHHPL levels have 
been measured on several occasions, in attack and in remission.
CASE 7 P.W. B o m  1948 Diagnosed 1969
This woman was diagnosed as having AIP in 1969 following 
an attack during her second pregnancy. Her first pregnancy 
three years earlier had resulted in the spontaneous delivery 
of a stillborn infant at 28 weeks gestation. Following the 
delivery of a full term healthy infant the patient developed 
a severe attack of porphyria which left her with a residual 
peripheral neuropathy.
Since then the patient has had frequent attacks invariably 
occurring in the week prior to menstruation. These attacks are 
characterised by severe abdominal pain, vomiting, acute depression, 
hypertension and tachycardia. Each treatment course lasted 2 - 
3 days consisting of laevulose with pethidine, promazine and 
propranolol for pain, neuropsychiatrie disturbance and hyper­
tension respectively.
This patient was one of the four cases in which urinary 
OHHPL was measured in attack and remission.
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CASE 9 A.O. B o m  1950 Diagnosed 1970
This 26 year old woman became ill in August, 1976 in 
Yugoslavia, with vomiting, abdominal pain, oonstipation and 
the passage of dark urine* She was flown back to Great 
Britain and became confused and hyponatraemic• At this time 
she was receiving phenobarbitone for epilepsy and had been 
taking the oral contraceptive pill since February, 1976. 
These were discontinued when the diagnosis of AIP was made. 
Following this she developed grand mal seizures, severe 
postural hypotension and proximal upper limb weakness. She 
was treated with intravenous laevulose, sodium valproate and 
clonazepam and slowly improved although proximal upper limb 
weakness remains.
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APPENDIX ?, Hamilton rating scale for assessment 
of psychiatric patients with N and P 
subscales.
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Dr McCreadie PIM 110 Gartnavel Royal Hospital
PHYSICIAN'S RATING SCALE
SUBJECT S NAME WARD PATIENT NUMBER
RATER'S NAME DATE
How direct and relevant are his responses 
to questions or to the topic discussed?
0 Direct and relevant
1 Somewhat rambling and tangential
2 For the most part irrelevant
3 Wholly irrelevant
Does he assume or maintain peculiar, unnatural 
or bizarre postures?
0 None
1 For short periods
2 Throughout most of the interview
3 Throughout the entire interview
Are his thoughts consistent with his mood, or 
is there a discernible lack of harmony between 
them?
0 Consistent ^
1 A little disharmonious
2 Distinctly disharmonious
3 Appeared totally unrelated
Does he exhibit any repeated peculiar gestures, 
grimaces or mannerisms?
0 None
1 Occasionally
2 Fairly frequently
3 Throughout the interview
Does he tend to suspect or to believe on 
slight evidence or without good reason that 
people and external forces are trying to or 
now do influence his behaviour and control 
his thinking?
0 No unjustified suspicion
1 Inclined to suspect
2 Believes others are trying to control him
3 Believes he is influenced or controlled
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P.6. Are the elements of his speech logically
consistent and connected by some idea or 
relationship, or do they tend to be inconsistent 
and disconnected? (Rate what is most represent­
ative during the interview.)
0 Coherent and consistent
1 Slightly incoherent and inconsistent
2 Distinctly incoherent and inconsistent
3 Conspicuously scattered, disconnected or
incoherent
N.7. Does he bear little hostility or a high degree
of ill will, resentment, bitterness or hate?
0 No hostility
1 Slight hostility
2 Moderate hostility
3 Much hostility
P.8. Does he have any insight into his hallucinations?
(Score 0 for no evidence of hallucinations.)
0 Full insight
1 Possibly full insight
2 Some insight
3 No insight
How frequently does he speak, mutter or mumble 
to himself, seemingly to carry on conversations 
with hallucinatory voices?
0 Not at all
1 Occasionally
2 Fairly frequently
3 Throughout the interview
Is there any evidence that the patient has 
auditory hallucinations?
0 None
1 Doubtful
2 Probable
3 Certain
Does the patient ever glance up as if listening 
to auditory hallucinations?
0 Not at all
1 Doubtfully or occasionally
2 Fairly frequently
3 Throughout the interview
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Does he repeat certain words or phrases 
in a meaningless, stereotyped or mechanical 
fashion?
0 Never
1 Occasionally
2 Fairly frequently
3 Almost constantly
Is his speech irregularly interrupted, halted 
or blocked for varying periods of time 
because of difficulty in finding words for his 
thoughts?
0 No speech blocks
1 A few interruptions
2 Many interruptions and conversation very
difficult
3 Patient is mute or almost mute
Does he have an exaggeratedly high opinion of 
himself, or an unjustified belief or conviction 
of having unusual ability, knowledge, power, 
wealth or status)
0 No exaggerated high opinion of himself
1 An exaggeratedly high opinion
2 Conviction of unusual power, wealth, etc.
3 Conviction of grandiose or fantastic power,
wealth, etc.
Does he tend to suspect or to believe on 
èlight evidence or without good reason that 
some people are against him (persecuting, 
conspiring, cheating, depriving, punishing) 
in various ways?
0 No unjustified suspicions
1 Inclined to suspect
2 Inclined to believe
3 Has firm conviction
Does he tend to suspect or to believe on slight 
evidence or without good reason, that some
people talk about, refer to, or watch him?
0 No unjustified suspicions
1 Inclined to suspect
2 Inclined to believe
3 Has firm conviction
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Is there evidence of false ideas or beliefs?
If present, are these ideas or beliefs (a) 
sufficiently plausible as to be accepted by a 
normal person uninformed as to the facts, (b) 
implausible but not impossible, (c) impossible 
or bizarre (e.g. mind controlled by radio waves, 
heart removed or dead)?
0 No evidence of false beliefs
1 Plausible to the uninformed
2 Implausible
3 Impossible or bizarre
Does the patient’s mood and emotional response 
show blunting?
0 Not at all
1 Slight blunting
2 Severe blunting
3 Complete apathy
178
. REFERENCES
AKHTAR, M., ABBOUD, N.M., BARNARD, G., JORDAN, P.,
ZAMAN, Z. (1976)
Mechanisms and stereochemistry of enzymic 
reactions involved in porphyrin biosynthesis. 
Philosophical Transactions of the Royal Society,
London B, 273: 117-136
ALLAIN, P., FOUSSARD, E., BOYER, J. (l977)
Relations entre le taux de zinc dans le sang et 
l’activitie de 1 *Ô-aminolevulinic acid dehydratase 
erythrocytaire chez l'homme.
Clinica Chiraica Acta, 78: 183-189
ANDERSON, K.E., ALVARES, A.P., SASSA, S., KAPPAS, A. (1976) 
Studies in porphyria: drug oxidation rates in
hereditary hepatic porphyria.- 
, Clinical Pharmacology and Therapeutics, 19: 47-54
BARNES, H.D., HURWORTH, E., MILLAR, J.H.D, (1968) 
Erythropoietic porphyrin hepatitis 
Journal of Clinical Pathology, 21: 157-159
BATTERSBY, A.R., McDONALD, E. (1976)
Biosynthesis of porphyrins and corrins.
Philosophical Transactions of the Royal Society,
London B., 273: I6I-I8O
BATLLE, A.M.,‘ BENSON, A., RIMINGTON, C. (1965)
Purification and properties of coproporphyrinogenase. 
Biochemical Journal, 97: 731-740
BECKER, D.M., KRAMER, S. (l977)
The neurological manifestations of porphyria - 
, a review.
Medicine, 56: 411-423
BECKER, D.M., YILJOEN, J.D., KR^iMER, S. (197I)
The inhibition of red cell and brain ATPase by 
6-aminolevulinic acid.
Biochimica et Biophysica Acta, 225: 26-34
BECKER, D.M., VILJOÈN, J.D., KATZ, J., KRAMER, S. (l977) 
Reduced ferrochelatase activity: a defect common
to porphyria varieg'ata and protoporphyria.
British Jcui'nal of Haematology, 36: 171-179
179
BENJAFIELD, J.G., RUTTER, L.F. (1975)
Significance of metabolic disorders in 
schizophrenia.
Lancet, 1: 785
BEREK, I., HUSZAK, I., DURKO, I. (1975)
The effect of kryptopyrrole on the porphyrin . 
auxotrophic strains of Bacillus subtilis.
Experientia, 51: 185
BERLIN, A., SCHALLER, K.H. (1974)
European standardised method for the determination 
of 6-aminolevulinic acid dehydratase activity in 
blood.
Zietschrift fur Klinische Chemie und Klinische 
Biochemie, 12: 589-590
BONKOWSKY, H.L., BLOOMER, J.R., EBERT, P.S.,
MAHONEY, M.J. (1975)
Heme synthetase deficiency in human protoporphyria : 
demonstrations of the defect in liver and cultured 
skin fibroblasts.
Journal of Clinical Investigation, 56: 1159-1148
BONKOWSKY, H.L., COLLINS, A., DOHERTY, J.M., TSCHUDY, D.P. 
(197?)
The glucose effect in rat liver: studies of
6-aminolevulinate synthase and tyrosine 
aminotransferase.
Biochimica et Biophysica Acta, 520: 561-576
BONKOWSKY, H.L., MAGNUSSEN, C.R., COLLINS, A.R.,
DOHERTY, .J.M., HESS, R.A., TSCHUDY, D.P. (1976)
Comparative effects of glycerol and dextrose on 
porphyrin precursor excretion in acute intermittent 
porphyria.
Metabolism, 25: 405-414
BOUCHERAT, M. (1977)
Aspects biochimiques de la porphyrie aiguë 
intermittente.
Lyon Pharmaceutique, 28: 125-152
BOULTON, A.A., MAJER, J.R. (1970)
Absolute quantitative detection of metabolites at 
the sub-microgram level.
Journal of Chromatography, 48: 522-527
180
BOYETT, J.D., BUTTERWORTH, C.E. (1962)
Lead poisoning and haemoglobin synthesis.
American Journal of Medicine, 32: 884-890
BRADLOW, H.L., ANDERSON, K., KAPPAS, A. (1976)
Differences between cutaneous and hepatic steroid 
A  -5® reductase in patients with acute intermittent 
porphyria.
In "Porphyrins in Human Diseases", p.175-178 
ed. Doss, M., Karger, Basle
BRODIE, M.J., MOORE, M.R., GOLDBERG, A. (1977&)
Enzyme abnormalities in the porphyrias.
Lancet, 2: 699-701
BRODIE, M.J., MOORE, M.R., THOMPSON, G.G.,
GOLDBERG, A. (1977b)
Treatment of acute intermittent porphyria with 
laevulose.
Clinical Science and Molecular Medicine, 55: 565-571
BRODIE, M.J., MOORE, M.R., THOMPSON, G.G., CAMPBELL, B.C., 
GOLDBERG, A. (l977d)
Is porphobilinogen deaminase activity a secondary 
control mechanism in haem biosynthesis in humans ? 
Biochemical Society Transactions, 5: I466-I468
BRODIE, M.J. THOMPSON, G.G., MOORE, M.R., GOLDBERG, A. 
(1976)
The enzyme abnormalities of the hereditary 
hepatic porphyrias.
Abstract S.16, Autumn meeting of the British 
Society of Gastroenterology
BRODIE, M.J., THOMPSON, G.G., MOORE, M.R., BEATTIE, A.D., 
GOLDBERG, A. (l977c)
Hereditary coproporphyria: demonstration of the
abnormalities in haem biosynthesis in peripheral 
blood.
Quarterly Journal of Medicine,46: 229-241
BROWN, E.G. (1958)
The relationship of the tricarboxylic acid cycle 
to the synthesis of 6-aminolaevulinic acid in 
avian erythrocytes.
Biochemical Journal,70: 315-521
181
BURNHAM, B.F., LASCELLES, J. (1965)
Control of porphyrin synthesis through a 
negative feedback mechanism.
Biochemical Journal, 87: 462-472
CHALLAND, G.S., RATCLIFFE, W.A., RATCLIFFE, J.G. (1975) 
Semi-automated radioimmunoassays for total 
serum thyroxine and triiodothyronine.
Clinica Chimica Acta, 60: 25-32
CHANCE, M.R.A., 'SILVERMAN, A.P. (1964)
The structure of social behaviour and drug action.
In CIBA Symposium "Animal behaviour and drug action", 
p.65-79
' ed. Steinberg, H., Churchill, London
CLARK, F., BROWN, W. (l970)
Free throxine index.
British Medical Journal, 2: 672
CONDIE, L.W., BARON, J., TEPHLY, T.R. (1976)
Studies on adrenal 6-aminolaevulinic acid 
synthetase.
Archives of Biochemistry and Biophysics, 172: 125-129
COOKSON, G.H., RIMINGTON, C. (1955)
Porphobilinogen: chemical constitution.
Nature, 171: 875-076
COOKSON, G.H., RIMINGTON, C. (1954)
Porphobilinogen.
Biochemical Journal, 57: 476-484
CUTLER, M.G., MACKINTOSH, J.H., CHANCE, M.R.A. (l975) 
Effects of cannabis resin on social behaviour 
in the laboratory mouse.
PsychopharmaCOlogica, 41: 271-276
CUTLER, M.G., MOORE, M.R. (l978)
Personal communication
DEAN, G. (1965)
Oral contraceptives in porphyria variegata.
South African Medical Journal, 59: 278-280
DSHLIN, D., ENERBACK, L., LUNDVALL, 0. (1973)
Porphyria.cutanea tarda: a genetic disease ?
Acta Medica Scandinavica, 194: 265-270
182
DE LEO, V.A., POH-EITZPATRICK, M., MATHEWS-ROTH, M.,
HARDER, L.C. (1976)
Erythropoietic protoporphyria: 10 years
experience.
American Journal of Medicine, 60: 8-22
DE MATTEIS, P. (I968)
Toxic hepatic porphyrias.
Seminars in Haematology,5: 409-423
DE MATTEIS, P., UNSELD, A. (1976)
Increased liver haem degradation caused by 
foreign chemicals: a comparison of the effects
of 2-allyl-2-isopropylacetamide and cobaltous 
chloride.
Biochemical Society Transactions,4: 205-209
DOEDENS, D.J. (1971)
Metabolic fate of the porphyrinogenic drug I; 
allylisopropylacetamide.
Dissertation Abstracts, 32: 29OI B
DONALDSON, E.M., MeCALL, A.J., MAGNUS, I.A., SIMPSON, J.R., 
CALDWELL, R.A., HARGREAVES, T. (l971)
Erythropoietic protoporphyria: two deaths from
hepatic cirrhosis.
British Journal of Dermatology, 84: 14-24
DOSS, M., MEINHOP, W., LOOK, D., HENNING, H.,
NAWROCKI, p ., DÔLLE, W., STROHNMEYER, G., PILIPPINI, L.
(1971)
Porphyrins in liver and urine in acute intermittent 
porphyria and chronic hepatic porphyria.
South African Medical Journal, 45: (Suppl.)
50-54
DOSS, M., SCHERMULY, E., KOSS, G. (1976)
Hexachlorobenzene porphyria in rats as a model 
for human chronic hepatic porphyrias.
Annals of Clinical Research, 8: supplement 17,
I7I-I8I
DOWDLE, E.B., MUSTARD, P., EALES, L. (1967)
ô-arainolevulinic acid synthetase in normal and 
porphyric human livers.
South African Medical Journal, 41: 1093-1096
DURKO, I., BEREK, I. HUSZAK, I. (l9?5)
Effects of kiyptopyrrole on porphyrin synthesis 
in Bacillus subtilis 168,
Hoppe-Seylers Zeitschrift fur Physiologie und Chemie,
356: 1679-1684
183
DURKO, I., BEREK, I., HUSZAK, I. (1976)
On complex formation between haem and oxidation 
products of kryptopyrrole as a possible explanation 
for enhanced porphyrin synthesis of Bacillus subtilis 
168 strain.
Tenth International Congress of Biochemistry,
(Abstracts) ÿ.l04
EDVARDS, A.M., ELLIOT, W.H. (1975)
Induction of 6-aminolevulinic acid synthetase in 
isolated rat liver cells by steroids..
Journal of Biological Chemistry, 250: 2750-2755
ELDER, G.H., EVANS, J.O., THOMAS, N., COX, R., BRODIE, N.J., 
MOORE, M.R., GOLDBERG, A., NICHOLSON, D.C. (1976)
The primary enzyme defect in hereditary coproporphyria. 
Lancet 2: 1217-1219
ELDER, G.H., TOVEY, J.A. (1977)
Uroporphyrinogen decarboxylase activity of human 
tissue.
Biochemical Society Transactions, 5: 1468-1470
ELLIS, J., JACKSON, A.H., JAIN, A.C., KENNER, G.W. (1964) 
Pyrroles and related compounds. Part III: syntheses 
of porphyrins from pyrromethanes and pyrrqraethenes. 
Journal of the American Chemical Society, 86: 1955-1949
ELLMAN, G.L., JONES, R.T., RYCHERT, R.C. (1968)
Mauve spot and schizophrenia.
American Journal of Psychiatry,125: 849-851
PEIGHNER, J.P., ROBINS, E., GAZE, S.B., WOODRUFF, R.A., 
VINOKUR, G., MUNOZ, R. (l972)
Diagnostic criteria for use in psychiatric research. 
Archives of General Psychiatry,26: 57-65
FELDMAN, D.S., LEVERE, R.D., LIBERMAN, J.S., CARDINAL, R.A., 
WATSON, C.J. (1971)
Presynaptic neuromuscular inhibition by porphobilinogen 
and porphobilin.
Proceedings of the National Academy of Sciences, U.S.A., 
68; 585-586
FISCHER, A., ORTH, H. (l954)
In "Die Chemie des Pyrrols", p.318-585 
Acadamie Verlag, Leipzig
184
FRESHNEY, R.I., PAUL, J. (l970)
Measurement of aminolaevulinate synthetase activity 
in normal mouse liver with 2-^^C glycine. 
Biochimica et Biophysics, Acta, 220: 594-601
FRYDMAN, B., FRYDMAN, R.B., VALASINAS, A., LEVY, E.S., 
FEINSTEIN, G, (1976)
Biosynthesis of uroporphyrinogens from PBG: 
mechanism and the nature of the process. 
Philosophical Transactions of the Royal Society, 
London B., 273: 137-160
FRYDMAN, R.B., FEINSTEIN, G. (1974)
Studies of porphobilinogen deaminase and 
uroporphyrinogen III cosynthetase from human 
erythrocytes.
Biochimica et Biophysics Acta, 350: 358-373
FRYDMAN, R.B., TOMARD , M.L., WANSCHELBAUM, A.,
ANDERSEN, E.M., AWRUCH, J., FRYDMAN, B. (1973) 
Porphobilinogen oxygenase from wheat germ: 
isolation, properties and products formed. 
Biochemistry,12: 5253-5262
FRYDMAN, R.B., TOMARO, M.L,, FRYDMAN, B.,
WANSCHELBAUM, A. (1975)
Porphobilinogen excretion in chemically induced 
porphyria: reversal by induction of porphobilinogen
oxygenase.
FEBS Letters, 51: 206-210
FUGIMORI, E., TAVLA, M. (1966)
Light-induced electron transfer between chlorophyll 
and hydroxyquinone and the effect of oxygen and 
beta-carotene.
Photochemistry and Photobiology, 5: 887-893
GAJDOS, A. (1976)
La nature enzymopathique des porphyries.
La Nouvelle Presse Médicale, 22, 1417-1422
GARROD, A.E. (1892)
The occurrence and detection of haematoporphyrin 
in the urine.
Journal of Physiology, 13: 598-620
GOLDBERG, A. (1959)
Acute intermittent porphyria: a study of 50 cases.
Quarterly Journal of Medicine, 110: 183-209
185
GOLDBERG, A. (1971)
Porphyrins and porphyrias.
In"Recent Advances in Haematology", p.302-356 
eds. Goldberg, A., Brain, M.C. : Churchill 
Livingston, Edinburgh and London
GOLDBERG, A., ASHENBRUCKER, H., CARTWRIGHT, G.E.,
WINTROBE, M.M. (1956)
Studies on the biosynthesis of haem "in vitro" 
by avian erythrocytes.
Blood, 11: 821-833
GOLDBERG, A., MOORE, M.R., BEATTIE, A.D., HALL, P.E.,
McCALLUM, J., GRANT, J.K. (1969)
Excessive urinary excretion of certain porphyrinogenic 
steroids in human acute intermittent porphyria.
Lancet, 1: 115-118
GOLDBERG, A., PATON, W.D.M., THOMPSON, J.W. (1954)
Pharmacology of the porphyrins and porphobilinogen. 
British Journal of Pharmacology, 9: 91-94
GOLDBERG, A., RIMINGTON, C. (1962)
In "Diseases of Porphyrin Metabolism",
Thomas, Springfield, Illinois
GOLDBERG, M.L. (1974)
The glucose effect: carbohydrate repression of
enzyme induction, RNA synthesis and glucocorticoid 
activity - a role for cyclic AMP and cyclic GMP.
Life Sciences, 17: 1747-1754
GRANDCHAMP, B., NORDMANN, Y. (1977)
Decreased lymphocyte coproporphyrinogen III 
oxidase activity in hereditary coproporphyria. 
Biochemical and Biophysical Research Communications, 
74: 1089-1095
GRANICK, S. (1966)
The induction in vitro of the synthesis of 
6-aminolevulinic acid synthetase in chemical 
porphyria: a response to certain drugs, sex
hormones and foreign chemicals.
Journal of Biological Chemistry, 241, 1359-1575
GRANICK, S., KAPPAS, A. (1967a)
Steroid induction of porphyrin synthesis in liver 
cell cultures 1. Structural basis and possible 
physiological role in the control of heme formation. 
Journal of Biological Chemistry, 242: 4587-4593
186
GRANICK, S., KAPPAS, A. (l967b)
Steroid control cf porphyrin and heme biosynthesis: 
a new biological function for steroid hormone 
metabolites.
Proceedings cf the National Academy of Sciences, 
U.S.A., 57: 1465-1467
GRANICK, S., URATA, G. (1965)
Increase in activity of delta-aminolevulinic acid 
synthetase in liver mitochondria induced by 
feeding of 5»5-dicarbethoxy-l,4-dihydrocollidine. 
Journal of Biological Chemistry,258: 821-827
GRANT, B.C., MACKINTOSH, J.H. (1965)
A comparison cf the social postures of some common 
laboratory rodents.
Behaviour,21: 246-259
GRAY, C.H., LIM, C.K., NICHOLSON, D.C. (1976)
Porphyrin profiles in Porphyrias.
In "High Pressure Liquid Chromatography in Clinical 
Chemistry", p.79-85
ed. Dixon, P.P., Gray, C.H., Lim, C.K., Stoll, M.S. 
Academic Press, London.
HABERMAN, H.F., ROSENBERG, F., MENON, I.A. (1975)
Porphyria cutanea tarda: comparison of cases
precipitated by alcohol and oestrogens.
Canadian Medical Association Journal, 115: 653-655
HAEGER, B. (1957)
Increased content of a 6-amino laevulinic acid like 
substance in the urine from workers in lead industry. 
Scandinavian Journal cf Clinical and Laboratory 
Investigation, 12: supplement 47
HAEGER, B. (l958)
Urinary 6-aminolaevulic acid and porphobilinogen in 
different types of porphyria.
Lancet, 2: 6O6-6O8
HALL, R., AMOS, J., ORMSTON, B.J. (l97l)
Radioimmunoassay of human serum thyrotrophin.
British Medical Journal, 1: 582-585
HALL, R., ANDERSON, J., SMART, G.A., BESSER, M. (1974)
In "Fundamentals of Clinical Endocrinology", p.105-127 
Pitman Medical, Bath.
187
HAMILTON, M., SMITH, A.L.G., LAPIDUS, H.E.,
CADOGAN, E.P. (i960)
A controlled trial of thiopropazate dihydrochloride 
(Dartalan), Chlorpromazine and occupational therapy 
in chronic schizophrenia.
Journal of Mental Science, 106: 40-55
HAPKE, H.J., PRIGGE, E. (l975)
Interactions cf lead and glutathione with delta- 
aminolevulinic acid dehydratase.
Archives cf Toxicology, 31: 153-l6l
HAYASHI, N., KTJRASHIHA, Y., KIKUCHI, G. (l972)
Mechanism cf allylisopropylacetamide induced 
increase of ALA.S in liver mitochondria. V 
Mechanism cf regulation by hemin of the level 
of ALA.S in rat liver mitochondria.
Archives of Biochemistry and Biophysics 148: 10-21
HAYASHI, N., YODA, B., KIKUCHI, G. (l970)
Difference in molecular sizes of 0-aminolevulinate 
synthetases in the soluble and mitochondrial 
fractions of rat liver.
Journal of Biochemistry, 67: 859-861
HELLMAN, E.S., TSCHUDY,'D.P., ROBBINS, J., RALL, J.E. (I963) 
Elevation cf serum protein-bound iodine in 
acute intermittent porphyria.
Journal of Endocrinology and Metabolism, 23: 1185-1191
HERNBERG, S., NIKKANEN, J. (1972)
Effect of lead on 6-aminolaevulinic acid dehydratase: 
a selective review.
Pracovni Lekarstvi, 24: 77-83
HOFFER, A., OSMOND, H. (1963)
Malvaria: a new psychiatric disease.
Acta Psychiatrica Scandinavica, 39: 335-336
HOLLANDER, C.S., SCOTT, R.L., TSCHUDY, D.P., PERLROTH, M., 
WAXMAN, A., STERLING, K. (1967)
Increased protein-bound iodine and thyroxine- 
binding globulin in acute intermittent porphyria.
New England Journal of Medicine, 277: 995-1000
HUSZAK, I., DURKO, I., KARSAI, K. (l972)
Experimental data to the pathogenesis cf cryptopyrrole 
excretion in schizophrenia.
Acta Physiologica Academiae Scientiarum Hungaricae,
42: 79-86
188
IPPEN, H. (1961)
Zur pathogenese der porphyria cutanea tarda 
Archiv fur Klinische Expérimentale Dermatologie,
212: 467-470
IRVINE, D.G. (1961)
Apparently ncn-indolic Ehrlich-positive 
substances related to mental illness.
Journal of Neuropsychiatry, 2; 292-305
IRVINE, D.G. (1974)
Kryptopyrrcle and other monopyrroles in molecular 
neurobiology.
International Review cf Neurobiology, I6: 145-182
IRVINE, D.G., BAYNE, W., MIYASHITA, H., MAJER, J.R. (1969) 
Identification -of kryptopyrrole in human urine 
and its relation to psychosis.
Nature, 224: 8II-8I3
IRVINE, D.G., BAYNE, W., MIYASHITA, H. (1975)
Synthetic dioxypyrroles isographic with urinary 
metabolites.
Proceedings of the Canadian Federation of 
Biology Societies,'16: 125
IRVINE, D.G., ELL, D., CRICHLOW, E.C. (1973)
Anticonvulsant and E.E.G. activities of kryptopyrrole 
and a possible underlying neurochemical mechanism. 
Fourth International Meeting of the International 
Society for Neurochemistry, p.359
IRVINE, D.G., WBTTERBERG, L. (l972)
Kryptopyrrole-like substance in acute intermittent 
porphyria.
Lancet, 2: 1201
IRVINE, D.G., WILSON, D.L. (1976)
Oxidized monopyrroles in porphyric disorders and 
related conditions.
In "Porphyrins in Human Diseases", p.217-224 
ed. Doss, M-, Karger, Basle.
IRVINE, D.G., ZDANIVSKY, G.B. (1971)
2,4-dimethyl-3-ethylpyrrole (Kryptopyrrole); a 
behaviourally active substances excreted by 
psychotics.
3rd International Meeting of the International 
Society of Neurochemists, Budapest
189
JACKSON, A.H., SANCOVICH, H.A., FERRAHOU, A.M., EVANS, N., 
GAMES, D.E., MATLIN, S.A., ELDER, G.H., SMITH, G.H. (1976) 
Macrocyclic intermediates in the biosynthesis of 
• porphyrins.
Philosophical Transactions cf the Royal Society,
London B., 273 : 191-207
JACOBSON, S.J., RAPOPORT, H., ELLMAN, G.L. (1975)
The nonoccurrence of herao and kryptopyrrole in urine 
of schizophrenics.
Biological Psychiatry, 10: 91-93
JARRET, A., RIMINGTON, C., WILLOUGHBY, D.A. (1956) 
ô-Aminolaevulinic acid and porphyria.
Lancet, 1: 125-127
JELLUM, E., STOKKE, 0., ELDJARN, L. (l973)
Application of gas chromatography, mass spectrometry 
and computer methods in clinical biochemistry.
Analytical Chemistry, 45: 1099-1106
JURGENSON, J.E., BEALE, S.I., TROXLER, R.F. (1976)
Biosynthesis of 6-aminolevulinic acid in the unicellular 
rhodophyte, cyanidium caldarium.
Biochemical and Biophysical Research Communications,
69: 149-157
KAPPAS, A., BRADLOW, H.L., GILLETTE, P.N., GALLAGHER, T.F. 
(1972a)
Studies in porphyria I: A defect in the reductive
transformation of natural steroid hormones in the 
genetic liver disease acute intermittent porphyria. 
Journal of Experimental Medicine, I36: 1043-1053
KAPPAS, A., BRADLOW, H.L., GILLETTE, P.N., LEVERE, R.D., 
GALLAGHER, T.F. (1972b)
A defect in steroid hormone metabolism in acute 
intermittent porphyria.
Federation Proceedings, 3I: 1293-1297
KAPPAS, A., GRANICK, S. (1968)
Experimental hepatic porphyria: studies with
steroids of physiological origin in man.
Annals of the New York Academy of Science I5I: 842-849
KAPPAS, A., MAINES, M.D., (1976)
Tin; a potent inducer cf heme oxygenase in kidney. 
Science, 192: 60-62
190
KATO, R., GILLETTE, J.R. (1965)
Sex differences in the effects of abnormal physiological 
states on the metabolism of drugs by rat liver microsomes. 
Journal cf Pharmacology and Experimental Therapeutics,
I5O: 285-291
KAUFMAN, L., MARVER, H.S. (l970)
Biochemical defects in two types of human hepatic 
porphyria.
New England Journal of Medicine, 285: 954-953
KRSIAK, M. (1974)
Kinds of aggressive behaviour in mice.
Research Communications in Chemical Pathology and 
Pharmacology, 2; 238-252
KURASHIMA, Y., HAYASHI, N., KIKUCHI, G. (l970)
Mechanism cf inhibition by heroin of increase of 
6-aminolevulinate synthetase in liver mitochondria^
Journal of Biochemistry, 67: 863-865
KUSHNER, J.P., BARBUTO, A.J., LEE, G.R. (1976)
An inherited enzymatic defect in porphyria cutanea tarda: 
decreased uroporphyrinogen decarboxylase activity.
Journal of Clinical Investigation, 58: 1089-1097
KUSHNER, J.P., STEINMULLER, D.P., LEE, G.R. (1975)
The role of iron in the pathogenesis of porphyria cutanea 
tarda: decreased uroporphyrinogen decarboxylase activity.
Journal of Clinical Investigation, 56: 66I-667
LAMON, J.M. (1977)
Clinical aspects of porphyrin measurement other than 
lead poisoning.
Clinical Chemistry, 23: 260-263
LASCELLES, J. (1964)
In "Tetrapyrrole Biosynthesis and its Regulation"
N.A. Bergamin Inc: New York.
LEES, R.S., SONG, L.S., LEVERE, R.D., KAPPAS, A. (1970)
Hyperbetalipoproteinemia in acute intermittent porphyria. 
New England Journal of Medicine, 282: 432-433
191
LEVERE, R.D., GRANICK, S. (1965)
Control cf hemoglobin synthesis in the cultured chick 
blastoderm by 6-aminclevulinic acid synthetase: 
increase in the rate of hemoglobin formation with 
0-aminolevulinic acid.
Proceedings of the National Academy cf Sciences,
U.S.A., 54: 134-137
LIGHTNER, D.A., CRANDALL, D.C. (1973)
The dye sensitized photooxygenaticn of kryptopyrrole. 
Experientia, 29: 262-264
LIGHTNER, D.A., NORRIS, R.D., KIRK, D.I., KEY, R.M. (l974)
Dye sensitised photooxygenaticn of hemopyrrole. 
Experientia, 30: 587-588
LLAMBIAS, E.B.C. (1976)
Enzymic conversion of mesoporphyrin to mesohaem. 
International Journal of Biochemistry, 7: 35-40
LONDON, I.M., CLEMENS, M.J., RANU, R.S., LEVIN, D.H.,
CHERBAS, L.P., ERNST, V. (1976)
The role cf hemin in the regulation of protein synthesis 
in erythroid cells.
Federation Proceedings, 35: 2218-2222
LOOTS, J.M., BECKER, D.M., MEYER, B.J., GOLDSTUCK, N., 
KRAMER, S. (1975)
The effect of porphyrin precursors on monosynaptic 
reflex activity in the isolated hemisected frog 
spinal cord.
Journal of Neural Transmission, 36: 71-81
LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L., RANDALL, R.J.
(1951)
Protein measurement with the folin phenol reagent. 
Journal of Biological Chemistry, 193: 265-275
LYBERATOS, C., ARAPAKIS, G., ARONIS, F., GARDIKAS, C. (l976) 
Variegate porphyria with unusual neurological 
manifestations.
American Journal of the Medical Sciences, 272: 211-214
McGILLION, F.B. (1975)
Behavioural effects cf chronic delta-aminolaevulinic 
acid administration in the rat.
IRCS Medical Science, 3: 624
192
McGILLION, F.B., MOORE, M.R., GOLDBERG, A. (l973)
The effect of 6-aminolaevulinic acid on the 
■ spontaneous activity cf mice,
Scottish Medical Jcumal, 18; 133
MeINTYRE, N., PEARSON, A.J.G., ALLAN, D.J., CRASKE, S.,
WEST, G.M.L., MOORE, M.R., BEATTIE, A.D., PAXTON, J.W., 
GOLDBERG, A. (l97l)
Hepatic 6-arainclaevulinic acid synthetase in an 
attack of hereditary coproporphyria and during 
remission.
Lancet, 1: 560-564
McKAY, H., DRUYAN, R., GETZ, G.S., RABINOWITZ, M. (1969) 
Intramitochcndrial localisation of 6-aminolevulinic 
acid synthetase and ferrochelatase in rat liver. 
Biochemical Journal, 114: 455-461
MAGNUS, I.A., JARRET, A., PRANKERD, T.A.J., RIMINGTON, C. 
(1961)
Erythropoietic protoporphyria: a new porphyria
syndrome with solar urticaria due to protopcrphyrinaemia. 
Lancet, 2: 448-451
MAINES, M.D., KAPPAS, A. (1974)
Cobalt induction of hepatic heme oxygenase; with 
evidence that cytcchrcme P-450 is not essential 
for this enzyme activity.
Proceedings of The National Academy of Sciences,
U.S.A., 71: 4293-4297
MAINES, M.D., KAPPAS, A. (1975)
Cobalt stimulation of heme degradation in the liver: 
dissociation of microsomal oxidation of heme from 
cytochrome P-450.
Jcumal cf Biological Chemistry, 250: 4171-4177
MAINES, M.D., KAPPAS, A. (l976a)
The induction of heme oxidation in various tissues by 
trace metals: evidence for the catabolism of
endogenous heme by hepatic heme oxygenase.
Annals of Clinical Research, 8, 39-46
MAINES, M.D., KAPPAS, A. (1976b)
Selenium regulation of hepatic heme metabolism: 
induction of 6-aminolevulinate synthase and heme 
oxygenase.
Proceedings of The National Academy of Sciences,
73: 4428-4431
193
MAINES, M.D., KAPPAS, A. (l977)
Enzymic oxidation cf cobalt protoporphyrin IX: 
observations on the mechanism of heme oxygenase. 
Biochemistry, 16: 419-425
MANN, J.G., de NARDO, G.L. (1965)
Acute intermittent porphyria associated with 
hyperthyroidism.
Journal cf Clinical Endocrinology and Metabolism,
25: 1151-1155
MARVER, H.S., COLLINS, A., TSCHUDY, D.P., RECHCIGL, M. (1966) 
Delta-aminolevulinic acid synthetase II. Induction 
in rat liver.
Jcumal of Biological Chemistry, 241: 4523-4329
MARVER, H.S., SCHMID, R. (1972)
The porphyrias.
In "Metabolic Basis of Inherited Disease", p.1087 
ed. Stanbury, J.B., Wyngaarden, J.B. and 
Fredrickson, D.S., McGraw-Hill, New York
MATSUOKA, T., YODA, B., KDCUCHI, G. (1968)
Mechanism of allylisopropylacetamide-induced increase 
of 6-amino le vul inapte synthetase in liver mitochondria 
III. Effects of triiodothyronine and hydrocortisone 
on the induction process.
Archives of Biochemistry and Biophysics, 126: 530-538
MAUZERALL, D., GRANICK, S. (1956)
The occurrence end determination of 6-aminolaevulinic 
acid in urine.
Journal of Biological Chemistry, 219: 435-446
MAXWELL, J.D., MEYER, J.A. (1976)
Effect of lead on hepatic 6-aminolaevulinic acid 
synthetase activity in the rat: A model for drug
sensitivity in intermittent acute porphyria.
European Journal of Clinical Investigation, 6:
373-379
MELANDER, A., BULOW, K., BURGER, A., ERICSON, L.E., 
INGÎMANNSON, S., UUNGGREN, J-G., NORBERG, K-A.,
PERRSON, B., SUNDQVIST, S-B,, SUNDLER, F., TIBBLIN, S., 
WESTGREN, U. (1976)
Influence of the sympathetic nervous system on 
thyroid activity in man.
Proceedings of the VIIth International Thyroid 
Conference, p.100-102
ed. Robbins, J., Braverman, L.E., Excerpta Medica
194
MIYAGI, K., PETRYKA, Z.J., BOSSENMAIER, I., CARDINAL, R., 
WATSON, C.J. (1976)
The activities of uroporphyrinogen synthetase and 
cosynthetase in congenital erythropoietic porphyria 
(CEP).
American Journal of Hematology, 1: 5-21
MOFFETT, R.B. (1968)
Central nervous system depressants. VIII Pyrroles. 
Journal of Medicinal Chemistry, 11: 1251-1252
MOORE, M.R., BATTISTINI, V., BEATTIE, A.D., GOLDBERG, A.
(1970)
The effects of certain barbiturates on the hepatic 
porphyrin metabolism cf rats.
Biochemical Pharmacology, 19: 751-757
MOORE, M.R., PAXTON, J.W., BEATTIE, A.D., GOLDBERG, A. (1975) 
17-oxosteroid control of porphyrin biosynthesis.
Enzyme, 16: 514-525
MOORE, M.R., TURNBULL, A.L., BARNARDO, D., BEATTIE, A.D., 
MAGNUS, I.A., GOLDBERG, A. (1972)
Hepatic 6-aminolaevulinic acid synthetase activity 
in porphyria cutanea tarda.
Lancet, 2: 97-100
MORGAN, R.O., FISCHER, W.F., STEPHENS, J.K., MARKS, G.S.
(1976)
Thyroid hormone enhancement of drug-induced porphyrin 
biosynthesis in chick embryo liver cells maintained 
in serum-free Waymouth medium.
Biochemical Pharmacology, 25: 2609-2612
MOSHELL, A.N., BJORNSON, L. (l977)
Photoprotection in erythropoietic protoporphyria: 
mechanism of photoprotection by beta-carotene.
Journal of Investigative Dermatology, 68: 157-160
NAKAO, H., WADA, 0., KITAMURA, T., UONO, K., URATA, G.
(1966)
Activity of amino laevulinic acid synthetase in normal 
and porphyric human livers.
Nature, 210: 858-859
OHASHI, A., KIKUCHI, G. (1977)
Studies on the mechanism of the conversion of cytosol 
6-aminclevulinic acid synthase to the mitochondrial 
enzyme in the liver of the allylisoprcpylacetamide- 
treated rat.
Archives of Biochemistry and Biophysics, I78: 607-616
195
OMURA, T., SATO, R. (1964)
The carbon monoxide binding pigment of liver 
microsomes•
Journal of Biological Chemistry, 259: 2570-2578
0»REILLY, P.O., ERNEST, M., HUGHES, G. (1965)
The incidence of malvaria.
British Journal of Psychiatry, 111: 741-744
ORMSTON, B.J., GARRY, R., CRYER, R.J., BESSER, G.M.,
HALL, R. (1971)
Thyrotrophin-releasing hormone as a thyroid 
function test.
Lancet, 2: 10-14
PADMANABAN, G., RAO, M.R.S., MALATHI, K. (1973)
A model for the regulation of 6-aminolaevulinate 
synthetase induction in rat liver.
Biochemical Journal, 154: 847-857
PAUL, K.G., THEORELL, H., AKESSON, A. (1933)
The molar light absorption cf pyridine 
ferroprotoporphyrin (Pyridine haemochromogen).
Acta Cheraica Scandinavica, 7: 1284-1287
PAXTON, J.W., MOORE, M.R., BEATTIE, A.D., GOLDBERG, A.
(1974)
17-Oxosteroid conjugates in plasma and urine cf 
patients with acute intermittent porphyria.
Clinical Science and Molecular Medicine, 46, 207-222
PERCY, V.A., SHANLEY, B.C. (1977)
Porphyrin precursors in blood, urine and cerebrospinal 
fluid in acute porphyria.
South African Medical Journal, 52: 219-222
PERLROTH, M.G., MARVER, H.S., TSCHUDY, D.P. (1965)
Oral contraceptives and the management of acute 
intermittent porphyria.
Jcumal cf the American Medical Association, 194: 1057-1042
PERLROTH, M.G., TSCHUDY, D.P., WAXMAN, A., ODELL, W.D. (I967) 
Abnormalities of growth hormone regulation in 
acute intermittent porphyria.
Metabolism, I6: 87-90
196
PIMSTONE, N.B. (l975)
The hepatic aspects cf porphyria.
In "Modem trends in Gastroenterology - 5”» p.573-417 
ed. Read, A.E., Butterworth, London
PIMSTONE, N.R., ENGEL, P., TENHUNEN, R., SEITZ, P.T., 
MARVER, H.S., SCHMID, R. (l97l)
Further studies of microsomal haem oxygenase: 
mechanism for stimulation cf enzyme activity and 
cellular localization.
South African Medical Journal, 45: (Suppl)
LCM 169 - LCM 175
PIOMELLI, S., LAMOLA, A.A., POH-FITZPATRICK, M.B.,
SEAMAN, C., HARBER, L.C. (1975)
Erythropoietic protoporphyria and lead intoxication: 
the molecular basis for difference in cutaneous 
photosensitivity.
Journal cf Clinical Investigation, 56: 1519-1527
POULSON, R., POLGLASE, W.J. (l975)
Enzymic conversion of protoporphyrinogen IX to 
protoporphyrin IX: protoporphyrinogen oxidase 
activity in mitochondrial extracts of 
Saccharomyces Cerevisiae.
Jcumal of Biological Chemistry, 250: 1269-1274
RAPOPORT, H. (1976)
Personal communication.
RATCLIFFE, V.A., CHALLAND, G.S., RATCLIFFE, J.G. (1974)
A critical evaluation of separation methods in. 
radioimmunoassays for total triiodothyronine and 
thyroxine in unextracted human serum.
Annals of Clinical Biochemistry, 11: 224-229
RATCLIFFE, W.A., MARSHALL, J., RATCLIFFE, J.G. (1976)
The radioimmunoassay cf 5,3',5'-triiodothyronine 
(reverse T5) in unextracted human serum.
Clinical Endocrinology, 5: 65I-64I
RITKIND, A.B., GILLETTE, P.N., SONG, C.S., KAPPAS, A.
(1975)
D m g  stimulation of 6-aminolevulinic acid synthetase 
and cytochrome P-450 in vivo in chick embryo liver. 
Jcumal of Pharmacology and Experimental Therapeutics, 
185: 214-225
197
RIMINGTON, C. (l97l)
Quantitative determination of porphobilinogen 
and porphyrins in faeces and erythrocytes.
Association of Clinical Pathologists Broadsheet 40.
RUSSELL, C.S. (1974)
Biosynthesis of porphyrins II.
Journal of Theoretical Biology, 47: 145-151
SASSA, S., GRANICK, S. (l970)
Induction of 6-aminolevulinic acid synthetase in 
chick embryo liver cells in culture.
Proceedings of the National Academy of Sciences,
U.S.A. 67: 517-522
SCHACTER, B.A., YODA, B., ISRAELS, L.G. (1976)
Cyclic oscillations in rat hepatic heme oxygenase 
and 6-aminolevulinic acid synthetase following 
intravenous heme administration.
Archives of Biochemistry and Biophysics, 175: 11-17
SCHMID, R. (i960)
Cutaneous porphyria in Turkey.
New England Jcumal of Medicine, 263: 397-398
SCHMID, R., SCHWARTZ, S., WATSON, C.J. (1954)
Porphyrin content cf bone marrow and liver in various 
forms cf porphyria.
Archives of Intemal Medicine, 93: 167-190
SCHMIDT, D., SCHYMURA, G., STITCH, W. (1973)
Zur Enstehung der Delta-Aminolaevulin-acidurie bei 
der Bleivergiftung.
Klinische Wcchenschrift, 51: 709-714
SCHULMAN, M.P., RICHERT, D.A. (1956)
Utilization of glycine, succinate and 6-aminolevulinic 
acid for heme synthesis.
Federation Proceedings, 15: 349
snmiN, D. (1955)
In "Ciba Foundation Symposium on Porphyrin Biosynthesis 
and Metabolism".
ed. Wolstenholme, G.W., Churchill, London.
198
SHEMIN, D. (1976)
6-aminclaevulinic acid dehydratase; structure 
function and mechanism.
Philosophical Transactions of the Royal Society 
of London B., 275: 109-116
SIBGWICK, N.V. (1966)
in "The organic chemistry of nitrogen", p.634 
Clarendon Press, Oxford
SOHLER, A., BECK, R., NOVAL, J. (l970)
Mauve factor reidentified as 2,4-&imethyl-3- 
ethylpyrrole and its sedative effect on the 
C.N.S,
Nature, 228: I3I8-I32O
SOHLER, A., RENZ, R.H., SMITH, S., KAUFMAN, J. (1967)
Significance of hydroxyskatole and mauve factor 
excretion in schizophrenia.
International Journal of Neuropsychiatry, 4: 327-331
SONG, C.S., BONKOVSKY, H.L., TSCHUDY, D.P. (l974)
Salicylamide metabolism in acute intermittent 
porphyria.
Clinical Pharmacology and Therapeutics, 15: 431-435
STEIN, J.A., TSCHUDY, D.P. (l970)
Acute intermittent porphyria: a clinical and
biochemical study of 46 patients.
Medicine (Baltimore), 49: 1-16
STEPHENS, J.K., FISCHER, P.W.F., MARKS, G.S. (l977)
Porphyrin induction: equivalent effects of 5«H and
5pH steroids in chick embryo liver cells.
Science, 197: 659-660
STRAND, L.J., FELSHER, B.F., REDEKER, A.G., MARVER, H.S. (l970) 
Enzyme abnormality in heme biosynthesis in intermittent 
acute porphyria. Decreased hepatic conversion of 
porphobilinogen to porphyrins and increased 6-aminolevulinic 
acid synthase activity.
Proceedings of The National Academy of Sciences, U.S.A.,
67: 1315-1320
TADDEINI, L., NORDSTROM, K.L., WATSON, C.J. (1964) 
Hypercholesterolemia in experimental and human 
hepatic porphyria.
Metabolism, 13: 691-701
199
TEN EYCK, F.V., MARTIN, W.J., KERNOHAN, J.W. (I96I)
Acute porphyria: necropsy studies in nine cases.
Proceedings of the Mayo Clinic, 36: 409-422
TENHUNEN, R., MARVER, H.SPIMSTONE, N.R., TRACER, W.F., 
COOPER, D.Y., SCEMID, R. (1972)
Enzymic degradation of heme: oxygenative cleavage
requiring cytochrome P-450.
Biochemistry, 11: 1716-1720
TOMARO, M.L., FRYDMAN, R.B., FRYDMAN, B. (l973)
Porphobilinogen oxygenase from rat liver. Induction, 
isolation and properties.
Biochemistry, 12: 5263-5268
TOMIO, J.M., GARCIA, R.C., SAN MARTIN DE VIALE, L.C., 
GRINSTEIN, M. (1970)
Porphyrin biosynthesis VII. Porphyrinogen carboxy- 
lyase from avian erythrocytes: purification and
properties.
Biochimica et Bicphysica Acta, 198: 353-363
TOURNEY, G., HATFIELD, L. (1972)
Plasma androgens in male schizophrenics.
Archives of General-Psychiatry, 27: 753-755
TSCHUDY, D.P. (1974)
Porphyrin metabolism and the porphyrias.
In "Duncan’s Diseases of Metabolism", p.774-791 
ed. Bondy P., Rosenberg L., W.B. Saunders,
Philadelphia.
TSCHUDY, D.P., BONKOWSKY, H.L. (l972)
Experimental porphyria.
Federation Proceedings, 3I: 147-159
TSCHUDY, D.P., PERLROTH, M.G., MARVER, H.S., COLLINS, A., 
HUNTER, G., RECHCIGL, M. (I965)
Acute intermittent porphyria: the first overproduction
disease localised to a specific enzyme.
Proceedings of The National Academy of Sciences, U.S.A., 
53: 841-847
TSCHUDY, D.P., VALSAMIS, M., MAGNUSSEN, C.R. (1975)
Acute intermittent porphyria: clinical and
selected research aspects.
Annals of Internal Medicine, 83: 85I-864
200
TSCHUDY, D.P., WELLAND, F.H., COLLINS, A., HUNTER, G.W. Jnr. 
(1964)
The effect of carbohydrate feeding on the induction 
of 5-aminolevulinic acid synthetase.
Metabolism, 13: 396-406
UNSELD, A., DE MATTEIS, F. (1976)
Isolation and partial characterisation of green 
pigments produced in rat liver by 2-allyl-2- 
isopropylacetamide.
In "Porphyrins in Human Diseases", p.71-75 
ed. Doss, M., Karger, Basle.
VOGEL, A.I. (1970)
In "Practical Organic Chemistry", p.301-511 
Longman, London
WALDENSTROM, J. (1937)
Studien uber porphyrie.
Acta Medica Scandinavica (Suppl. 82)
WALDENSTROM, J., WAHLQUIST, B.C. (1939)
Studien uber die Entstehung der roten Hampigmente 
bei der akuten Porphyrie aus ihrer farblosen Vorstufe. 
Hoppe-Seyler’s Zeitschrift fur Physiologie und Chemie, 
260: 189-209
WALKER, J.L, (1975)
Neurological and behavioural toxicity of kryptopyrrole 
in the rat.
Pharmacology, Biochemistry and Behaviour, 3: 243-250
WATSON, C.J., PIERACH, C.A., BOSSENMAIER, I., CARDINAL, R.
(1977)
Postulated deficiency of hepatic heme and repair by 
hematin infusions in the "inducible" hepatic porphyrias. 
Proceedings cf the National Academy of Science, U.S.A., 
74: 2118-2120
WELLAND, F.H., HELLMAN, E.S., COLLINS, A., HUNTER, G.W., 
TSCHUDY, D.P. (1964)
Factors affecting the excretion of porphyrin precursors 
by patients with acute intermittent porphyria %. The 
effect of diet.
Metabolism, 13: 232-250
WETTERBERG, L. (1967)
A neuropsychiatrie and genetical investigation of 
acute intermittent porphyria.
Svenska Bokfdrlaget, Stockholm.
201
WETTERBERG, L., FORMGREN, B. (l97é)
Pharmacological and biochemical properties of 
kryptopyrrole and its oxidation products 
possibly related to acute intermittent porphyria.
Annals cf Clinical Research, 8: (Suppl.17) 162-167
WRITING, N.J., ELLIOT, W.H. (1972)
Purification and properties cf solubilized 
mitochondrial 6-aminolevulinic acid synthetase 
and comparison with the cytcsol enzyme.
Journal cf Biological Chemistry, 247: 6818-6826
WOOLDRIDGE, T.A., LIGHTNER, D.A. (1977)
Synthesis of "oxidised" haemcpyrrole and kryptopyrrole: 
porphyric monopyrroles.
Journal cf Heterocyclic Chemistry, 14: 1283-1284
WU, W.H., SHEMIN, D., RICHARDS, K.E., WILLIAMS, R.C.
(1974)
The quaternary structure of 6-aminolevulinic acid 
dehydratase from bovine liver.
Proceedings of the National Academy of Sciences, U.S.A., 
71: 1767-1770
YEO, P.B.B., LEWIS, M., EVERED, D.C., (l977)
Radioimmunoassay of free thyroid hormone concentrations 
in the investigation of thyroid disease.
Clinical Endocrinology, 6: 159-167
YEO, P.B.B., VICE, P.A., GREEN, E., LEWIS, M.,
EVERED, D.C. (l978)
Serum free thyroid hormone levels in pregnancy and 
oral contraceptive therapy.
Proceedings of the Society for Endocrinology.
In press
ZDANIVSKY, G.B., IRVINE, D.G. (l972)
The effect of kryptopyrrole cn standardized 
discriminated avoidance task.
Proceedings of the Saskatchewan Psychiatric 
Research Meeting, p.188
ZIPRKOVSKY, L., KRAKOWSKY, A., CRISPIN, M.,
SZEINBERG, A. (1966)
Porphyria cutanea tarda hereditaria.
Israel Journal of Medical Science, 2: 338-340
202
PUBLICATIONS
BRODIE, N.J., GRAHAM, D.J.M., THOMPSON, G.G., MOORE, M.R., 
GOLDBERG, A. (1976)
The porphyrinogenic effects of kryptopyrrole in the rat 
and the occurrence of urinary kryptopyrrole in human 
hereditary hepatic porphyria.
Clinical Science and Molecular Medicine, 50: 431-434
GRAHAM, D.J.M., MOORE, M.R., THOMPSON, G.G., GOLDBERG, A. 
(1976) ,
The effect of 4-ethyl-5-hydroxy-5,5-<limethyl-ZA - 
pyrrolin-2-one on porphyrin synthesis in the rat. 
Biochemical Society Transactions, 4: 1089-1091
GRAHAM, D.J.M., THOMPSON, G.G., MOORE, M.R., BRODIE, M.J., 
GOLDBERG, A. (l977) ,
The effect of 4-ethyl-5-hydroxy-5,5-dimethyl-^ - 
pyrrolin-2-one on haem metabolism in the rat. 
Biochemical Society Transactions, 5: 1468 - 1470
BRODIE, M.J., GRAHAM, D.J.M., GOLDBERG, A., BEASTALL, G.H., 
RATCLIPPE, W.A., RATCLLPPE, J.G., YEO, P.P.B. (1978)
Thyroid function in acute intermittent porphyria :- 
A neurogenic cause of hyperthyroidism ?
Hormone and Metabolic Research - in press
GRAHAM, D.J.M. (l978) '
Quantitative determination of 5-ethyl-5-hydroxy-4 $ 5- 
dimethy1 - -pyrrolin-2-one in urine using gas- 
liquid chromatography.
Clinica Chimica Acta, 85: 205-210
GRAHAM, D.J.M., BRODIE, M.J., McCOLL, K.E.L., MOORE, M.R., 
GOLDBERG, A.
Quantitation of 3-ethyl-5-hydroxy-4,5-dimethyl-^- 
pyrrolin-2-one in the urine of patients with acute 
intermittent porphyria.
Submitted
203
COMMUNICATIONS TO SCIENTIFIC MEETINGS
g r a h a m, D.J.M., MOORE, M.R., GOLDBERG, A.
The effect cf 4-ethyl-5-hydroxy-3,3-dimethyl-/\?- 
pyrrolin-2-one on porphyrin synthesis in the rat.
Biochemical Society - 565th meeting, Stirling, 1976
GRAHAM, D.J.M., BRODIE, M.J., MOORE, M.R., GOLDBERG, A.
Quantitaticn of a urinary pyrrolic metabolite found in 
excess in acute intermittent porphyria.
Scottish Society for Experimental Medicine, Aberdeen 1977
GRAHAM, D.J.M., THOMPSON, G.G., MOORE, M.R., BRODIE, M.J., 
GOLDBERG, A.
The effect cf 4-e thyl-5-hydrcxy-3,5-dime thy l-2^i^- 
pyrrolin-2-one on haem metabolism in the rat.
Biochemical Society, 570th meeting, Cardiff, 1977
GRAHAM, D.J.M., McCOLL, K.E.L., GOLDBERG, A., MOORE, M.R.
Urinary pyrrolic pigment excretion in psychosis and 
the acute porphyrias.
Royal College of Psychiatrists (Scottish Divn.), 
Glasgow, 1977
GRAHAM, D.J.M., MOORE, M.R., McCOLL, K.E.L., BRODIE, M.J.
The urinary excretion cf monopyrroles in acute 
intermittent porphyria.
Tetrapyrrole Group, 2nd meeting, London, 1978
204
